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Anecdotal observations about the existence of a bypass circulation in the presence of an 
arterial obstruction, spontaneous or induced, exist since a long time. It may have started in the 
Royal deer park of King George where Dr. Hunter occluded vessels feeding the deer’s antler 
and where the site of occlusion was bypassed by collateral vessels without disturbing the 
growth of the majestic trophy. Centuries later post mortem studies in humans showed that 
most hearts are endowed with collateral vessels even in the absence of arterial occlusions, 
notably the human heart. The descriptive part of research culminated in the work of Fulton [1, 
2] who showed the marked enlargement of pre-existing collaterals in human hearts in the 
presence of arterial occlusive disease. Dr. Fultons impressive angiograms were, apart from his 
scientific insights, the results of technical refinements, i.e., the use of a contrast material with 
high density for “soft” X-rays and 3-D viewing. About a decade later in-vivo coronary 
angiography took off and showed for the first time coronary collaterals in the beating heart, 
and cases were reported where these vessels had enlarged just in time to prevent an infarct. 
The important life and tissue-saving role of collaterals was questioned, again a decade later, 
when angiographers showed that the degree of collateralization correlated with the degree of 
coronary disease [3, 4], and the erroneous conclusion was drawn that collaterals were rather a 
bad omen for the downhill course of the disease. This was finally straightened out by studies 
showing the beneficial effect of collaterals [5]. Basic science became interested in the 
mechanisms of vascular growth and studies on the rate of growth, the functional capacity, the 
structure and ultra-structure appeared, because it was obvious that this new knowledge was 
potentially useful to design new types of therapy, which would benefit patients [6]. However, 
the interest in vascular research suffered setbacks by allegedly easier and more profitable 
types of therapy that consisted also of bypasses but this time produced by surgeons, or by 
eliminating occlusions and stenoses by balloon dilatation and stent deployment at the hands of 
cardiologists. Only when the stents became occluded, interest in vascular research soared 
again [7]. Another impediment to “Arteriogenesis”, as research into collateral vessel 
development was now called, was the flood of publications that followed the claim by Dr. 
Folkman [8] that with the advent of vascular growth factor the scourges of mankind, i.e., 
arteriosclerosis and cancer, could be cured by application of one single principle: 
angiogenesis and its antidote, anti-angiogenesis. Since this almost coincided with the 
discovery that genetic targeting of the newly discovered vascular endothelial growth factor 
(VEGF) was embryonic lethal [9], research in endothelial biology received an enormous 
boost, almost completely neglecting the fact that, at least in arterial disease with tissue 
ischemia, no shortage of endothelial cells exists and that diseased arteries cannot be replaced 
by capillaries. Clinical studies using vascular growth factors remained inconclusive in arterial 
disease [10, 11] and growth factors were not included into the armamentarium of standard 
therapies. Antiangiogenic therapy in cancer did also not live up to initial expectations [12]. 
In spite of these impediments arteriogenesis has made great strides forward and we know now 
that bone marrow derived cells, in particular monocytes, play an essential role [13, 14]. We 
know now the principal players in the field, thanks to the availability of genetically altered 
mice. We know that increased fluid shear stress [15, 16], as it occurs in pre-existent arteriolar 
collaterals as a consequence of an acute occlusion, is the primary physical stimulus, which is 
responded to by changes in the activity of numerous ion channels, in the up-regulation of NO-
producing enzymes [17] and in gene expression. We do not know enough about the molecular 
signaling that originates from the activated endothelium to the smooth muscles in the media, 
the major players in arteriogenesis, because their multiplication and remodeling results in the 
vessel enlargement by a factor of up to 10-fold its original diameter and tissue mass 
(depending on species and organ supplied and size of occluded artery). The smooth muscles 
of the media, stimulated somehow by signals from the activated endothelium, produce 
monocyte chemoattracting protein-1 (MCP-1) [18], which is responsible for the accumulation 
of monocytes in the wider adventitial space of the developing vessel. Surprisingly, NO plays 
also a defining role [17]. Surprising, because NO is an anti-mitogen for smooth muscles [19], 
the most important players in arteriogenesis. However, L-NAME, a non-specific inhibitor of 
iv
all NO producing enzymes, prevents arteriogenesis and the double knock-out of eNOS+iNOS 
seconds that. 
Can we now hope that we have come closer to the development of a new therapeutic principle 
applicable to human patients? Yes, we can! However, we have to overcome strong 
competition and perhaps even adversaries. Any new drug or vector has to be superior to the 
well-established revascularization procedures of the surgeons and cardiologists. Industry has 
to be convinced that it is worthwhile to invest into vascular research again. Again, because 
most pharmaceutical companies had closed their labs for cardiovascular research in favor of 
the development of high priced anti-cancer drugs. However, there is hope, but only when we 
succeed in the complete unraveling of the pathways that rule the development of arterial 
bypasses, which would enable us to find the limiting step that had escaped evolutionary 
selection pressure and that we have to stimulate to better Mother Nature. 
Wolfgang Schaper 
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Arteriogenesis describes the growth, remodelling and maturation of pre-existing collateral 
arteries into true arteries. Functioning as natural bypasses these collaterals are able to 
compensate for nonfunctional stenotic/occluded arteries and, therefore, may, in the hopefully 
not too distant future, substitute for clinical interventions such as balloon dilatation or even 
heart transplantation. Pre-existing collateral arteries, the growth of which is triggered by 
increased mechanical stress, occur not only in the heart, but virtually in every organ of the 
body. Research on molecular mechanisms of arteriogenesis aiming to comprehend this 
naturally occurring physiological process in order to induce it therapeutically where needed, 
started several years ago. A first book reporting basic and current knowledge on 
arteriogenesis was released in 2004 (“Arteriogenesis”, Wolfgang Schaper and Jutta Schaper 
(eds.)). Since then, a lot of progress has been made on understanding how mechanical stress 
(fluid shear stress) is translated into the diverse biological signal transduction cascades finally 
resulting in cell proliferation and arterial growth. With the publication of this volume, we 
want to update the current knowledge in collateral artery growth.  
Wolfgang Schaper gives an overview of the basics and focuses on the mechanistic role of 
physical forces, the innate immune system and nitric oxide; Kerstin and Christian Troidl 
report on the function of Ca2+ and Ca2+ channels, as well as on downstream signaling 
mechanisms. Due to the pro- as well as anti-arteriogenic properties of nitric oxide, the 
involvement of the NO-system in arteriogenesis has been heavily discussed for several years 
and Joseph Unthank depicts in detail the influences of NO and reactive oxygen species on 
vascular remodeling. In a more systemic approach, Paul Quax and Vincent van Weel report 
on the role of bone-marrow-derived cells. Elisabeth Deindl discusses epigenetic influences; 
James Faber gives insight into genetic and environmental mechanisms controlling the 
formation and maintenance of collateral arteries; Ferdinand Le Noble addresses the molecular 
pathway controlling arteriolar branching in the developing embryo and Florian Limbourg 
summarizes the role of the Notch signaling pathway for arterial cell types in embryonic 
development and postnatal life. 
While the first part of this book concentrates more on the molecular mechanisms of collateral 
artery growth, involving also the embryonic development of collaterals, the second part deals 
with the current clinical situation and therapeutically approaches. Niels van Royen illustrates 
the relevance of collateral arteries in patients with vascular diseases and reviews the 
therapeutic options to stimulate arteriogenesis. Ivo and Eva Buschmann delineate the function 
of external counterpulsation and Christian Kupatt and Teresa Trenkwalder present the features 
of thymosin beta4. Finally, Imo Hoefer introduces novel intra-arterial delivery platforms 
defined to enable clinicians to promote arteriogenesis locally. In summary, this volume aims 
to provide a comprehensive update of the current knowledge in the challenging and 
increasingly important field of arteriogenesis continuing a series in the timely form of an e-
book. The story begins now… 
Elisabeth Deindl 
Wolfgang Schaper 
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$ Most tissues have arteriole-like vessels that cross-connect one or more of the outer-most branches 
of opposing arterial trees.  These pre-existing “native collaterals” have unique characteristics and functions—
as unique from vessels of the general and lymphatic circulations as the latter are from each other.  Rare in 
number, these vessels somehow defy the developmental patterning cues that assure that branching proceeds 
from arteriole-to-capillaries-to-venule in the general circulation.  As a consequence, blood flow and shear 
stress in collaterals of healthy tissues are exceedingly low and oscillatory, and circumferential wall stress is 
high, relative to elsewhere in the microcirculation. Yet these vessels persist in this unusual hemodynamic 
environment—one that favors inflammation, hemostasis and vessel pruning elsewhere in the general 
circulation. Their persistence is crucial:  When blood flow to an arterial tree is reduced or blocked by acute or 
chronic obstructive disease, native collaterals serve as endogenous bypass vessels, providing retrograde 
perfusion from the adjacent unobstructed tree.  The amount of perfusion and thus ischemic injury is initially 
dependent on the extent (density and diameter) of these vessels, and subsequently on their ability to 
anatomically enlarge, a process termed “arteriogenesis”.  Despite the uniqueness and importance of the 
collateral circulation, until recently almost nothing was known about when or how it forms, ie, 
“collaterogenesis”.  Moreover, evidence suggests that the extent of this circulation varies widely among 
healthy individuals.  Yet only recently have the responsible mechanisms begun to be examined.  This chapter 
will review recent work that is beginning to answer these questions and also to identify how genetic and 
environmental factors govern formation and maintenance of the native collateral circulation.   

Introduction:  Collaterals  -- the “Third” Circulation 
In recent decades much has been learned about the mechanisms governing formation of the 
General arterial-venous and Lymphatic circulations. These circulations are uniquely 
different, with regard to certain differentiation molecules and morphogenic processes that 
mediate their development, as well as in their anatomic features, functions and physiological 
regulation.  In many ways, collateral vessels are as different from general and lymphatic 
vessels, as the latter are from each other.  So much so that collaterals might be regarded as 
comprising a “third” circulation – the Collateral circulation.     
How so?  Most healthy adult tissues have a population of native (pre-existing) collaterals 
that cross-connect one or more distal-most arterioles of one arterial tree with those of an 
opposing arterial tree.  There are also large, anatomically named collateral conduit arteries 
in certain regions of the body (eg, the recurrent radial artery around the elbow).  This 
chapter will focus on the microvascular collaterals. These have a much more varied 
abundance and importance in coronary artery disease (CAD), peripheral artery disease 
(PAD) and intracranial thromboembolic stroke.  Native collaterals average 10-40 microns in 
diameter in healthy tissues.  They are relatively rare.  For example, the thigh of the mouse is 
estimated to have 10-20 of these vessels [1], while similarly sized arterioles in the thigh’s 
general circulation number in the thousands.  Native collaterals are unique in four major 
ways.  By inter-connecting arterioles from adjacent trees, the process by which they form 
somehow defies instructions from canonical patterning molecules (eg, ephrin-B2 and eph-
B4) that in the general circulation insure that arterioles connect to capillaries that, in turn, 
connect to venules.  Perhaps more remarkable—owing to absence of a consistent pressure 
drop across them—blood flow in collaterals in healthy tissues is exceedingly low and 
disturbed or oscillatory [2], conditions that in the general circulation promote vascular wall 
inflammation, hemostasis and pruning.  Yet native collaterals persist in these conditions of 
low shear stress and high circumferential wall-stress.   
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A third unique feature of collaterals is that they undergo extensive growth in the radial and 
longitudinal directions over a period of days-to-weeks, when unidirectional shear-stress is 
induced by obstruction of flow into one of the trees they cross-connect.  This growth 
response, termed “arteriogenesis” by Schaper and colleagues [3], increases diameter up to 
10-fold.  This greatly increases collateral conductance and thus the protective function of 
these vessels as “endogenous bypass vessels” to restore perfusion in the dependent tissue 
towards resting values.  However, the extent (ie, density and diameter) of these vessels in a 
healthy tissue determines not only the blood flow and therefore severity of ischemic tissue 
injury immediately after acute thromboembolic obstruction, but also the number of 
collaterals that are then able to undergo arteriogenesis over time.  A fourth special feature is 
that the extent of the native collateral circulation varies dramatically among healthy 
individuals as a function of not only genetic background [4,5] but also from environmental 
factors (see below). Yet, the general and lymphatic circulations in such individuals are 
comparable in both form and function.  

<  Individual variation in genetic background and environmental factors accounts for variation in risk 
factors and complex disease traits, which in turn are responsible for phenotypic variation in vascular diseases.  
As well, variation in protective mechanisms, including extent of the native collateral circulation and its 
capacity to remodel in obstructive disease, can be ascribed to individual differences in genetic and 
environmental factors. 
Despite these special features, until recently almost nothing was known about when or how 
this circulation forms, how these vessels are able to persist in such disturbed hemodynamic 
conditions, or the basis for the wide variation in extent of this circulation among otherwise 
healthy individuals.  As with other phenotypic differences, variation in collateral extent is 
attributable to genetic and/or environmental factors (Fig. <). However, the nature of these 
factors has, until recently, been unknown.  This chapter will summarize recent studies that 
have begun to address these questions.  Mechanisms of collateral remodeling in obstructive 
disease—discussed in subsequent chapters and recent reviews—will be limited to 
summarizing evidence identifying genetic factors that impact this process. 
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Embryonic and early postnatal formation of the native collateral circulation 
It is estimated that one-fifth of patients with CAD are not candidates for percutaneous 
coronary intervention or coronary artery bypass grafting [6].  Hence, arteriogenic therapies 
to boost positive remodeling of exiting collaterals, or collaterogenic therapies to induce 
formation of additional ones, have been pursued for more than a decade.  However, no drug 
has emerged for clinical use with either benefit, owing to lack of efficacy, co-morbidities or 
unacceptable side effects [7].  Understanding how native collaterals naturally form could 
provide important clues about how to induce more to form when obstructive disease strikes.  
Unfortunately, there are major outstanding questions about this process, although they are 
now beginning to be addressed. 


=   Native pial collaterals (denoted by red dotted lines) interconnecting distal arterioles of the middle 
cerebral and anterior cerebral artery trees in an adult mouse.  The vasculature was dilated, fixed and filled with 
a high-viscosity material that does not cross capillaries, followed by clearance of tissue refractance, to 
highlight penetrating arterioles (two are denoted) and confirm that native collaterals are confined to the pial 
surface.  From Ref 16.   
When and how do native collaterals form and grow to their mature density, diameter, length 
and characteristic tortuosity in healthy tissues?  In the embryo, neonate or during growth to 
adulthood?  Surprisingly, very little has been reported, although several possibilities have 
been proposed [8]. What information we have comes from early studies examining the 
cerebral circulation, where anastomoses were noted to already be present in newborn mice 
[9] and rats [10] cross-connecting some of the distal-most branches of the anterior, middle 
and posterior cerebral artery (ACA, MCA, PCA) trees.  Such collaterals, which range from 
10-40 microns in diameter, are present in all adult mammalian species examined (including 
humans) [11], as well as in birds and reptiles [12,13], and in most tissue types.  We have 
recently begun to address the above questions in murine brain and several other tissues.  The 
cerebral cortex is particularly well suited because, as Figure = shows in an adult mouse, its 
collateral circulation resides outside of the brain in the pia mater where it can be imaged 
with high fidelity after craniotomy, dilation, fixation and staining or filling with casting or 
contrast material [4,14-16].  Penetrating arterioles branch from both pial arteries and 
collaterals into the cortex, where they supply intracerebral terminal arterioles (“end 
arteries”), capillaries and post-capillary venules [16].  
Studies in newborn mice have confirmed that pial collaterals are already present by 
postnatal day-1 (P1) [15,16].  We have also found that “gene-dose-dependent” reduction or 
increase in expression of either Vegfa or Clic4 (Chloride Intracellular Channel-4) reduces or 
C57BL/6
ACA
branchMCA
branch
mid-saggital
sulcuspial collaterals 
penetrating arterioles
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increases collateral number and diameter at P1, respectively (Fig. >) [15,16]. Altered 
expression of these proteins also modulates an obligate postnatal pruning process that 
reduces the collateral density by the end of the third postnatal week to the density present in 
the adult (Fig. >). Experimentally targeted changes in collateral abundance significantly 
impact the severity of stroke after MCA occlusion (Fig. >) [15,16]. Thus, the collateral 
circulation is established sometime during embryogenesis and subsequently undergoes early 
pruning, with the above two genes involved in both processes.   






 >   The number of native pial collaterals interconnecting the MCA and PCA trees (per cerebral 
hemisphere) in healthy adult mice is affected by VEGF-A expression.  Mice are hypo- or hypermorphic for 
VEGF-A expression at one allele.  Infarct volume (white region), measured 24h after permanent unilateral 
MCA occlusion, correlates closely with collateral number.  From Ref 15.  Comparable findings were obtained 
in intact hindlimb and after femoral artery ligation (Ref 4), and also in both brain and hindlimb for CLIC4 
expression (Ref 16).   





0   Wide difference in native pial collateral density (red stars) between MCA, ACA and PCA in two 
inbred mouse strains.  BALB/c have almost no collaterals and suffer massive strokes after MCAO, compared 
to C57BL/6 where they are small and cause little or no functional impairment.  The vasculature was dilated, 
fixed and filled with a high-viscosity fluorescent material unable to cross capillaries.  Collateral density in 
skeletal muscle and intestine in the two strains shows a similar but less dramatic difference.  From Ref 14.   
• Same findings in hindlimb COLs
VEGFLo/+
VEGFHi/+
wildtype


 
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But when in the embryo do collaterals form? What is the nature of the postnatal maturation 
phase?  What are the responsible mechanisms and does genetic background affect them?  
We [2] focused on two strains of mice, C57BL/6 and BALB/c, with large differences in 
adult collateral density in multiple tissues (Fig.0) [2,4,14,17]. In fact, these strains have the 
largest difference among more than 15 adult inbred strains examined [4]. We reasoned that 
comparing collaterogenesis in such divergent strains may begin to answer the above 
questions.  In both strains, collaterals appear by ~E14.5-15.5 as a plexus of ring-like ephrin-
B2-positive endothelial tubes interconnecting the crowns of the cerebral artery trees (Fig.
?1,) [2].  This “primary collateral plexus” appears abruptly after the cerebral artery trees 
have become well-developed.  Collateral density increases during expansion of the plexus 
through ~E18.5 (Fig.?). 

? A,B, Collaterogenesis in the mouse cerebral circulation.  Collaterals begin forming at ~E15.5 as a 
proto-collateral plexus of ephrin-B2-positive endothelial cell tubes in the region between the already-formed 
cerebral artery trees that expands through E18.5.  BALB/c mice form fewer collaterals during embryogenesis.  
The nascent collateral circulation of BALB/c mice undergoes greater postnatal pruning.From Ref 2. 
However, many fewer proto-collaterals form in the BALB/c strain.  This is not due to the 
presence of fewer endothelial cells, ie, the area of the primary embryonic capillary plexus 
present at ~E9.0 and E12.5 in the region between the cerebral artery trees that will become 
the “collateral zone” is similar in both strains [2]. Nor is it from differences in brain size or 
branching morphogenesis of the cerebral artery trees [2]. The nascent collaterals of BALB/c 
mice also undergoe more pruning, which occurs from E18.5 through the first few weeks 
after birth, ie, the collateral maturation phase (Fig. ?).  Collaterals that are retained during 
this phase increase their diameter and length and begin to acquire tortuosity – a 
characteristic of collaterals. However, BALB/c collaterals are smaller in diameter at birth 
and grow less in both length and diameter during maturation, features in common with mice 
deficient in VEGF-A or CLIC4 expression [15,16]. These differences are also not due to 
differences in mural cells.  Pericyte density on nascent collaterals is comparable in both 
strains [2], and acquisition of SMCs does not occur until after P7 (Fig.@2).     
So if not from the above mechanisms, what is responsible for formation of fewer, smaller 
diameter collaterals in the BALB/c embryo and less growth of those that do form in the 
neonate?  In silico analysis to test for the presence of expression quantitative trait loci 
(eQTL), using a database obtained from a recombinant inbred set of mice derived from 
C57BL/6 and BALB/c parentals, suggested the presence of a polymorphism at or near the 
Vegfa locus linking low VEGF-A expression (a feature of the BALB/c strain) to predicted 
low PDGF-B and high angiopoietin-2 expression, compared to C57BL/6 mice [14]. We 
recently confirmed these differences in baseline expression in tissue samples taken from the 
collateral zone between the MCA and ACA trees of perinatal mice (Fig. @") [2]. Adult 
BALB/c mice also express less VEGF-A during another time of vascular growth—during 
ischemia/hypoxia in skeletal muscle, brain and pulmonary airways [14,15,18,19]. Mutant 
mice haplo-insufficient for VEGF-R1 (Flt1) also form fewer collaterals in the embryo 
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(unpublished). These studies suggest that VEGF-A, VEGF-R1, angiopoietin-2, PDGF-B 
and CLIC4 are important in formation and maturation of the proto-collateral plexus in the 
embryo and neonate and thus in determining the extent of the collateral circulation in the 
adult. Additional studies are needed to define how the above factors, which are key 
regulatory molecules in branching morphogenesis, muralization and pruning of the general 
circulation [20-23],  impact these processes in collateral formation, as well as to identify 
other candidate molecules, localize their expression, and alter their activity for effect on 
collateral formation and maturation. As well, whether common mechanisms control 
collaterogenesis in different tissues is not known, although qualitatively similar strain-
specific differences in density have been found in skeletal muscle, brain and intestine of 
several adult inbred and mutant mouse strains [14-16]. Collaterals in mouse skeletal muscle 
are well-developed at birth (Fig.A), indicating that their formation in tissues in addition to 
brain also occurs during embryogenesis. 

@  A, Confocal image of isolectin-B4 (red), anti-NG2 (green) and Draq5 (blue); stars, pericytes. B, 
Number of pericytes per collateral length-x-width and per length are not different between strains on postnatal 
day1 (P1, shown) (or E15.5 (data not shown)).  C, Collaterals do not acquire smooth muscle cell coverage 
until after P7 (H Zhang, unpublished).  D, qPCR of tissue samples taken from the collateral zone between 
MCA and ACA.  BALB/c collaterals have increased angiopoietin-2, reduced PDGF-B and reduced VEGF-A 
expression.  Data normalized to 18S rRNA.  Data in A, B and D from Ref 2. 
VEGF-A is a determinant of collateral formation in the embryo 
Given the above data suggesting that VEGF-A levels influence collateral formation in the 
embryo [15], we have begun to further investigate its involvement using mouse embryos 
constitutively over- and under-expressing global endogenous VEGF-A [24,25].  Collaterals 
between the MCA and ACA trees first become evident shortly after emergence of the ACA 
tree from the mid-saggital sulcus at E14.5, with  the number that  form being  greater in  
over-expressing and smaller in under-expressing embryos (Fig.B). The vessels first appear 
as thin extensions (Fig. B,1 arrows), often at points where penetrating arterioles that 
descend into the cortex.  These extensions appear to arise from sprouting of endothelial tip 
cells.  Interestingly, these extensions span the opposing arterial trees by forming on top of 
the existing pial capillary plexus (Fig. B,).  This is consistent with formation of the primary 
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embryonic collateral plexus well after formation of the primary embryonic capillary plexus 
[2].  This is also different from how the pial arterial trees form, which involves remodeling 
of the primary embryonic capillary plexus.  Moreover, the collateral plexus forms as an 
artery-fated plexus of endothelial cell tubes expressing ephrin-B2 [2]. Current studies are 
using inducible mice to pinpoint the cell source and time-frame over which VEGF acts to 
modulate collateral formation.  No doubt, the above process likely has some features that 
are specific for the special anatomy of the pial circulation.  However as mentioned above, 
evidence suggests common signaling molecules and genetic polymorphisms control 
collaterogenesis in different tissue types despite their unique anatomic arrangements of the 
general circulation.    



A Collaterals in the adductor musculature form during embryogenesis and are well developed at 
postnatal day 1.  Scale bar=500μm. 
Intriguing results from Vogel, Marti et al. [26-28] support the concept that VEGF 
expression regulates collateral formation.  These investigators [27] designed a transgenic 
mouse with increased expression of VEGF driven by a neuron-specific promoter to 
investigate effects on cerebral vascular function.  Total vascular volume increased, as 
determined by micro-CT, but maximal cerebral blood flow was only minimally increased.  
The authors proposed an increase in formation of arteriole-to-arteriole “anastomoses” to 
account for the findings, although segmental analysis could not distinguish such structures 
for confirmation [28]. Another study found that these mice experienced smaller infarct 
volumes and neurological deficits after MCA occlusion, plus an increase in blood flow in 
the ACA distribution [26]. These findings are consistent with an increase in ACA-supplied 
collateral-dependent flow to the outer penumbral region of the occluded MCA tree.  This 
would be expected if pial collateral density and/or diameter are increased.   
Once nascent collateral connections form in the embryo, how are they maintained?  Platelet-
derived growth factor (PDGF)-B promotes the migration of mesenchymal cells to newly 
formed vessels, where they differentiate into pericytes that stabilize the endothelial network 
[29,30]. Price et al. [20] examined the progression of coverage of the developing 
vasculature by cells expressing smooth muscle actin in the early postnatal rat gracilis.  They 
found that coverage of arteriole arcades (anastomoses; possibly in the process of formation) 
by cell processes that express smooth muscle actin, was continuous on the opposing 
arterioles but sparsely distributed on the capillary-like arcade segment. This observation is 
consistent with the hypothesis that collaterals form from the fusion of capillary-like 
Femoral 
artery
Late 
caudal 
femoral 
artery
collaterals
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branches sprouting from established arterioles rather than forming de novo.  This concept is 
also congruent with our findings that proto-collaterals express the arterial endothelial cell 
marker, ephrin-B2 [2]. Why collaterals form only between certain distal arterioles is not 
known but may be related to small localized differences in oxygen tension and VEGF 
gradients or hemodynamic forces.  The latter would be highly disturbed when sprouting 
nascent collaterals first cross-connect opposing arterial trees and experience high pressure 
from both ends.  In this regard, both increased shear stress and wall stress can increase 
VEGF-A expression in vascular tissue [31-33].  Interestingly, as discussed above, BALB/c 
embryos, which form many fewer collaterals than C57BL/6, have sharply reduced 
expression of PDGF-B in the pial collateral zone at E18.5 [2].  These findings support the 
idea that PDGF-B expression during embryogenesis is necessary to recruit pericytes to 
newly formed collaterals and insure their persistence.  


 B  A, VEGF-A expression dictates pial collateral density at embryonic day (E)16.5.  Embryos 
underexpressing VEGF (Vegf lo/+) form fewer collaterals at this developmental stage than wildtype 
littermates.  Conversely, embryos overexpressing VEGF (Vegf hi/+) form significantly more collaterals.  B, 
Collateral vessels are forming by ~E14.5 and often appear as narrow endothelial cords situated superficial to 
the existing pial capillary plexus. 
Based on the above findings, a model of cerebral collateral formation during embryogenesis 
is beginning to emerge (Fig8 C).  CLIC4 deficient mice form fewer collaterals [16], and 
CLIC4 is known to promote endothelial proliferation, lumenization and network formation 
[34,35].  Shukla et al. showed in vascular smooth muscles cells that TGF-β signaling 
stimulates cytoplasmic CLIC4 to associate with the transcription factor Schnurri-2 [36], plus 
activated Smads and β-catenin, leading to nuclear translocation and induction of VEGF-A 
expression [37]. VEGF has an essential role in vessel formation, branching and guidance.  
The longer splice isoforms (VEGF164 and VEGF188) contain basic amino acids that 
interact with negatively charged heparin sulfate side chains on cell surfaces and 
extracellular matrix molecules, serving to anchor VEGF near the secreting cell.  Endothelial 
cells respond to this gradient via Flk1 (VEGFR2) and initiate/interact with multiple 
intracellular signaling cascades (see [38-40] for recent reviews) that modulate cell activity 
and phenotype.  During angiogenesis, VEGF signaling in tandem with notch/delta signaling 
lead to the “selection” of an endothelial tip cell that undergoes cellular changes and extends 
filopodia toward the VEGF source.  Neighboring cells are signaled to become stalk cells, 
trailing behind the mobile tip cell.  Together they extend a cord that becomes a branch of the 
existing vessel.  The local concentration of VEGF available to bind to Flk1 is modulated by 
the presence of Flt1 (VEGFR1), which in turn regulates endothelial branching [41,42].  Flt1 
has high affinity for VEGF and is believed to act as a VEGF sink, reducing the amount of 
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VEGF available to bind to Flk1 and initiate kinase activity.  This cord of cells extends and 
joins with a similar cord, or to an arterial branch.  The cord then develops a lumen, becomes 
pressurized by blood and forms a proto-collateral. This simplified model of collaterogenesis 
can be expected to undergo much refinement as future work unfolds.    
Extent of the collateral circulation varies widely among individuals 
In the late 19th century various mammalian species were noted to have differences in both 
the presence of inter-coronary artery collaterals and the amount of tissue injury after ligation 
of one coronary artery [43].  Schaper [44] was the first to systematically compare infarct 
size, risk zone and collateral-dependent flow.  Rat, rabbit, pig, sheep, pony, baboon and 
wild boar sustained large transmural infarctions after coronary ligation, in association with 
low collateral flow, while dog and cat experienced more slowly developing and incomplete 
infarctions associated with greater collateral flow, and guinea pig sustained little or no 
infarction and had collateral flows approximating those present before ligation.  These 
findings were confirmed by Maxwell et al. [45]. Large variations in collaterals and ischemic 
lesion size have also been described in humans with regard to the presence and diameter of 
the ophthalmic artery collaterals and the bilateral anterior and posterior communicating 
arteries of the circle of Willis (the so-called “primary” cerebral collaterals) [46,47].  Similar 
variability in these primary collaterals has been described in experimental animals, 
including inbred mouse strains [48].   

C  Model depicting possible mechanisms of collaterogenesis in the cerebral circulation of the embryo.  
TGF-β, CLIC4 and other factors increase VEGF expression.  VEGF isoforms and Flt1 create a local VEGF 
gradient which causes endothelial cells to express a tip cell phenotype, extend filopodia and mobilize up the 
gradient.  Neighboring endothelial cells receive tip cell signals that suppress the tip cell phenotype and initiate 
a stalk cell phenotype. This proto-collateral plexus extends over the pial capillary plexus and joins other 
chords emanating from opposing arterioles, followed by lumen formation and cross-connection of the arterial 
trees.  See text for additional details. 
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There is also recent evidence of significant variation in the pial collateral circulation in 
humans (discussed below).  And large variation in clinical outcomes of patients with PAD 
suggests significant variation in collaterals to the lower extremities.  However, due to the 
small size of most collaterals, an analysis of the native collateral circulation in the 
extremities of healthy individuals has not been conducted.  Thus, it is not known whether 
this variation reflects differences in collateral extent before disease, or differences in 
remodeling after it develops.    
The severity of tissue injury and functional impairment in patients with CAD, PAD and in 
individuals suffering acute thromboembolic stroke are known to vary widely.  Although 
much effort has been directed at identifying the potential sources of this variation, the 
possibility that individual differences in the native collateral circulation exist and contribute 
significantly has received little attention.  Findings from several recent studies, however, 
support this hypothesis.  In an important recent paper, Meier, Seiler and colleagues [5] 
reported data collected over ten years from 106 healthy human subjects showing that 
pressure-derived coronary collateral flow index (CFIp), an index of conductance of the 
collateral circulation, varied by 10-fold.  This variation is remarkable, since these 
individuals were free of known disease.  Although CFIp may be affected by other factors 
[49], this suggests that significant variation exists in extent of the native coronary collateral 
circulation in humans.  That is, the variation they measured could not result from 
differences in collateral remodeling, which is known from animal studies to vary depending 
on degree and duration of obstruction [50-57].  In contrast, other studies—whether using 
CFIp or other measures (eg, angiography)—examined patients with CAD or PAD, wherein 
differences in collateral remodeling confound any interpretation vis-à-vis extent of the 
native collateral circulation.   
Additional findings in patients with stroke support the concept that collateral extent varies 
in healthy human tissues.  Building on earlier studies [eg, 58], Bang et al. [59] and others 
[60-62] used dynamic angiography in patients suffering acute proximal obstruction of the 
MCA and found that retrograde perfusion of the MCA tree downstream from the occlusion, 
which is dependent on collateral extent between the MCA, ACA and PCA trees, varies 
substantially.  Since obstruction is sudden in thromboembolic stroke, individual differences 
in collateral remodeling are eliminated as a complication.  However, variation in other 
factors, such as downstream stagnant thrombosis, thrombolysis and arterial pressure, can 
affect collateral-dependent retrograde perfusion.  Further support for significant variation in 
collateral abundance is provided by the well known observation that residual flow to the 
extremities shows large differences after acute trauma-induced interruption of a major 
proximal artery in otherwise healthy individuals [63].  
Natural genetic variation contributes to variation in the native collateral circulation 
The above differences could be due, in part, to polymorphisms in genes controlling the 
formation and maturation phases of collaterogenesis. Until recently [2,4,14-16], nothing was 
known about this possibility.  Zhang and coworkers [4] quantified native pial collateral 
dimensions in 15 inbred mouse strains.  Remarkably, pial collateral density differed by 15-
fold (Fig. <D). They then correlated this and other parameters with infarct volumes 
measured 24h after permanent MCA occlusion, the latter reported by Keum and Marchuk 
for the same strains [64]. A Poiseuille-like equation—incorporating collateral number, 
diameter, length, hematocrit and MCA territory among the strains—closely predicted 
variation in infarct volume [4]. These investigators also measured increased collateral lumen 
diameter (remodeling) induced by permanent MCA occlusion, and observed wide 
differences among the strains [4]. Interestingly, the variation did not follow the strain-
specific pattern for native number and diameter shown in Figure <D. This suggests that 
different signaling mechanisms are responsible for collateral formation versus remodeling 
(confirmed below).  The finding of such large natural genetic variation in the collateral 
circulation is surprising, since the general and lymphatic circulations appear to be 
comparable in these strains.  This work also provided a mouse phenotype database useful 
for future work aimed not only at studying stroke, but also for identifying the genetic loci 
underlying this wide collateral variation, including optimal strains to cross for QTL and 
haplotype mapping to identify candidate genes regulating collaterogenesis and remodeling.   
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As discussed above, variation in coronary collateral abundance has been described among 
non-murine mammalian species [44,45]. Since those species examined were mostly inbred 
or domesticated, it is not clear if the differences reflect true variation among species, or if 
other inbred strains within a given species would exhibit the range of variation seen in mice 
[4] and, potentially, humans [5].  In this latter study in which 739 patients with stable CAD 
were followed over a 10-year interval, individuals with good collateral flow index (CFIp >
0.25) had a 75% decrease in mortality, compared to those with poor CFIp values.  However, 
as in previous studies examining patients with ischemic disease, it is not possible to 
differentiate the contribution of variation in native extent versus collateral remodeling.  
Elsewhere, in patients with acute thromboembolic MCA stroke, those with angiographic 
evidence of good pial collateral flow had better functional recovery and less incidence of 
hemorrhage following thrombolytic therapy [58-62].  These benefits were attributed to less 
ischemic destruction of brain tissue and blood vessel walls, secondary to better collateral-
dependent retrograde perfusion of the MCA tree.  However, since pial collaterals could not 
be directly imaged, whether differences in retrograde perfusion in stroke patients reflect 
differences in native collateral extent versus other mechanisms awaits advances in imaging. 

 <D  Wide variation in infarct volume 24h after permanent unilateral MCA occlusion is highly 
correlated with wide variation in collateral number and diameter (per hemisphere), and less with MCA tree 
territory, among 15 inbred mouse strains (stain names arranged in same order in all 3 bar graphs).  B6, 
C57BL/6.  From Ref 4.  Infarct volume from Ref 64. 
Genetic loci linked to variation in the native collateral circulation and severity of 
ischemic tissue injury 
Besides using the candidate gene approach, which showed that variation in expression of 
VEGF-A and CLIC4 contributes to variation in collaterogenesis [15,16], we recently 
undertook an unbiased approach to define the underlying genetic architecture and regulatory 
loci governing variation in collateral extent [65].  Pial collateral number and diameter were 
determined in 221 progeny of a C57BL/6 x BALB/c reciprocal intercross, and subjected to 
genome-wide mapping to identify QTL governing the large difference in these traits in the 
parental strains.  Four highly significant QTL were identified on chromosomes 1, 3, 7 and 8, 
including epistasis between the first two loci.  The loci together account for 70% of the 15-
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fold variation in native collateral number present in the F2 population (the same variation 
seen in the parentals).  The most significant QTL on chromosome 7 (accounting for 37% of 
the variation in number) was also highly linked to variation in native collateral diameter (no 
other QTL for diameter were found).  Chromosome substitution strain (CSS) analysis, using 
lines from the A/JC57BL/6 strain set, confirmed the functional (causal) importance of this 
locus.  Association mapping using the above-mentioned 15-strain database pinpointed a 
significant (p=0.00002) region within the chromosome 7 QTL harboring several candidate 
genes that are currently under investigation.  Interestingly, variation in collateral remodeling 
after permanent MCA occlusion was linked to a QTL on chromosome 11.  No differences in 
native collateral extent or remodeling were evident as a function of sex or parental 
genotype. 
Thus, collateral number, diameter and collateral remodeling are heritable complex traits, 
with one QTL on chromosome 7 accounting for the majority of the variation in number and 
diameter between the C57BL/6 and BALB/c strains [65].  Interestingly, using identical F2 
crosses, the same QTL on chromosome 7 was linked to necrosis score and recovery of blood 
flow after femoral artery ligation [66] and to infarct volume 24h after permanent MCA 
occlusion [63].  CSS analysis confirmed causality in both studies.  Our findings suggest that 
this locus has a central role in collaterogenesis, and through this effect, constitutes a major 
physiological mechanism underlying these previously reported QTL.  Recently, Meier, 
Seiler and colleagues [67] examined gene expression in 50 patients stratified for poor versus 
well developed collateral flow (CFIp < vs. > 0.21, respectively—the latter with no 
angiographically significant CAD).  Four genes, ACTN1, EGFL7, LIMS1 and RPS6KA3, 
were differentially expressed, consistent with the concept that genetic factors may play a 
role in determining the abundance of native coronary collaterals in healthy individuals.  
Interestingly, EGFL7 is a stalk cell protein.  Zhang, Doevendans et al. [68] genotyped 226 
CAD patients, stratified for good versus poor collaterals, at SNPs in 54 genes potentially 
involved in collateral remodeling, identifying 9 that may be linked to the abundance of 
angiographically visible collaterals.  These interesting studies identify genes that may be 
involved in variation in formation of the collateral circulation or its remodeling in 
obstructive disease. 
Environmental factors cause variation in the native collateral circulation: Collateral 
rarefaction
The mouse studies discussed above identify several signaling molecules important in 
collateral formation and show that natural variation in specific genes or regulatory loci are 
causally involved.  What about “environmental” (as opposed to “genetic”) factors?  Are 
there conditions, risk factors or diseases that cause loss of collaterals, narrowing of their 
diameter or an increase in their length/tortuosity?  Are there environmental factors that have 
opposite effects, providing protection should occlusive disease develop?  Like most of the 
topics addressed in this chapter, little is known.  This is, in part, because studies examining 
collateral function in disease or in the presence of risk factors have not examined native 
collateral extent—which is not easily measured.  Indeed as discussed in subsequent 
chapters, several decades of research have identified a number of diseases and risk factors 
that alter (mostly impair) collateral remodeling in arterial obstructive settings.  
Nevertheless, recent studies are beginning to examine these questions.  Although collateral 
density and diameter in young adult mice (3 months age) are largely specified within the 
first 3 postnatal weeks (Fig. ?) [2,14-16], collaterals—at least in the brain—continue to 
increase in length (ie, tortuosity) during growth to adulthood [2]. This change, plus the early 
postnatal phase of collateral maturation [2] (eg, Fig. ?), suggests that environmental 
factors present after birth could impact the extent of the collateral circulation in adults.      
One unavoidable risk factor strongly influenced by environment is natural aging (although 
aging also evidences significant genetic variation).  It is well known that aging is associated 
with poor collateral remodeling in obstructive disease [69-71]. Aging may also cause 
arteriolar [72,73] and capillary rarefaction in certain tissues [74,75].  Our group together 
with S. Epstein and colleagues recently examined whether aging affects the native collateral 
circulation [unpublished results].  Collateral density and diameter declined progressively 
among 3, 16, 24 and 31 month-old mice, and collateral tortuosity increased.  These changes 
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were associated with a decrease in conductance of the pial collateral circulation, eg, 8-fold 
in the 24 month-old group. Furthermore, this collateral rarefaction occurred in both 
hindlimb and brain, in association with “age-dose-dependent” increases in ischemia and 
tissue injury after femoral artery and MCA ligation.  In support, an earlier study noted fewer 
pial arteriolar anastomoses in aged rats [73].  While the mechanism for these changes has 
not yet been determined, age-associated rarefaction of arterioles has been linked to reduced 
eNOS/NO activity/bioavailability [Epstein et al., unpublished]. Furthermore, although 
eNOS (and eNOS/iNOS) deficient mice have no difference in collateral extent at birth or 3 
weeks later in hindlimb or brain—indicating that eNOS/iNOS is not required for collateral 
formation or maturation—collateral density declines by 3 months and more by 6 months of 
age in both tissues [77].  These data show that eNOS is required for maintenance of the 
native collateral circulation. They also suggest that aging, “life-style” factors, and 
pathologic conditions that induce endothelial dysfunction could cause collateral circulatory 
insufficiency before obstructive disease develops.   

Environmental factors that increase extent of the native collateral circulation  
Neocollateral formation.  Can native collateral density or diameter be increased by 
pathologic or other environmental conditions? Could preventative physiologic or 
therapeutic strategies be developed to achieve this before or after onset of obstructive 
disease?  Other chapters in this volume address the mechanisms whereby increased flow 
and shear stress imposed by arterial obstruction initiate collateral remodeling.  However, 
whether new collaterals (“neocollaterals”) can form in adult tissue is a long-standing 
controversial question.  If genetic background can limit the extent of the collateral 
circulation in healthy tissues, understanding if it is possible—and how—to induce formation 
of neocollaterals in obstructive disease are critical questions that need to be answered in 
order to enable development of collaterogenic therapies.   
It has been difficult to determine if the appearance of more collaterals in experimental or 
clinical studies of artery obstruction in heart or peripheral limbs are from formation of 
neocollaterals or from shear-dependent positive remodeling of collaterals that were too 
small to be detected before obstruction.  Counting smooth muscle actin-positive vessels in 
tissue sections taken from the region between the crowns of artery trees, given their 3-
dimensional distribution deep in most tissues, also has limitations.  Location of their 
collateral zones is needed to prevent counting distal arterioles within the trees themselves.  
This is further complicated by the fact that chronic dilation and increased flow within an 
arterial tree stimulate proliferation and migration of smooth muscle cells onto the arterial 
end of the capillaries [77-79].  These muralized capillaries then enlarge their diameters and 
lengthen the terminal arteriole end of the tree—a process termed distal muscularization or 
arterialization [77]. Chronic dilation and increased flow in the arterial feed vessels upstream 
of a collateral are also caused by the drop in resistance and pressure below the collateral 
when the trunk of the arterial tree downstream from it becomes obstructed.  Predicted flow-
mediated dilation of the upstream arterial feed vessels could also contribute to this.  We 
have recently confirmed that an immediate and sustained dilation and increased flow occur 
in the arteries immediately upstream of hindlimb collaterals after femoral artery ligation. 
This provides a significant “feed-forward” component of collateral perfusion to the at-risk 
limb [76].  Prolonged upstream dilation may also promote outward remodeling of the feed 
arteries [80].  Clearly, better understanding of the environmental (and genetic) factors that 
control and modulate collateral outward remodeling in healthy and obstructed tissues is 
needed. 
Distal muscularization alone cannot form a neocollateral between two opposing trees when 
one is occluded.  Formation requires muscularization across the length (ie, hundreds of 
microns) of a pre-existing or newly formed capillary.  The latter can occur from ischemic 
sprouting or intussusception, followed by lumen expansion, muralization and wall 
thickening.  Pruning of connections to venules is also required.  Price and Skalak used 
theoretical modeling to show how pruning in a collateral circuit could occur [81].  And 
experimental studies have confirmed that elevated shear stress across obtuse branch angles 
caused by reversed flow can induce pruning [82-85].  Although native collaterals are more 
easily quantified in the brain than in other tissues, whether neocollaterals form after 
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permanent MCA occlusion is nevertheless also controversial [86,87].  We have recently 
found supportive evidence [4]: Among 15 inbred mouse strains, 4 strains formed 
neocollaterals after MCA occlusion, and these were strains that had particularly low pre-
existing collateral densities (including BALB/c).  This genetic variability in the capacity to 
form neocollaterals could help explain some of the previous disagreements in the literature.  
In addition, capillaries in the pia mater are lost after birth.  Thus, it may be particularly 
difficult to form neocollaterals after stroke, compared to other tissues.   Mac Gabhann and 
Price recently demonstrated in an elegant study that neocollaterals form in the mouse 
spinotrapezius muscle after arterial ligation [109].  Recovery of perfusion in BALB/c mice 
was associated with arterialization of capillaries interconnecting the ligated and intact 
arterial trees, followed by remodeling of their diameter to twice normal.  These findings [4] 
begin to address a long-standing question that has clinical significance and provide model 
systems to study basic mechanisms responsible for—and possible therapeutic approaches 
to—induce neocollateral formation.   
The intriguing A-V fistula hindlimb model [80] may provide a model to investigate shear 
stress as a potential stimulus for neocollateral formation.  In addition, two interesting 
embryo ligation models have been introduced.  le Noble et al. [88, see also Chapter 2] 
showed in the early embryonic chick yolk sac that ligation of the right vitelline artery 
caused the distal venous plexus that it flows into to reverse flow, express arterial endothelial 
cell markers and remodel into an extension of the left vitelline artery tree into the right side 
of the yolk sac.  There it drained into the distal right vitelline artery tree which, experiencing 
reversed flow, remodeled into a venous tree expressing venous endothelial cell markers.  
Gray et al. [89] showed something similar in the zebrafish embryo.  Ligation of the aorta at 
its midpoint induced remodeling of intestinal inter-connections to form a collateral circuit 
back to the aorta distal to the ligation, resulting in little or no disturbance in tail growth.  
Defining the molecular mechanisms guiding formation of these collateral-like networks, 
which in these models involve ligation-induced co-opting of venous plexi in the highly 
plastic embryonic vasculature, may provide insight into how neocollaterals might form in 
the adult.  Whether neocollateral formation in occlusive disease is driven by ischemic and/or 
hemodynamic signals is an important unanswered question.  In addition, understanding the 
molecular-genetic mechanisms governing formation of the collateral circulation in the 
embryo may provide clues regarding the signaling molecules responsible for formation of 
neocollaterals in the adult.   
Does chronic “exercising of collaterals” increase extent of the native collateral 
circulation?
Many reports have shown that exercise training has a beneficial effect in patients with CAD 
[90,91] and PAD [92] and in animal models of arterial occlusion [93]. The latter have 
identified several mechanisms, including enhanced collateral remodeling, improved flow-
mediated dilation of arterial beds upstream of the collateral network, and lower resistance 
below the collaterals.  However, Yang and colleagues found no evidence that exercise 
training increases collateral extent [94]. Six weeks of treadmill training of adult rats 
augmented collateral-dependent flow by 70%, when measured after acute femoral artery 
ligation at the end of the training period and compared to sedentary controls.  However, the 
increase was abolished by acute L-NAME given 30 minutes before blood flow 
measurement.  This, together with pressure measurements, suggested that all of the training-
induced increase was derived from improved NO-dependent flow-mediated dilation 
upstream of the collaterals and reduced microvascular resistance below them [94].  Despite 
these negative findings, it is noteworthy that metabolic arterial dilation during increased 
tissue activity favors increased pulsatile and mean pressure in collaterals.  If prolonged, this 
could increase oscillatory shear and wall stress, ie, could “exercise” collateral endothelial 
and mural cells.  This may induce collateral remodeling in healthy tissue.  Zbinden et al.
reported that a marathon runner free of angiographic CAD evidenced an increase in CFIp
after 6 months of aerobic training (although lower arterial pressure may also have factored 
into this) [95]. None of the above studies measured collateral diameter after exercise 
training—a metric that could be obtained in experimental animals. 
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In line with the above concept, coronary perfusion occurs predominantly during diastole, 
when coronary resistance vessels are partially dilated due to reduced extravascular 
compression and smooth muscle tone. Thus, prolonging diastole could enhance 
hemodynamic stimulation of collateral endothelial and mural cells, and like the possible 
effect of exercise, promote collateral outward remodeling.  Patel et al. [96] retrospectively 
studied angiographic collateral scores in acute MI patients with heart rates ≤ 50/min (30 
patients) vs. ≥ 60/min (31 patients). They found a significantly greater proportion with sinus 
bradycardia had well-developed collaterals than the control group.  Whether this could also 
occur to native collateral diameter in healthy individuals is not known.  In animal models, 
bradycardia induced by either pacing or alinidine treatment, increased capillary density in 
hearts, with potential involvement of elevated levels of angiogenic factors such as VEGF, 
bFGF, etc [97-99].  Also, combining acute coronary artery ligation or ameroid-mediated 
progressive occlusion with drug-induced bradycardia in rat, Dedkov, Tomanek et al. [100] 
observed increased arteriolar length density, improved regional coronary perfusion, and 
better preservation of cardiac function.  The authors postulated that increased myocardial 
preload (stretch) and/or enhanced perfusion augments the native collateral circulation [100-
102], possibly by increasing collateral remodeling.  Likewise, aortic balloon pump and 
external counterpulsation (ECP), which favor increased coronary perfusion during diastole, 
improve collateral-dependent myocardial perfusion (see Chapter 12).  It would be 
interesting to know if these intriguing findings could be extrapolated to native collaterals, ie, 
if bradycardia or ECP (or exercise) could augment collateral diameter in healthy individuals 
at risk from poor native abundance. 

Genetic and environmental contributions to variation in arteriogenesis 
Extensive research examining “environmental” factors, such as disease processes and risk 
factors (diabetes, smoking, etc), physiological mechanisms (eg, leukocyte homing, 
cytokines, growth factors) and therapeutic approaches (eg, protein, vector-delivered, cell-
based), for effects on collateral remodeling has been reviewed recently [24,25,52-57] (see 
also other Chapters in this book) and will not be discussed here.  Instead, our comments 
below address recent evidence that genetic factors can also impact arteriogenesis (see also 
Chapter 7 regarding epigenetic contributions).  Scholz and co-workers first called attention 
to this possibility in their seminal study showing that recovery of perfusion after femoral 
artery ligation differed significantly between C57BL/6 and BALB/c mice [1].  This was 
subsequently confirmed [14,17,66,103-106], including studies that differentiated collateral 
remodeling from differences in angiogenesis, arterial pressure and native collateral extent—
factors that affect recovery of perfusion [14,17].  The influence of genetic background on 
arteriogenesis has recently been further defined in the 15-strain mouse study of Zhang et al.
[4].  Interestingly, findings in this and previous studies [14-16] examining both pial and 
hindlimb collaterals, indicate that genetic differences in collateral remodeling may be shared 
among the collateral circulations of different tissues, suggesting similar mechanisms direct 
collateral remodeling in different tissues.  However, this may not be the case for flow-
mediated outward remodeling of collaterals versus arteries; the order of mouse strain 
responsiveness reported in two studies of carotid artery remodeling do not agree with our 
findings for collateral remodeling:  The amount of flow-mediated outward remodeling of 
the carotid was A > AKR > FVB/N > SWR > C57BL/6 > C3H/He > SJL > DBA/2 > 
BALB/c > 129/Sv in one study [108; measured 4 weeks after complete left carotid ligation] 
and was C57BL/6 > FVB/N > DBA/2 > SJL = C3H/He in another study [109; 2 weeks after 
partial left carotid ligation).  In contrast, outward remodeling of pial collaterals after MCA 
occlusion was: SWR > A > AKR > C3H/He > CBA2 > KK/HI > 129S1/Svlm > NZW/Lac 
> NOD/ShiLt > BALB/cBy > C57BL/6 = SJL = DBA/2 > C57BLKS = FVB/N [4]. In 
addition, collaterals grow vigorously in the longitudinal direction during remodeling, 
compared to conduit artery remodeling (however, this increase in collateral tortuosity 
increases resistance).  Together, the above findings demonstrate that genetic polymorphisms 
among individuals not only affect baseline extent of the native collateral circulation 
available for remodeling, but also affect activity of the arteriogenic pathways and/or 
responsiveness of collaterals to endogenous and exogenous arteriogenic molecules and, 
potentially, therapies.   
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Concluding comments – More questions than answers 
The importance of the native collateral circulation is beginning to come into focus.  Several 
unanswered questions, in addition to those stated above, warrant mention.  Does the native 
collateral circulation serve a function in healthy tissues?  Does it provide an adaptive 
advantage when abundant?  Arterioles commonly branch off of collaterals in brain (eg, Fig. 
2) and other tissues.  In fact, pial collaterals in 15 strains of mice, including strains with only 
one or two collaterals, give rise to on average ~3 penetrating arterioles per collateral, 
regardless of strain [4].  So collaterals can serve as arteriole “scaffolds” across the collateral 
zone, supplying the surrounding tissue.  It is possible that collaterals in tissues, particularly 
those subjected to mechanical activity (eg, muscle, intestine), insure better overall 
oxygenation under all functional states. For example, cerebral pial collaterals may 
contribute importantly to the well known and important “steal” behavior so prominent in 
this circulation.  However, unlike the general and lymphatic circulations, the collateral 
circulation is clearly not required.  For example, the distance between the crowns of the 
MCA and ACA trees in SWR and BALB/c strains—strains with almost no pial collaterals—
are comparable to other strains with abundant collaterals.  The general circulation of these 
strains apparently solves the dearth of collateral scaffolding by forming more extensive 
intracerebral terminal arteriolar trees to perfuse the cerebral parenchyma that underlies the 
would-be pial collateral zones. But does “fitness” then follow collateral extent?  
Unfortunately, it is not clear from existing phenome databases whether the mouse strains 
that we have identified with poor collateral extent perform more poorly in exercise or 
mental (or digestive?) tests. 
Why is there such wide genetic variation in the collateral circulation, compared to the 
general and lymphatic circulations?  This may arise because the collateral circulation is not 
required for survival.  It thus may not have evolved redundancies that compensate for small 
(or large) changes in expression or protein function of collaterogenic genes—whether 
occurring by naturally arising gene variants or by epigenetic or environmental 
mechanisms—that have evolved in pathways governing formation of the general and 
lymphatic circulations.  For the same reason, little selective pressure may exist to remove 
deleterious mutations in collaterogenic genes within a population.  Of course, the collateral 
circulation does aid survival and fitness when obstructive disease strikes. However, these 
diseases and adverse environmental effects commonly arise or accumulate over time, well 
after the peak reproductive years.  
At least in mice, the primary collateral plexus forms in a narrow and relatively late 
embryonic window. And these nascent collaterals then mature in a similarly narrow 
postnatal window.  Are the signaling pathways governing these processes particularly 
susceptible to environmental disturbances?  Are collateral endothelial cells specialized to 
insure that these vessels persist despite the adverse local hemodynamic environment?  Are 
they specialized to direct the robust radial and longitudinal collateral remodeling in 
occlusive disease?  Answers to these questions await us.    
A better understanding of how collaterals form and are maintained—and the genetic, 
epigenetic and environmental factors that affect these processes—may lead to new 
approaches to recognize, prevent and possibly treat collateral insufficiency before or after 
occlusive disease strikes.  Moreover, since native collateral number and diameter vary 
widely in mice and apparently also in humans, the failure to stratify patients in previous 
clinical trials of angiogenic/neovascular treatments may have contributed to the poor 
outcomes.  Stratification of test groups according to pre-existing collateral extent may aid 
future trials.  As well, patients with scarce native collaterals might benefit less from 
therapies aimed at augmenting collateral remodeling.  Finally, the development of less 
invasive assessments of collateral extend could allow assignment of risk severity for stroke, 
CAD and PAD in healthy individuals, and aid adoption of preventive lifestyles or other 
measures.  
In conclusion, the collateral circulation—at least in the cerebral circulation of the mouse, 
forms initially as a plexus late in embryogenesis, after the general arterial-venous 
circulation has formed.  This plexus then undergoes pruning and maturation early 
postnatally.  Genetic background has dramatic effects on these processes. Individual 
differences in the extent of this circulation may arise from natural polymorphisms that alter 
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expression of genes driving collaterogenesis, as well as environmental factors impacting 
formation and maintenance of these unique vessels.  A more thorough understanding of 
collateral biology is not only fundamental, but may also help identify genetic variants and 
signaling pathways underlying differences in collateral abundance in humans. Such 
information may help in the development of therapies to promote formation of new 
collaterals in individuals that have or are at risk for occlusive disease. 

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$: Arteriogenesis, the outward remodeling of preexisting small collateral arterial networks, occurs as a 
response to vascular occlusion or stenosis and importantly determines the clinical outcome of ischemic 
cardiovascular diseases. Distinct differences exist between animal strains, and patients with regard to collateral 
development. Besides differences in the efficiency of collateral recruitment and maintenance, this may also be 
explained from differences in the arterial branching architecture and number of pre-existing collaterals, prior to 
the occurrence of arterial occlusion. Since the branching architecture of the major arteries and their side-
branches is established before birth, and during early post-natal stages, we postulate that conditions during early 
life, contribute to establishing the native collateral arterial network. In higher vertebrates, formation of branched 
vascular networks during embryogenesis involves a genetically hardwired component regulated by neural 
guidance genes and members of the notch signaling family, as well as a hemodynamic component. For 
establishing a stable branching architecture, the interaction of hemodynamics and neural guidance genes is of 
central importance. Hemodynamic forces can control the global branching architecture of the arterial network, 
vessel dimensions, and maintenance of vessel identity by regulating neural guidance genes. Neural guidance 
genes control arterial-venous identity and mediate guidance events that control and fine-tune positioning of 
growing vessels. Here we want to address the molecular pathways controlling arteriolar branching architecture 
during embryogenesis, in the context of the formation of preexisting collateral networks, and highlight the 
conserved function of molecules relevant for arterial differentiation in the embryo, during adult arteriogenesis.
Introduction  
Arteriogenesis, the formation of a collateral artery network to bypass a stenosis, is 
physiologically the most relevant process for restoring perfusion to hypoperfused or ischemic 
vascular beds. Although the functional significance of arteriogenesis is appreciated, its 
biology is still poorly understood. The recent failures of clinical therapeutic angiogenesis 
trials aimed at stimulating vascular growth in ischemic cardiovascular diseases emphasizes 
the need for a more rational approach to this area of clinical cardiovascular medicine. Both 
clinical experience, and experimental analyses in pigs, dogs, rats and mice uncovered distinct 
differences between species, animal strains and between patients with regard to spontaneous 
collateral development, suggesting involvement of a strong genetic component. The nature of 
the genetic differences in arteriogenesis responses may involve variability in responsiveness 
to hemodynamics (flow/pressure), the ability to recruit blood derived cells 
(macrophages/monocytes/progenitor cells), or anatomical variability in arterial branching and 
number of preexisting collateral arteries. Clinical and experimental evidence indicate that 
hemodynamic forces exerted by blood flow, are crucial to initiate and propagate collateral 
growth. The molecular pathways linking the biophysical signals exerted by arterial flow with 
arterial growth are only partly characterized but involve activation of molecules relevant for 
controlling vascular tone (including nitric oxide, Klf2), vessel wall remodeling (matrix 
metalloproteinases), members of the Wnt-signaling pathway, VE-Cadherin, VEGF receptors, 
and the Notch signaling pathway (see the chapter by Limbourg). Clinical interventions aimed 
at stimulating hemodynamic forces in patients suffering from arterial stenosis show the first 
positive results and are discussed in more detail in Chapters 12 (Buschmann).  In addition, 
experimental evidence suggests that growing collaterals are in an inflammatory state. The 
remodeling process associates with increased expression of adhesion molecules (ICAM-1, 
VCAM-1), chemoattractants (including MCP-1), supporting attraction, and invasion of 
circulating cells. Especially circulating monocytes/macrophages appear to positively affect 
arteriogenesis. Therapeutic interventions with GM-CSF have shown that stimulating influx of 
monocytes associates with increased arteriogenesis, but unfortunately also adversely affects 
atherosclerotic plaque progression, a major risk factor for developing arterial occlusion. Also 
application of various progenitor cell types have been shown to give a functional flow 
improvement to hypoperfused areas albeit at the risk for developing tissue neoplasia or 
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tumors. Therapeutic interventions with such agents are discussed in Chapters 11 (van Royen). 
Besides hemodynamics and inflammatory pathways, a third component relevant for 
arteriogenesis that has thus far not received a lot of attention is the arterial architecture and 
design of preexisting arterial collateral networks. In general, more preexisting arterial 
collaterals, with a larger vessel caliber, predicts a more efficient recruitment and enhanced 
flow delivery upon arterial stenosis. From the standpoint of prevention of ischemic damage, 
understanding how number and size of preexisting collaterals can be modulated is of clinical 
relevance. Especially in those organs where arterial occlusion results in severe end-organ 
damage, for example in the brain, and where spontaneous collateral development or 
pharmacological stimulation maybe to slow, optimizing collateral circulations prior to 
stenosis, is an intriguing therapeutic challenge. Recent experimental evidence provided by the 
group of Faber (see contribution in Chapter 1) has clearly shown a direct association between 
cerebral arterial branching architecture and stroke volume upon occlusion of the mid-cerebral 
artery. The challenge is to find genetic loci that link vascular architecture with improved 
collateral flow and clinical outcome after arterial stenosis. Since the architecture of the major 
arteries and their side branches is established at time of birth, some genetic components 
relevant for collateral arteriogenesis, maybe operational during fetal life. From developmental 
biology point of view, the outstanding questions are therefore: a) when are preexisting 
collateral arterial networks formed, b) which molecular pathways are involved in determining 
the number, size and maintenance of preexisting collateral arteries, and c) how does their 
functionality arise (type and amount of smooth muscle cells, wall dimensions, capacity to 
dilate/constrict). Extensive research during the last decade has led to the discovery of several 
novel cellular processes and molecular pathways, governing growth of arterial-venous 
networks during embryogenesis. Here, these new developments will we discussed in the 
context of the collateral arteriogenesis, and potential therapeutic strategies. 
Choice of arterial patterns relevant for collateral arteriogenesis 
The potential contribution of the arterial branching pattern in arteriogenesis can be 
demonstrated based on two examples (Fig. <).  
In one case (Fig. <, left panel) we consider a completely dichotomous arterial branching 
pattern, as for example can be observed in the coronary system. The other case (Fig. <, right 
panel) is an arterial pattern with many arterial-arterial connections, as for example can be 
observed in the intestinal circulation. In the arterial tree with a dichotomous branching 
pattern, exposed to arterial occlusion, the lack of preexisting arteriolar-arteriolar connections, 
prevents the fast recruitment of collateral pathways, leading to insufficient blood flow 
delivery to sites distal of the occlusion in the acute phase after stenosis. Pending the oxygen 
needs of the target organ, this scenario can lead to severe tissue damage and loss of organ 
function. Theoretically, it may be argued that due to the occlusion and redistribution of blood 
flow, adaptive remodeling occurring at the capillary level induces formation of collateral 
connections. Some of the most distal small arterioles are interconnected via the capillary 
network, and increasing the caliber of such connections may facilitate collateral flow. Since 
arterial stenosis results in shunting of flow to other parts of the arterial tree, and increased 
blood flow is a stimulus for capillaries to be “upgraded” into small arterioles, such process 
may indeed result in the formation of small collateral connections in distal areas. However, 
this adaptive remodeling process occurs relatively slow, and it is therefore debatable whether 
it has physiological relevance during the early phase after arterial occlusion.  In contrast, 
organs with an arterial system with many preexisting arterial-arterial connections (Fig. <, right 
panel), most likely don’t suffer form loss of organ function after occlusion. In this case, after 
occlusion, many preexisting pathways prevent complete loss of flow to the areas distal of the 
occlusion. Of course, the efficacy of flow delivery in this scenario depends on the caliber of 
such arteriolar connections and their contractile status. Thus far, most experimental evidence 
indicates that the redistribution of flow after arterial occlusion, results in increased shear 
stress in collateral arterioles concomitantly with activation of vasodilatory pathways (see 
chapters on NO by Schaper, Unthank), collectively resulting in a positive outward remodeling 
of the preexisting arteriolar connections. Pending on the site of occlusion, pressure gradients 
may also change, and modulate smooth muscle cell responsiveness to growth factors, or 
recruitment of progenitors into the growing collaterals. The differential contribution of shear 
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and wall stress are discussed in more detail elsewhere in this book (see chapter by Schaper). 
Since in general the number of side-branches in the proximal part of the arterial tree is 
limited, the principle of recruitment of preexisting collateral anastomoses functions more 
efficiently in parts with numerous side branches, hence the distal parts of the arterial tree. For 
occlusions occurring in the most proximal part of the arterial, other interventions for restoring 
blood flow should be considered.  

 < Effects of branching architecture on blood flow distribution after arterial stenosis. Left panel: 
dichotomous arterial branching pattern without arterial anastomosis connections. Arterial stenosis indicated with 
red circle. The arterial blood flow direction after stenosis is indicated with red arrows. In this scenario, upon 
arterial stenosis, the absence of arterial bypass connections impairs flow delivery distal to the occlusion, 
resulting in a large area at risk (dotted line) for hypoperfusion and tissue ischemia.  Right panel: arterial pattern 
with many artery-to-artery anastomosis connections. Arterial stenosis indicated with red circle. The arterial 
blood flow direction after stenosis is indicated with red arrows. In this scenario, blood flow can efficiently be re-
routed around the stenosis. Pending on the speed of flow induced outward remodeling, and the functionality of 
the preexisting arterial-arterial connections, this scenario is likely to result in a small area at risk.  
Ontogenesis of arterial collaterals 
Collateral arteriogenesis is defined as the positive outward remodeling of preexisting 
collateral arterial connections that bypass a stenosis resulting in restoration of blood flow to 
the hypoperfused region. In addition, in response to arterial occlusion, de novo formation of 
blood vessels involving angiogenesis, and “upgrading” of capillaries into small arterioles may 
occur. Recruitment of preexisting arteries/arterioles implies that they have to be present at 
time of occlusion. Heterogeneity exists between organs with respect to collateral arterial 
network development, but the organ specific molecular cues involved herein remain to be 
uncovered. Recent experimental evidence obtained from adult mouse brain, has clearly shown 
that the positive association between number of preexisting arteriolar connections in the 
cerebral circulation, and stroke volume upon arterial occlusion, involves a genetic component.  
Using artery specific reporter mice, we could show that such arterial collateral connections 
are already detectable during neonatal stages, implying that they were established before birth 
(Fig. =; LeNoble, unpublished). We therefore focus on the genetic regulation of arterial 
patterning in the embryo. 
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=  Arterial collaterals in the cerebral circulation of neonatal mice. Left panel: overview of the arterial 
branching pattern of the cerebral circulation in mice selectively expressing GFP in arteries. Note the connections 
between the ACA and MCA. Right panel: detail of boxed area in the left panel. Note the numerous preexisting 
arteriolar-arteriolar connections (asterisk) in the distal part. In case of an occlusion occurring in the MCA, blood 
flow from the MCA can be shunted through these collateral anastomoses, and potentially limit perfusion deficits. 
(LeNoble, unpublished)
Vascular development during embryogenesis 
The formation of a properly branched vascular system is critical for embryo development and 
survival. Two successive processes called vasculogenesis and angiogenesis, achieve blood 
vessel formation during embryonic development. Vasculogenesis is the in situ differentiation 
of angioblasts and endothelial cells from mesenchyme [1,2], and their coalescence into tubes 
of the primary vascular plexus. This process is responsible for the formation of the central 
axial vessels (dorsal aortae, and the cardinal veins), and a meshwork of capillaries that 
collectively can accommodate the cardiac output, once heartbeat commences.  
Expansion of the primitive vascular system formed by vasculogenesis occurs through 
sprouting and intussusception angiogenesis [3]. These distinct angiogenesis processes lead to 
the remodelling of the primary vascular plexus into a hierarchical vascular tree, consisting of 
branched arteries, capillaries, and branched veins [4]. Sprouting angiogenesis involves the 
budding, and extension of new segments from preexisting vessels, that grow into previously 
avascular areas. The main driving forces for this process are gradients of vascular endothelial 
growth factor (VEGF) and hypoxia. Sprouting angiogenesis will be discussed in more detail 
in the next paragraphs.  
Intussusceptive angiogenesis is a relatively recently discovered mode of blood vessel 
formation, and occurs by internal division of the preexisting capillary plexus without 
sprouting. In the first step of intussusceptive angiogenesis, the capillary plexus expands by 
insertion of numerous transcapillary tissue pillars, so called intussusceptive microvascular 
growth (IMG). One important difference with sprouting angiogenesis is that the IMG process 
is fast, and can give rise to new capillary segments within 4-8 hours, does not require 
substantial changes in endothelial proliferation, and is less dependent on vascular endothelial 
growth factor (VEGF), when compared to sprouting angiogenesis. IMG leads to a 
considerable increase in capillary surface area, and has been well described in the developing 
lung. In the second intussusception step, a vascular tree with distinct arterial and venous 
segments arises from the primitive capillary plexus as a result of intussusceptive pillar fusion, 
a process called intussusceptive arborisation (IAR). During IAR, rows of pillars are 
transformed to tissue septa by pillar reshaping and pillar fusions. This pillar reshaping 
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demarcates prospective supplying and collecting vessels, and leads to the lifting off and 
extraction, of the new vascular entity into an adjacent (feed/draining) vessel layer.  
In addition to IMG and IAR, a third special form has been described, intussusceptive 
branching remodelling (IBR), which is involved in shaping branching angles of developing 
vascular networks. It is postulated that IBR results in optimization of branching angles, and 
lumen dimensions at vessel bifurcations contributing to minimizing power consumption and 
constant shear stress throughout the vascular system. IBR occurs rapidly (within hours) in 
response to changes in flow.  
While the functional relevance of intussusceptive angiogenesis is recognized, still little is 
known about the detailed molecular and cellular events regulating this important process.  
Also the extent to which different organs use sprouting or intussusception for vascular 
network development remains to be established. Given the role of IAR in establishing arterial 
segments from capillary networks, and the potential regulatory role of blood flow herein, it 
may have importance for shaping pre-existing collateral networks.  
Recruitment of pericytes and smooth muscle cells, around the endothelial cell layer, 
completes the anatomical formation of the vascular wall. During embryogenesis, vascular 
smooth muscle cells may originate from the ventrolateral mesoderm and mesectodermal 
derived neural crest cells. It is suggested that the vascular smooth muscle cells in the media of 
the large central arteries arise from neural crest cells. Subsequently, during fetal development, 
smooth muscle cells mature, acquire functional properties, and attract (sympathetic) nerves 
allowing central control of vascular tone. The ontogenesis of organ characteristic features of 
smooth muscle cell structure and function remains to be determined. 
Regulation of vessel identity and branching morphogenesis 
The branching hierarchy of the major vessels is highly stereotyped within and across species. 
Secondary sprouts branching from the major axial vessels like the intersomitic vessels, or the 
main arteries penetrating different organs and the limbs, form at anatomically designated 
sites. In general, the gross vascular anatomy of the mouse, chick or zebrafish embryos is 
characterized by highly reproducible branching patterns. In the more distal areas, embryonic 
vessel development is highly dynamic and subjected to active remodelling. Vessel segments 
can be disconnected and reconnected to facilitate growth of new vascular beds, or pruned 
pending the local hemodynamic conditions. Furthermore, environmental cues derived from 
the expanding organs contribute to patterning. Oxygenation of developing embryonic tissues 
is one of the determining factors for vessel patterning. Regions of hypoxia generate strong 
attractive signals for angiogenic sprouts, which are lacking in organs with normoxia or 
hyperoxia. In peripheral tissues, the patterning of arteries and nerves is often congruent. In the 
skin of the mouse embryo limbs, nerves can supply growth factors allowing local 
differentiation and patterning of small arterioles. 
During the last decade, extensive research addressing the formation of vascular networks has 
shown that endothelial cells consists of genetically and morphologically distinct populations 
of cells essential for establishing arterial-venous identity, and branching. Depending on the 
stage of development and the vascular bed investigated imprinting of vessel identity and 
branching can be regulated by two distinct mechanisms: 1) genetic hardwiring of vessel 
positioning and identity, 2) flow controlled vascular patterning events and maintenance of 
vessel identity [5]. The expression of neural guidance genes in vessels plays a fundamental 
role in both mechanisms [6]. Neural guidance genes were originally described in C. elegans to 
mediate various aspect of neuronal development. In 1998, the group of David Anderson was 
the first to provide genetic evidence showing that neural guidance molecules of the ephrin 
family can specify arterial-venous identity in vessels, essential for remodelling of capillaries 
into arteries and veins during embryogenesis. They showed that reciprocal interactions 
between ephrinB2 selectively expressed in arteries, and EphB4 selectively expressed in veins, 
triggers separation of arterial and venous domains, allowing arterial-venous network 
development. These results implied, for the first time, that genetic programming of arterial 
and venous identity in endothelial cells is essential for establishing proper vascular network 
morphogenesis. In 2003, the group of Holger Gerhardt showed that angiogenic sprouts also 
consist of genetically distinct populations of cells. Angiogenic sprouts are spearheaded by so 
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called endothelial tip cells. Tip cells are migratory and extend numerous filopodia to sense the 
local microenvironment and guide the direction of sprout growth. Tip cells are followed by so 
called stalk cells. These stalk cells proliferate, form a vessel lumen, essential for local flow 
delivery. While VEGF is the main activator of tip cell differentiation and angiogenic 
sprouting, tip cell filopodia can also express neural guidance receptors, controlling tip cell 
behaviour and sprout positioning. The function of neural guidance molecules in the tip cells 
shows striking similarities with their role in the developing neural system. Growing axons are 
guided by axonal growth cones, which express guidance receptors that are capable of sensing 
attractive and repulsive cues from the surrounding extracellular compartment, controlling the 
direction of axonal growth. The functional equivalent in the vascular system is the endothelial 
tip cell (for more reviews see [5,6]).  
Taking into account that vessels arose later during evolution than nerves, the concept emerged 
that the developing vascular system has coopted growth control mechanisms from the 
neuronal system to mediate vascular guidance events and specify arterial-venous cell fate in 
blood vessels. This concept is now firmly established, and functional roles for several ligands 
and receptors of the main neural guidance gene families, in vascular development, have been 
reported.  
Endothelial tip and stalk cells: 
Endothelial tip cell behaviour and function have been well assessed in the mouse embryo 
hindbrain, mouse neonatal retina, and in zebrafish embryo intersegmental vessel branching. 
The concepts presented here are mainly derived from observations in these model systems. 
Here we will address why some endothelial cells become tip cells, and how tip cell guidance 
is achieved. In the mouse retina, VEGF is the major player inducing tip cell differentiation, 
and tip cells express VEGF-receptor-2 (Kdr/Flk1) on their filopodia, essential for sensing 
extracellular VEGF [7]. Local tissue growth in the expanding retina is accompanied by 
hypoxia and local production of VEGF by astrocytes, resulting in a gradient of VEGF and the 
attraction of angiogenic sprouts towards the hypoxic regions. Scavenging local VEGF with 
soluble Flt1 (soluble VEGF-receptor-1), or injection of VEGF-receptor-2 neutralizing 
antibodies, induces tip cell filopodia retraction and loss of tip cell numbers [7]. The 
continuous presence of a VEGF gradient is necessary to maintain filopodia, and sprout 
extension towards the hypoxic region. When sprouts subsequently fuse and start to deliver 
flow and oxygen, hypoxia, hence the trigger for VEGF production, disappears, and sprouting 
stops.  VEGF is spliced in several isoforms with distinct effects on sprouting extensions. The 
magnitude of attraction, short or long range, varies between the VEGF-isoforms and is related 
to the extracellular matrix binding capacity [8], and affinity for the VEGF co-receptor and 
guidance molecule neuropilin-1 [9]. The diffusible form of VEGF seems to act as a short 
range attractor, whereas the extracellular matrix bound VEGF isoforms act as long range 
attractors. Interestingly, ectopic VEGF perturbs extrinsic vessel pattering cues, suggesting 
that the VEGF gradient provides insufficient information for sprout guidance in the 
immediate vicinity of the parent vessels, and that additional cues, most likely involving 
soluble VEGF-receptor-1 (soluble Flt1), must exist.  While membrane bound Flt1 is mainly 
expressed on stalk cells and assumed to repress tip cell identity in stalk cells, it was shown 
that developing mouse blood vessels produce sFlt1, coordinating local sprout guidance [10]. 
Soluble Flt1 is produced and secreted around the lateral base areas, immediately adjacent to 
the developing sprout. Here sFlt1 neutralizes VEGF, and sharpens the VEGF gradient 
towards the tip cell front region, hence providing a corridor for sprout extension pushing the 
sprout in the proper direction. Next to VEGF-R2, also VEGF-R3 (Flt4) is expressed strongly 
on tip cells and mediates angiogenic sprouting in mouse and zebrafish. In mouse, VEGF-R3 
is highly expressed in angiogenic sprouts of retina and tumor vessels, and genetic ablation of 
VEGF-R3 signalling, or blocking of VEGF-R3 with neutralizing antibodies, reduces 
sprouting [11]. Moreover, stimulation of VEGF-R3 augments VEGF induced angiogenesis, 
even if VEGF-receptor-2 signalling is blocked.  
While VEGF and VEGF receptors regulate tip cell behaviour, it has become clear that the 
Notch signalling pathway plays a central role in modulating tip – stalk cell differentiation.  
Recently, a series of studies addressing the molecular mechanism controlling specification of 
endothelial tip cells in mouse and zebrafish showed a key-role for Notch receptors 
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(presumably Notch-1) and the Notch ligands, Delta-like-4 (Dll4) and Jagged-1 (Jag1)[12-15]. 
Dll4 is predominantly expressed on endothelial tip cells, whereas the Notch receptors and 
Notch signalling mainly occurs on the stalk cells. Genetic deletion of one allele of Dll4 results 
in supranumerous amounts of endothelial tip cells, as evidenced by the increased expression 
of the tip cell markers Pdfgb, Flk1, Flt4, Unc5B, and apelin, augmented filopodia extensions, 
excessive angiogenic sprouting resulting in increased capillary network formation [12,13]. 
Pharmacological inhibition of Notch signalling using compounds that inhibit gamma-
secretase (for example DAPT), hence, the release of notch intracellular cleaved domain 
(NICD, which is normally released after stimulation of Notch receptors) phenocopies the 
vascular phenotype observed in the genetic models. In zebrafish, knockdown of Notch1b and 
rbpja (orthologue of mouse Rbpj), and treatment with DAPT also results in excessive 
branching, confirming the potential role of Notch signalling in restricting tip cell 
differentiation, and angiogenic cell behaviour. Interestingly, the Notch ligand Jagged-1 (Jag1) 
appears to act as an antagonist of Dll4-Notch signalling in tip cell differentiation. Using loss 
and gain of function models in mice, the group of Ralf Adams has shown that endothelial 
specific loss of Jag1 leads to impaired retinal angiogenesis and fewer tip cells [16]. In 
contrast, overexpression of Jag1 in retinal endothelium resulted in increased angiogenesis and 
more tip cells. Expression analysis of endothelial cells isolated from the retina showed that 
Notch signalling is more active in the absence of Jag1, concomitantly with an inhibitory effect 
on vessel growth. At the cellular level, this response depended on the presence of Fringe, 
which function as modifiers of Notch receptors, controlling Dll4/Jag1 signalling efficiency. 
Expression of Jag1 in stalk cells prevents that co-expressed Dll4 can activate Notch in these 
endothelial cells. This activity of Jag1 depends on Fringe, which reduces Notch activation by 
Jag1, enhances signalling by Dll4, thus leading to a competition between an agonist (Dll4) 
and antagonist (Jag1). Since Jag1 is predominantly expressed on stalk cells, and Dll4 on tip 
cells, such complementary expression patterns support a model in which Jag1 negatively 
regulates Dll4 mediated Notch activation. In stalk cells, residual Dll4 expression that could 
potentially block angiogenesis is present, and by antagonizing these signals, Jag1 may 
promote stalk cell activation, allowing sprouting behaviour and VEGF responsiveness. 
The physiological concept that arises from these studies is that endothelial cells expressing 
VEGF-receptor-2, in response to a VEGF gradient can start to express Dll4 on its cell 
membrane, and function as a tip cell. Dll4 subsequently activates (presumably) Notch-1 
receptors on the adjacent stalk cells. The activation of Notch-1 suppresses tip cell 
differentiation in these stalk cells. As a result, only the cell that initially differentiated into a 
tip cell will remain tip cell, from the spear-head of the angiogenic sprout and grow towards 
the VEGF gradient, usually induced by local tissue hypoxia (associated with organ growth). 
This unique model thus results in limiting the amount of sprouts that respond to a hypoxic 
challenge. However, in this model, the default pathway for an endothelial cell is considered to 
be tip cell. Hence, in the context of arteriogenesis and formation of preexisting collateral 
pathways, modulation of any signalling element of the tip-stalk cell differentiation cascade, 
may influence the design of the natural occurring bypass circulation!  
The principle in which a differentiating cell represses the differentiation of adjacent cells, as 
occurs during tip-stalk cell differentiation is called lateral inhibition. This growth principle is 
well established in the developing nervous system furthermore highlighting the similarities 
between both systems. 
Tip cell guidance and neural guidance molecules 
Neural guidance gene function has been well documented in the nematode. Genetic screens of 
nematode locomotor (uncoordinated, unc) mutants led to the discovery of several ligands and 
receptors relevant for commissural and motor axon guidance, including unc5 and the ligand 
unc-6, netrin. Studies in higher vertebrates subsequently showed that their function in the 
developing nervous system is preserved. Surprisingly, recent evidence shows that for many 
neural guidance genes, their function even extends to the growing vascular system. This led to 
the concept that during evolution, neural guidance gene function has been co-opted by the 
developing vascular system to mediate guidance events. To what extent neural guidance 
genes can play a functional role in shaping collateral bypass circulation has not been explored 
well. In the developing nervous system, axonal guidance depends on the growth cone, the 
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migrating distal tip of the growing axon. These growth cones send out numerous filopodia 
and lamellipodia that scan the local environment for attractive and repulsive guidance cues. In 
the growing vasculature, the functional equivalent of the axonal growth cone, the endothelial 
tip cell, also expresses neural guidance receptors determining sprout positioning. This has 
been best documented for UNC5B and its ligand netrin-1 [6,17].  
In mice the UNC5B receptor is selectively expressed in arteries and endothelial tip cells. 
Genetic ablation of UNC5B resulted in increased capillary sprouting in the hindbrain, 
intersomitic vessels and retina. In the retina and hindbrain, administration of netrin-1, a ligand 
for UNC5B, resulted in filopodia retraction. Endothelial tip cells exposed to netrin-1 in vitro 
moved away from the netrin-1 gradient. Moreover, morpholino mediated knockdown of the 
zebrafish orthologues for UNC5B or netrin-1 resulted in misguidance of intersegmental 
vessels. Aberrant path finding in both UNC5B and netrin-1a morphants occurred at the level 
of the horizontal myoseptum (the natural occurring source for netrin-1), instead of extending 
dorsally. As a result, vessel branching was increased, resulting in a phenocopy of the vascular 
patterning defect observed in the UNC5B mouse mutant [17]. Interestingly, loss of function 
studies in mouse and zebrafish indicate that the plexinD1-semaphorin3E signalling pathway 
may act in a similar way albeit at different positions in the growing vascular tree [18,19].  It is 
therefore postulated that the developing embryo has several tissue specific guidance 
checkpoints that control local branching morphogenesis.  At present the full repertoire of 
guidance genes is not known. 
Regulation of arterial-venous identity in blood vessels 
After the formation of the initial vascular plexus through vasculogenesis and angiogenesis, 
vessels have to differentiate into arteries and veins in order to allow proper perfusion [20]. 
Arteries and veins in adult networks differ considerably in morphology and function. These 
differences arise during embryogenesis and involve neural guidance genes expressed in the 
vascular system.  
Several signalling molecules have been discovered, which differentially label arterial or 
venous endothelial cells from early developmental stages onward, prior to the onset of 
circulation. Many of these molecules are also expressed in the nervous system, where they 
regulate cell fate decisions and guide migration of neuronal precursors as well as of 
developing axons [21-24]. Arterial EC in chick, mouse and zebrafish selectively express 
ephrin-B2, neuropilin-1 (NRP-1) and members of the notch pathway, including notch3, 
DLL4, and gridlock [25-31]. Other molecules are specifically expressed in the venous system, 
most notably EphB4, the receptor for arterial ephrin-B2 [32], neuropilin-2 (NRP-2) [25,33] 
and Coup-TFII [34]. Mutations of the ephrinB2 tyrosine kinase and its receptor EphB4 both 
lead to early embryonic lethality around E9.5 [30,32,35,36]. Remodelling of the primary 
vascular plexus into arteries and veins was arrested in both receptor and ligand mutants. 
These findings suggest important roles for ephrinB2/EphB4 interactions on arterial and 
venous endothelial cells, respectively.  
The currently proposed genetic mechanism regulating arterial identity involves VEGF, 
binding to its heterodimeric receptor VEGFR-2 and neuropilin-1, activating the Notch 
signalling pathway, Hey transcription factors, leading to induction of ephrinB2 and 
suppression of EphB4 [12,37].  During normal development, expression of COUP-TFII in 
venous endothelium suppresses neuropilin-1 and inhibits Notch signalling and the expression 
of artery specific genes [34]. Without neuropilin-1 and Notch signalling, venous markers like 
EphB4 are expressed and venous identity maintained. Ablation of COUP-TFII in endothelial 
cells enables veins to acquire arterial characteristics including expression of ephrinB2, 
neuropilin-1 and Notch signalling molecules. However, it was noted that the acquisition of the 
arterial identity in veins of COUP-TFII mutant mice was not sufficient to convert mutant 
veins fully into arteries suggesting additional control mechanisms including cells in the vessel 
wall [34].  
Chick quail chimera studies [27] and in vitro endothelial-smooth muscle spheroid cell culture 
experiments [38] indeed indicate a potential role for vascular smooth muscle cells in 
molecular instruction of endothelial cells with an arterial identity. Alternatively, such cues can 
also come from the perivascular nerves as has been demonstrated for sensory nerves in the 
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developing mouse skin vasculature [39]. However not all arteries become innervated by 
autonomic nerves, and most arteries differentiate before development of nervous innervation.  
Taken together these data indicate that, before the onset of heart beat, genetic hardwiring of 
arterial-venous differentiation is essential to allow proper vascular development. Genetic 
hardwiring of arterial-venous identity is essential for the proper development of the in- and 
outflow tract of the heart, and the establishment of the aorta and cardinal vein which will 
allow delivery of cardiac output to the developing organs once the heart starts beating. 
After the start of heartbeat and generation of cardiac output, the developing vascular system 
shows a high degree of endothelial cell plasticity. Using a combination of in vivo molecular 
imaging and vascular grafting studies we showed that endothelial cells are not genetically 
committed to their initial phenotype but plastic and adapt their identity continuously 
depending on local epigenetic cues including hemodynamics [40]. In addition we obtained 
evidence showing that the global patterning of arteries and veins in peripheral organs like the 
yolk sac depends on hemodynamics and local tissue compliance. We observed several novel 
morphological events essential for arterial-venous differentiation and branching during 
embryogenesis. These included 1) flow driven fusion of small calibre vessels into large tubes, 
a process accounting for the formation of the large vitelline arteries and veins, 2) selective 
disconnection of endothelial cells from the arterial system and reuse of these endothelial cells 
to fashion growth of the venous system, 3) shear stress driven guidance of lumenized vessel 
sprouts.  We could show that in the absence of cardiac output and active flow perfusion of the 
yolk sac, despite the expression of arterial markers like ephrinB2, AV differentiation and 
patterning would not take place. In addition, perfusing an embryonic artery with venous 
blood, transformed this artery genetically and morphologically into a vein. Arterial markers 
like neuropilin-1 and ephrinB2 were downregulated whereas venous markers including 
neuropilin-2 were upregulated [40]. From these observations we concluded that 
hemodynamics control arterial-venous differentiation and are essential for the maintenance of 
AV vessel identity in the yolk sac vasculature.  
Arterial – venous vessel plasticity is also observed in the developing trunk vasculature of the 
zebrafish embryo [41]. In early stage embryos, primary vessel sprouts grow between the 
somites to form the intersomitic vessel. This vessel subsequently branches laterally into the 
caudal and cranial regions to from the dorsal lateral anastomising vessel (DLAV). At this 
stage, the intersomitic vessel is connected to the aorta and is considered arterial, carrying 
arterial flow. During subsequent stage so called secondary sprouts that originate from the 
cardinal vein form. These venous sprouts grow parallel and in close proximity to the 
intersomitic arterial vessel. Occasionally, these venous sprouts fuse with the intersomitic 
arterial segment, which progressively loses its connection with the aorta as the intersegmental 
vessel turns into a vein [41]. As a consequence of the vein fusing with the arterial segment 
process, the flow direction in the intersomitic arterial segment is reversed. The exact cellular 
and molecular mechanism accounting for this process is not known. It is suggested that the 
fusion of veins with arteries is the result of a stochastic process and essential to balance local 
perfusion. Similar to the morphological events observed in the developing chick embryo, 
plasticity of arterial segments seems to be important to obtain functional perfused networks. 
To what extent such plasticity events occur in other organs during development remains to be 
elucidated. 
Recent evidence shows that blood flow is also essential for driving vascular remodelling in 
the mouse embryo yolk-sac [42]. Using Mlc2a-/- mutant mice, which display a selective 
cardiac contractility defect impeding proper control of cardiac output, it was clearly 
demonstrated that without adequate flow, yolk sac remodelling does not occur.  This could be 
attributed to the mechanical properties of the early blood, not the presence of circulation 
angiogenic factors or changes in oxygen carrying capacity [42]. Using elaborate erythroblast 
trapping techniques and injection of high molecular weight synthetic sugars, it was 
demonstrated that the mechanical force, normally imparted by the flow of circulating 
erythrocytes, is necessary and sufficient to induce vessel remodelling in the yolk-sac of early 
mouse embryo [42]. It remains to be tested whether erythrocyte mediated changes in viscosity 
also affect vascular remodelling in other model systems and pathological conditions. 
The zebrafish embryo can generate the aorta, cardinal vein and segmental sprouts in the 
absence of perfusion. However, in some mutant fish, blood flow driven arteriogenesis can be 
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observed [43]. The gridlock mutant zebrafish embryo is characterised by permanent occlusion 
of the proximal aorta [44] caused by a mutation in the Hey2 transcription factor that is 
involved in arterial specification. In early development, as a result of this occlusion, the distal 
aorta does not carry flow. With time, gridlock mutant embryos recover blood flow in the 
distal aorta via communications with the intestinal vasculature [43]. This arteriogenesis 
response can be phenocopied by laser-induced proximal aortic occlusion. Pharmacological 
inhibition of nitric oxide synthesis using L-NAME attenuated collateral formation in gridlock
mutants indicating involvement of nitric oxide. Morpholine knockdown of pu.1 to prevent 
myeloid development also reduced restoration of distal aorta flow [43], suggesting that 
analogue to the adult situation, the presence of myeloid cells may accelerate arteriogenesis 
[45]. Analysis of hypoxia markers including HiF-1α, revealed that in gridlock mutants 
collateral flow develops independently of tissue hypoxia or ischemia. Thus, collateral aortic 
blood flow in gridlock mutants was dependent on both nitric oxide and myeloid cells. More 
recent evidence shows that blood flow is also relevant for arterial growth in the cerebral 
circulation of zebrafish embryos. 
Taken together increased levels of shear stress, as well as the independence from ischemia are 
three unique features in arteriogenesis, which are present in both, mammals as well as 
zebrafish, during embryogenesis and in the adult. These observations suggest that flow driven 
arteriogenesis is highly conserved. 
Flow driven arteriogenesis in the chicken embryo 
In the chicken yolk sac circulation, hemodynamic factors are important for the regulation of 
the expression of arterial-venous identity genes. In addition, we noted that changes in the 
arterial blood flow distribution evoked dramatic changes in the overall patterning of the 
vitelline arteries and veins (Fig. >). To understand the nature of this flow controlled arterial 
patterning, we performed detailed time-lapse imaging, and hemodynamic characterizations in 
vivo, and observed a striking resemblance with “adult arteriogenesis” including flow driven 
enlargement of small arterioles, and the use of pre-existing vascular segments to build the 
collateral arterial network [46].  
We observed that the direction of outgrowth of the arterial tree, closely associated with the 
direction of the arterial blood flow distribution (Fig. >,) obtained after arterial occlusion. In 
normal embryos, cardiac output is distributed toward the left (LVA) and right (RVA) vitelline 
arteries (Fig. >). In the posterior pole, the arterial blood flows into the vitelline vein plexus 
in this area (Fig. >1). Selective ligation of the RVA using a metal clip changes the blood 
flow distribution in the yolk-sac (Fig. >,). In the ligation model, the cardiac output is now 
distributed to the LVA, resulting in increased shear stress values throughout the LVA arterial 
tree. In response to exposure to elevated shear stress levels, LVA arterioles grow, resulting in 
a structural increase of lumen diameter. In the posterior pole of ligation embryos, flow is 
distributed towards the vitelline vein, and the terminal arterioles of the RVA. In the latter, the 
blood flow direction is reversed (Fig. >,, blue arrows) compared to control unligated 
embryos.  The reason for this change in blood flow direction is that occluding the RVA, 
results in “low pressure” immediately distal of the occlusion. This will subsequently attract 
blood flow towards this area (it functions as a sink). This blood flow is attracted from the 
posterior pole, and the sinus vein, involving retrograde perfusion of pre-existing RVA 
segments. In the posterior pole, there is competition between blood flowing back to heart 
through the vitelline vein, and blood flowing back to the heart, via the pre-existing RVA 
arterioles.  
With time, the amount of blood flowing to the RVA arterioles increases, whereas the amount 
of blood flowing back through the posterior vein (which is oriented perpendicular to the 
preferential flow direction after ligation) decreases. As a result of the reduction in blood flow, 
the posterior vitelline vein adapts with structural inward remodeling and is finally pruned. In 
contrast, the pre-existing vessel segments that are in line with the new flow direction, obtain 
more flow, show structural outward remodeling and extend toward the right hand side of the 
embryo. Thus, after ligation, the creation of a “low pressure point” at the occlusion site, now 
results in steal of blood flow from the posterior vein, resulting in a change in flow direction, 
ultimately evolving into flow mediated diameter and arterial patterning changes. 
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>: Flow distribution and formation of arterial collateral networks upon right vitelline artery occlusion in 
the chicken embryo. (A) Normal blood flow distribution. Note that the flow (black arrows) from the left (LVA) 
and right (RVA) vitelline artery, both drain into the vein located in the posterior area. (B) Blood flow 
distribution after selective ligation (circle) of the RVA with metal clip. Note that the blood flow from the LVA is 
distributed towards the vein, and the pre-existing arterioles of the RVA. The flow direction in the LVA arterioles 
is reversed (blue arrows). (C) Normal arterial-venous pattern in control embryos. (D) Typical collateral arterial 
network as observed 24 hours post-ligation of the RVA. Note that the arterioles branching from the LVA, 
followed the flow pattern (blue arrows in B), and extend across the previously venous domain in the posterior 
part, projecting towards the right hand side. The vitelline vein in posterior area, regressed. (E) Collateral arterial 
network pattern variation-1. (F) Collateral arterial network pattern variation-2, huge collateral arterioles 
developed in the posterior pole. (adapted from Buschmann&leNoble, [46]. 
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These observations suggest, that in this organ, during this stage of embryonic development, 
the directionality in the arterial blood flow component may guide the global patterning of the 
arterial network at the macro level, as opposed to the tip cell mediated guidance events at the 
capillary, micro level. In our setting, exposureing the complete embryo to hypoxia did not 
accelerate arteriogenesis. In this setting (global hypoxaemia) arteriogenesis proceeded slower 
and associated with reduced cardiac function and tissue perfusion. This indicates that for the 
yolk sac vasculature, blood flow, and not oxygen availability per se, maybe the main driving 
force for vessel development, as opposed to endothelial tip cell sprouting which clearly 
involves a hypoxia driven (and VEGF gradient) component.  
Another characteristic feature of “adult arteriogenesis” is the variability in the collateral 
arterial architecture among patient populations or between mouse strains. Similar 
observations were made in the chicken embryo ligation model. While in the majority of cases 
investigated, the collateral arterial architecture resembles the pattern presented in (Fig. >"), in 
some case (less than 1%) we noted alternative patterns as presented in (Fig. >) (variation-1) 
and (Fig. >) (variation-2). In the case of collateral architecture variation-1, collateral 
arterioles developed fast, and reconnected to the stem of the RVA, just distal from the 
occlusion. The collateral arterioles carried flow, and perfused the RVA in the normal forward 
direction (Fig. >). The number of collateral arterioles appears smaller when compared to the 
typical collateral pattern (Fig >,). In collateral architecture variation-2, we noted the 
formation of comparatively large arteries. The pattern resembled, to some extent the collateral 
architecture obtained in the rabbit shunt model as developed by Eitenmueller and Schaper. 
Indeed, in our setting these large caliber collaterals were also high flow vessels. The 
mechanism accounting for this natural variability is not known but may involve a genetic 
component or specific aspects of the yolk sac vasculature at the time of ligation, which remain 
to be determined. 
Collateral Arteriogenesis: from embryo to adult 
The outstanding question in the field is how the recent advancements in understanding the 
molecular and cellular regulation of vascular development translate into the formation of 
functional collateral arterial networks that can be recruited after stenosis of a main feed artery. 
The research focus should therefore be at elucidating how the “embryonic” growth 
mechanisms can lead to patent collaterals.  
Unfortunately, most studies addressing the “embryonic principles” in adult vascular 
development thus far focused on involvement in angiogenesis in ischemic tissue, or tumor 
growth. Since angiogenesis and (collateral) arteriogenesis differ considerably, alternative 
approaches aimed at quantifying the fetal contribution to branching patterning, maintenance 
of collateral circulations, and assessment of functional adaptive responses in such networks, 
including maturation of the vessel wall function should be considered. It is clear that an 
important part of vessel identity and arterial branching is regulated by genetically hardwired 
components. It is to be expected that any alteration in VEGF gradients, VEGF receptor 
expression and signaling, neural guidance molecules (UNC5B, PlexinD1), perivascular 
nervous innervation, as well as modifications in Notch receptors and ligands may affect 
arterial specification, and branching morphogenesis. Indeed, recent studies by the group of 
Faber has shown that VEGF and Flt1 are determinants of native collateral formation [47,48].  
Another unsolved issue is the maintenance of potential collateral arteriolar side-branches that 
branch from a main feed artery. The embryonic and fetal vasculature is highly plastic and 
many vessel segments are pruned, thus not all side-branches generated through sprouting or 
intussusceptive angiogenesis, will result in a patent arteriole or venule. Hemodynamic factors 
play a significant role in the remodeling of embryonic/fetal vascular networks, and at 
bifurcations adaptation to shear stress predicts the regression of the smallest side branches. 
Therefore, next to understanding formation of vessels, insight into the mechanisms that 
prevent pruning is needed. For example, if collateral arterial connections are detectable at 
birth, but pruned during subsequent stages of life, either evoked by local hemodynamic 
adaptations or triggered by cardiovascular risk factors such a smoking, therapeutic strategies 
could aim at preventing regression of such arteriolar connection, perhaps by intensive shear 
stress training (see chapter by Buschmann).  
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Next to the genetic factors, environmental factors may influence collateral arterial network 
design before birth. Epidemiological and experimental studies have shown an association 
between low birth weight and cardiovascular diseases later in life [49]. These studies suggest 
that exposing a developing fetus to adverse conditions in utero, for example fetal hypoxia or 
malnutrition, results in long-lasting structural and functional changes in the cardiovascular 
system predisposing for ischemic cardiovascular diseases [50]. Exposure to hypoxia affects 
fetal cardiac pump function, and organ perfusion. Given the important role for blood flow in 
controlling the design of the arteriolar architecture, such hypoxic stress insults, via changes in 
cardiac output and arterial flow, may modulate preexisting collateral number, thereby 
predisposing for ischemic cardiovascular diseases. 
Taken together: branched arterial networks are generated during embryonic development 
controlled by myriad genetic networks and hemodynamics. In the context of collateral 
arteriogenesis, two aspects from analyzing embryo development surfaced that may be relevant 
for novel therapeutic interventions: a) understanding the molecular growth control 
mechanisms determining preexisting collaterals, b) preventing the pruning of potential 
collateral connections that were generated during early life. The future challenge is to identify 
the full repertoire of molecules involved in the design of the arteriolar architecture, and 
collateral artery development. 
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 Development and adaptation of arteries are controlled by genetic programs and environmental cues. 
The evolutionary conserved Notch signaling pathway plays a major role in a distinct arterial gene program which 
fashions the unique features of the arterial system. Notch ligands and receptors are involved in many different 
aspects of arterial development and growth. These include the specification of arterial identity, regulation of 
sprouting angiogenesis, differentiation of arterial smooth muscle cells, arterial wall assembly and postnatal 
arteriogenesis. However many aspects of the molecular mechanisms remain unexplained. The present chapter 
aims to summarize the current knowledge about Notch signaling in development, adaptation and disease of 
arteries. Expression patterns of Notch ligands and receptors in the vascular system will be reviewed and 
phenotypes of general and conditional Notch pathway mutants will be discussed. Finally, to provide perspectives 
for future research, this chapter will raise some unanswered questions how Notch controls arterial growth and 
homeostasis. 
Introduction 
The vascular system of all mammalian and most non-mammalian species is a highly 
diversified hierarchical tree of differently sized tubes. These tubes share a single common 
lumen whose wall is made up from endothelial cells (EC), which set up a morphological and 
physiological barrier between flowing blood and the surrounding tissue. The embryonic de 
novo development of immature vessels from angiogenic blood islands is termed 
vasculogenesis [1,2]. The resulting first primitive vascular network consists only of EC. 
Outgrowth of capillaries is called sprouting angiogenesis, a process which is initiated by 
specialized EC and takes place both in embryonic development and in postnatal life. The 
immature vascular network in the embryo further differentiates into arteries and veins, which 
was thought to be driven by the onset of blood flow by the beating heart [3,4]. However, a 
number of seminal studies changed this paradigm by demonstrating that the differentiation of 
arteries and veins is regulated by a molecular program, which is activated independent of 
blood flow [1,5,6]. This molecular program is controlled by the evolutionary highly 
conserved Notch signaling pathway, which is instructive for arterial differentiation. 
Development and postnatal growth of arteries share many morphological and molecular 
features. Both development and growth comprise the proliferation and temporo-spatial 
assembly of EC, smooth muscle cells (SMC), and in some cases pericytes to build or to 
enlarge an arterial vessel. Arteriogenesis, i.e. the growth of postnatal collateral arteries to 
conductance vessels, recapitulates many molecular and functional aspects of arterial 
development. Here we summarize the role of the Notch signaling pathway for each arterial 
cell type in embryonic development and postnatal life. Additional information is provided in 
tables summarizing markers of EC and SMC identity, regulators of Notch ligands, Expression 
of Notch pathway members and phenotype of mutant mice. Understanding the numerous 
aspects of Notch signaling in the embryonic arterial system is both essential and suggestive 
for fully discovering its role for postnatal adaptation and growth. 
The Notch signaling pathway 
The Notch signaling pathway is an evolutionary conserved intercellular signaling pathway. It 
plays several critical roles during development and physiology, primarily in the vascular 
system [7,8], the nervous system [9] and hematopoiesis [10-12], but also for skin, liver and 
gut development. In general, the Notch signaling pathway can act through diverse 
mechanisms, e.g. making binary cell-fate decisions, controlling boundary formation and 
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regulating cellular proliferation or differentiation. In mammals it consists of four 
transmembrane receptors (Notch1 through Notch4) and five ligands (Delta-like 1/-3/-4, 
Jagged1, Jagged2). Unlike in most other signaling pathways ligands of the Notch family are 
present only at the cell surface and not known to be secreted. Thus Notch signaling depends 
on an intimate cell-cell contact to allow ligand-receptor binding, which restricts it to signaling 
between neighboring cells. This type of action is also known as juxtacrine signaling. Upon 
binding of the ligand the receptor protein is proteolytically cleaved by membrane-tethered 
enzymes of the ADAM metalloprotease family and the gamma-secretase complex (Fig. <) 
[13]. Cleavage results in the release of the intracellular domain of the Notch receptor (NICD) 
into the cytoplasm. NICD then shuttles into the nucleus because of the presence of nuclear 
localization signals. Here it binds to recombination signal binding protein for 
immunoglobulin kappa J region (RBPj)1, a sequence-specific DNA-binding protein. Upon 
binding of NICD, RBPj converts from a transcriptional repressor to a transcriptional 
activator inducing Notch target gene expression. Known Notch target genes are the basic 
helix-loop-helix (bHLH) transcriptional repressors of the hairy and enhancer of split (Hes1, 
Hes5) and hairy and enhancer of split related with YRPW motif (Hey1, Hey2) family [14]. 

< Overview of the Notch signaling pathway. Ligand-bearing cells activate Notch in adjacent cells by 
binding the receptor protein, which requires intimate cell-cell contact. This mode of signaling is also called 
‚juxtacrine’. After cleavage of the receptor its intracellular domain (NICD) translocates into the nucleus, binds to 
RBPj and leads to target gene expression. 
This signaling cascade is termed the canonical Notch signaling pathway. However, there is 
some evidence for non-canonical Notch signaling, i.e. signaling without involvement of 
RBPj [15]. Further details on the intracellular signaling mechanisms can be found in several 
recent reviews [13,14,16-18]. Upon receptor binding the ligand is internalized by the sender 
cell. Ligand internalization may also exert specific effects in the sender cell known as reverse 
signaling [13,19], since modification of the cytoplasmic domain of the ligand causes a 
phenotype [20]. 
Notch usually signals in trans, i.e. the ligand bearing cell activates Notch in an adjacent cell. 
In some cases the same cell carries both the ligand and the receptor, e.g. arterial EC. Notch 

1 RBPj is also named C-promoter binding factor 1 (CBF1) in mammals and suppressor of hairless [Su(H)] in 
Drosophila melanogaster. 
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signaling in cis, i.e. one cell is sender and receiver at the same time, also takes place [21,22]. 
In contrast to trans signaling this process is believed to be inhibitory [18,23,24]. However, 
whether there is a significant role for cis [18] signaling in vivo is poorly understood. 
Compelling evidence suggests that every action of Notch depends on a specific ligand-
receptor pair in a given temporo-spatial setting and that such pairs exert specific effects in a 
given context. Even if the general role of Notch in vascular development and disease has been 
well established, exact roles of specific ligand-receptor pairs remain to be characterized [8]. 
Embryonic arteriogenesis 
Arterial identity is derived from a predefined molecular program in EC (Fig. =), which 
precedes establishment of mature arteries. In embryonic development, a primitive endothelial 
network is formed in situ [25-28]. This primitive tubular network is then remodeled into a 
highly diversified and complex network of differently sized arteries, capillaries and veins. The 
fully developed vascular system has a distinct anatomy on every step of the vascular tree [29]. 
The aorta is the biggest artery whith a strong wall containing a thick layer of smooth muscle 
cells, which gets thinner the smaller the artery becomes. Blood flow, blood pressure and 
oxygen tension change throughout the vascular tree. After the onset of the circulation the 
morphological and functional diversity of the vascular tree becomes more and more apparent. 
Thus, it was long believed that hemodynamic forces, starting as the heart begins to beat, drive 
the diversification of the immature and primitive vascular network into a complex system of 
arteries and veins [3,4]. However, pivotal studies on vascular identity before onset of the first 
heart beat demonstrated that distinct genetic programs precede blood flow, challenging the 
paradigm that flow determines that decision [6,30,31]. 
The developing zebrafish embryo allows detailed investigation of vascular formation [32]. 
Zebrafish are translucent and several transgenic lines expressing fluorescent proteins in 
different cell types are available. This makes this model organism an ideal system to perform 
real time analysis of the growing vasculature, mostly done by time lapse video microscopy. In 
the developing zebrafish two main vessels form early after gastrulation: The dorsal aorta and 
the posterior cardinal vein. The study of the formation of these two vessels offers a 
comfortable opportunity to study arteriovenous differentiation. The molecular difference 
between arterial and venous EC was first shown by the identification of ephrin-B2 as an 
artery-specific endothelial ligand and EphB4 as a venous-specific receptor [6,33,34]. Lineage 
tracing in zebrafish embryos revealed that the hemangioblast is molecularly dedicated to give 
rise to either arterial or venous EC but not both [30]. Notch is upstream of ephrin-B2 and 
required for arterial identity and dorsal aorta formation [30,35-37]. Notch mutant embryos 
show an impaired formation of the dorsal aorta and the posterior cardinal vein and exhibit 
fusion of the two vascular beds without intervening capillaries. In these embryos arterial 
markers such as ephrin-B2 are lost and venous markers like EphB4 are gained, indicating 
defective arteriovenous differentiation. The Notch target gene seems to mediate arterial 
differentiation signals: Targeting gridlock in zebrafish leads to a disruption of dorsal aorta 
formation [30,35]. 
Mutant phenotypes were also extensively studied in mice. The developing yolk sac of mice 
demonstrates all stages of vascular development: vasculogenesis, angiogenesis and 
arteriogenesis. In yolk sacs of Notch1-/- mice a primitive plexus forms which lacks any further 
remodeling, indicating that stages above vasculogenesis require Notch1 signaling [38]. The 
phenotype of global Notch1 mutant mice is mainly due to a loss of Notch1 in the vascular 
endothelium. Ablation of Notch1 specifically in EC with a Tie2-driven Cre deleter in 
conditional Notch1flox/flox mice fully recapitulates the global Notch1-/- phenotype [39]. 
A direct link in mice from canonical Notch signaling to arterial identity was made by using 
RBPj-/- mice which carry a lacZ transgene under the control of the ephrin-B2 promoter. The 
yolk sac of these mice lacks all remodeling beyond initial vasculogenesis. It does not show 
any expression of ephrin-B2 compared to a strong signal in RBPj+/+ mice carrying the same 
transgene [40]. These data confirm that canonical Notch signaling is required for plexus 
maturation and arterial cell fate specification. 
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Studies in the developing zebrafish embryo further uncovered the signaling cascade 
responsible for arterial differentiation. Expression of vascular endothelial growth factor 
(VEGF) is regulated by the secreted morphogen sonic hedgehog (shh) along the axial midline 
[41]. Shh is necessary for arterial identity, and overexpression of Shh induces ectopic arterial 
marker expression in the cardinal vein [41]. Loss of Shh can be rescued by vegfa mRNA 
injection, and vegfa overexpression again induces arterial markers in the cardinal vein. Vegfa
mutants exhibit the same phenotype as Shh mutants which can be rescued by a Notch1
transgene [41]. These results showed that Shh, VEGF-A and Notch1 act in sequence during 
arterial differentiation in developing vessels. 
Knockout mice lacking ephrin-B2 either in the 
whole body or specifically in EC showed a similar 
defect like Notch1 mutants: Formation of the 
primitive vascular network occured, but 
differentiation into hierarchical networks of vessels 
of different size and identity was missing [6,42]. As 
Notch directly regulates ephrin-B2 [41,43,44] and 
the knockout phenotypes of Notch1 and ephrin-B2 
are highly similar, it is now clear that Notch acts 
upstream of ephrin-B2 in the arterial differentiation 
cascade. 
EphB4, the receptor for ephrin-B2, is a specific 
marker for venous EC. Interstingly, loss of either 
ephrin-B2 or EphB4 leads to a similar 
embryonically lethal phenotype lacking 
arteriovenous differentiation [6,33,34]. This 
demonstrates that bidirectional signaling between 
ephrin-B2 and EphB4 determines EC fate, which in 
turn is controlled by canonical Notch signaling. 
Expanding the results from mice and zebrafish 
recent studies have placed the Notch ligand Dll4 into 
this signaling cascade. VEGF-A regulates Dll4 
through VEGF-Receptors 1 and -2 and the 
phosphatidylinositol 3-kinase/Akt pathway [45]. 
Dll4-deficient embryos as well as RBPj mutants 
and Hey1/Hey2 double-mutant embryos do not express arterial markers [40,46-49]. Dll4-
mediated Notch signaling induces ephrin-B2 expression in EC in vitro [50] and the ephrin-B2
gene has recently been shown to be a direct Notch target gene [44], demonstrating a direct 
and instructive role for Dll4-mediated Notch signaling in arterial differentiation. 
Mutant mice which lack Foxc1 and Foxc2, transcription factors of the forkhead family, show 
severe defects in the developing yolk sac and the embryo proper [51], mimicking the Dll4 or 
Notch1 knockout phenotype. These mice also exhibit accompanying AV-malformations. 
Foxc1 and Foxc2 directly activate dll4 and hey2 transcription in EC by binding to the 
respective promoters [52,53], which is enhanced by VEGF-A. Thus there is strong evidence 
that Foxc1 and Foxc2 are directly involved in arterial specification of the developing 
vasculature by regulating Dll4. These findings further extend the signaling network 
responsible for arterial specification of EC. 
Whether adoption of arterial or venous cell fate is irreversible has remained an important 
question since it has implications for understanding the mechanisms of vascular 
differentiation and regeneration. Insights into EC plasticity came from transplantation 
experiments: EC from transplanted embryonic quail arteries or veins colonize both recipient 
arteries and veins in the developing chick embryo, suggesting some EC plasticity. However 
this is only the case at specific stages of embryonic development: Grafts isolated from quail 
embryos after E7 progressively lose plasticity, and EC grafted after E11 only colonize vessels 
from which they originated [54], indicating that EC fate is fixed at late stages of development. 
However, experiments in chicken embryos during early phases of development demonstrated 
that hemodynamic forces are sufficient to revert EC identity, supporting that EC plasticity is 

 =  The molecular cascade which 
controls endothelial differentiation during 
vascular development. Dll4-mediated Notch 
signaling both determines arterial identity and 
inhibits venous differentiation. 
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present in early development [55]. Notch signaling determines the homing behaviour of 
transplanted EC in zebrafish: EC in which Notch1 is overexpressed integrate into arteries. On 
the other hand, RBPj deficient EC integrate into veins, indicating predefined identity and 
homing of EC, but also demonstrating that Notch signaling specifies cell fate cell-
autonomously in this context [56]. A very recent study found that coronary arteries develop 
from venous endothelial cells [57], which likely reflects that cardiac arteriogenesis is special 
and differs from vascular development in other territories. Irreversibility of differentiated EC 
identity can also be observed in humans: Veins used as bypass homografts between the aorta 
and the coronary arteries on human hearts morphologically adapt to the new flow conditions 
but do not gain full arterial identity, which underlines the inherited molecular identity of a 
given vessel [58]. Taken together EC plasticity seems to be present at early developmental 
stages, but fully established EC identity in a developed vascular system is irreversible. 
Many experimental findings demonstrate that Notch signaling is instructive for arterial 
differentiation and at the same time suppresses venous fate. This led to a paradigm that an 
undifferentiated endothelial cell adopts arterial identity once Notch is activated or aquires 
venous fate by default. However venous fate is regulated by chicken ovalbumin upstream 
promoter–transcription factor II (COUP-TFII) [59]. COUP-TFII suppresses Neuropilin-1 
expression which is important for the arterial differentiation cascade downstream of VEGF-A. 
In COUP-TFII mutant mice venous EC adopt arterial markers but still express considerable 
amounts of EphB4, suggesting incomplete arterial differentiation. On the other hand, arterial 
vessels of transgenic mice overexpressing COUP-TFII have completely lost arterial identity 
and adopt venous fate [59]. These findings further expand the current knowledge about 
arteriovenous differentiation from a vertical cascade to a complex system which regulates 
endothelial identity.  
However, given the pleiotropic role of VEGF for the vascular system it is not surprising that 
VEGF alone is not sufficient to determine arterial identity. VEGF120, a soluble VEGF 
isoform, is expressed by peripheral nerves and contributes to local arteriogenesis [60]. 
However venules are close by, are also exposed to locally produced VEGF and express the 
same high affinity VEGF receptors. But they do not express arterial markers, confirming that 
arterial identity is a predefined specificity and that VEGF alone is not sufficient for its 
determination. It is tempting to speculate that the combination of VEGF coreceptors like 
Neuropilin-1 and expression of Notch receptors may result in a general responsiveness of EC 
to different VEGF isoforms for determining arterial identity [61]. 
Sprouting angiogenesis 
During angiogenesis new vessels form from existing ones by capillary sprouting [62]. 
Specialized EC at the tip of the outgrowing sprout (‚tip cells’) guide the growing vessels 
along environmental cues [63-65]. Adjacent proliferating EC (‚stalk cells’) trailing behind the 
tip cell form the trunk of the new sprout.  
Two popular animal models exist for the investigation of sprouting angiogenesis: The 
formation of intersomitic vessels in the zebrafish embryo and vascularization in the retina of 
newborn mice. The retinal vascular system develops shortly after birth before opening of the 
eyes. The first vessels emerge at the insertion of the optic nerve in the retina centre, building 
an angiogenic front. This front migrates radially into the avascular zone towards the ora 
serrata. A gradient of matrix-bound VEGF, which is produced by local astrocytes, serves as a 
guidance cue for this migration process. The cells at the leading edge are specialized 
migrating tip cells extending numerous cellular filopodia which sense the VEGF gradient. All 
EC following the angiogenic front are called stalk cells, are highly proliferative and mainly 
build the vascular sprout. In this, EC recapitulate a general growth mechanism which is also 
utilized by other cellular networks, e.g. outgrowing neurons and the developing trachea [66-
68]. The combination of tip cell migration and stalk cell proliferation results in 
vascularization of the whole retina by a tubular plexus. In a second step this primitive 
vascular plexus is remodeled into large and small arterial and venous vessels. At all times the 
retinal vasculature is easily accessible both for investigation and manipulation, making the 
mouse retina model a very good model for studying vascular growth and postnatal arterial 
development.  
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Until recently the molecular mechanisms of tip and stalk cell selection and EC guidance were 
largely unknown. Some years ago a role for Notch signaling in tip cell physiology was first 
described [69]. In an in vitro system using human umbilical vein EC, inhibition of Notch 
signaling led to a tip cell phenotype and cell division, leading to two daughter tip cells. Notch 
activation inhibited sprout formation, while Notch inhibition enhanced it by increasing the 
number of tip cells and tip cell filopodia. 
This initial discovery was confirmed by recent landmark studies which independently 
discovered a general mechanism of Dll4-Notch1 signaling in VEGF induced sprouting [70]. 
The central findings of these studies were made in different model systems: the mouse retina 
and hindbrain [71-74], the developing zebrafish [56,75] and xenograft tumor models 
[74,76,77]. Dll4 is strongly expressed in tip cells due to VEGF-A stimulation from the local 
miroenvironment. Dll4 in turn activates Notch1 in adjacent stalk cells, which leads to 
downregulation of VEGF-R2. This results in decreased susceptibility of stalk cells to VEGF, 
which hinders the cell from becoming a tip cell. On the other hand, once Notch signaling is 
inhibited the number of tip cells and filopodia is excessively increased resulting in more 
sprouting. These studies further confirm that VEGF is upstream of Notch, because inhibition 
of VEGF reduces Dll4 expression, thereby controlling sprouting angiogenesis and vascular 
guidance [75]. In summary, Dll4 from tip cells inhibits sprouting angiogenesis by suppressing 
tip cell differentiation in neighbouring EC. 
However, vascular development in the mouse retina can only be investigated statically. This 
gap is elegantly filled by the analysis of intersomitic vessel formation in zebrafish. Similar to 
astrocytes in the mouse retina, somites produce a gradient of VEGF which is sensed by tip 
cell filopodia. It was found that the same mechanisms as in the mouse retina control 
intersomitic vessel formation: Upon VEGF exposure tip cells express Dll4, which activates 
Notch1 and downregulates VEGFR-2 in stalk cells, thereby hindering the stalk cell from 
becoming a tip cell [56,75].  
Vascular sprouts in Dll4 and RBPj morphant zebrafish embryos contain more EC compared
to wildtype embryos due to increased recruitment of EC to the growing vascular sprout and 
increased proliferation of EC within the sprout. This indicates the Dll4/Notch1 signaling 
suppresses proliferation of stalk cells. However these studies also showed that the RBPj
phenotype is more severe than the Dll4 phenotype, suggesting that other Notch ligands play 
an important role [56,75].  
The question how the complex patterning of the developing vascular system is modulated by 
different Notch ligands was elegantly answered by a recent pioneer study demonstrating 
opposing roles of Dll4 and Jagged1 in sprouting angiogenesis [78]. Jagged1 is strongly 
expressed in stalk cells during retinal angiogenesis. Mice which lack Jagged1 selectively in 
the endothelium show reduced vascularization and fewer tip cells with fewer filopodia in the 
angiogenic front. At the same time proliferation of EC is reduced when endothelial Jagged1 is 
lost. On the other hand Jagged1 overexpression in the endothelium leads to the opposite 
phenotype: Tip cell and filopodia numbers are increased and EC proliferation is enhanced 
resulting in augmented retinal angiogenesis. Since activation of Notch1 by Dll4 suppresses 
sprouting, how can Jagged1 promote angiogenesis? The study found that Jagged1 and Dll4 
are not only expressed in a complementary fashion, but that Notch target genes like Hes1 and 
Hey1 are induced when Jagged1 is lost. During sprouting angiogenesis Jagged1 therefore 
seems to be an inhibitory Notch ligand, which competes with Dll4. This led to a model in 
which two Notch ligands hold a balance of Notch activation resulting in tightly controlled 
angiogenesis. 
The glycosyltransferase fringe modulates Notch activation upon exposure to different ligands 
by posttranslational modification of the receptor protein [78]. Fringe enhances Dll4-mediated 
and reduces Jagged1-mediated Notch activation. These findings add another level of 
regulation beyond the distribution and subtypes of Notch ligands and receptors. 
The angiogenic response is mediated by VEGF receptors. Tip cells express VEGF-R3 and 
stalk cells VEGF-R2. This balance is supposed to be regulated by opposing actions of Dll4 
and Jagged1 [78]. Indeed, inhibition of VEGF-R3 by genetic targeting or with monoclonal 
antibodies blocks sprouting angiogenesis [79]. 
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In summary, all findings so far show that the Notch 
ligands Dll4 and Jagged1 control sprouting angiogenesis 
by balanced Notch activation, which regulates tip and 
stalk cell selection and their function by the regulation of 
VEGF receptors 2 and 3. 
However, important aspects of sprouting angiogenesis still 
remain to be explained. First, increased sprouting and 
branching results from inhibition of the Dll4/Notch axis at 
different levels, such as in Dll4+/- mice, by deleting 
Notch1 in EC or by pharmacological Notch inhibition. 
These phenotypes are similar in the gross view, but fine 
differences are evident: pharmacological Notch inhibition, 
which inhibits activation of all Notch receptors, increases 
sprouting only at places of active angiogenic migration. 
This leads to the formation of vascular syncytia. These 
syncytia strongly resemble AV malformations observed in 
Notch1 mutant zebrafish and mouse embryos (see below). 
This confirms that dysbalanced endothelial Notch 
signaling impairs vascular boundary formation. In Dll4 
mutant mice filopodia protrusion is increased in the whole 
retina but syncytia do not form to this extent. The fact that 
the phenotypes observed by different ways of Notch 
inhibition slightly vary suggests that the mechanisms of 
angiogenesis in this context are still not fully discovered. 
Second, stalk cells are thought to be highly proliferating 
cells to build the vascular trunk. Dll4 mediated Notch activation is known to suppress 
proliferation which stands in contrast to this. Maybe the initial paradigm of migrating tip cells 
on one hand and proliferating stalk cells on the other hand can not be maintained. The studies 
in zebrafish reveal that the tip cell at the leading edge undergoes cell division and leaves one 
daughter cell behind [56]. This would favour a model in which tip cells are asymmetrically 
dividing EC leading the sprout and forming the trunk at the same time. 
Third, it is still unclear how a cell becomes a tip cell, since it is believed that all EC ‚start’ 
with the same molecular equipment. Initially it was thought that only the cell that experiences 
the highest VEGF concentration becomes a tip cell, i.e. tip cell differentiation would be a 
stochastic event. However this might not fully explain the mechanism [71]. The VEGF 
gradient is believed to guide tip cells radially towards the ora serrata. Vascular growth and 
subsequent perfusion reduce local VEGF expression through astrocyte differentiation. But 
how do side branches form? Can a stalk cell become a secondary tip cell to found a side 
branch, and is there a role for hemodynamic forces? After sprouting angiogenesis has covered 
the retinal surface vertical branching seeds a deep vascular plexus [78]. How is vertical 
branching regulated? It is in several aspects different from sprouting: It occurs from an 
established vascular plexus and not in parallel to vascular sprouting despite VEGF is present. 
Sprouting EC on the retinal surface do not need to migrate through tissue layers in contrast to 
branching EC. Taken together the current concept of sprouting angiogenesis does not explain 
vertical branching and three-dimensional vascular network formation. 
At last stalk cell identity and function are not well understood. If VEGF determines tip cell 
identity, then in the next step Dll4 would suppress tip cell identity in the neighbouring EC, 
resulting in a stalk cell. But what happens to the stalk cell behind the stalk cell? Do stalk cells 
constitute a homogenous population of EC? It is still unclear whether Jagged1, even if it is 
expressed in most stalk cells, determines stalk identity in following EC. 
Notch signaling also plays an important role in tumour angiogenesis, which is in many 
aspects similar to physiological sprouting. Tumour growth critically depends on oxygenation, 
and most tumours induce pathological angiogenesis for their own survival [80]. Many human 
solid tumours therefore express large amounts of VEGF and also the Notch ligand Dll4 at 
high levels [47]. Anti-VEGF antibodies are approved for treatment of many human tumours, 

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 >  Dll4 and Jagged1 control 
angiogenic sprouting by balancing 
endothelial Notch activity. 
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and novel therapies targeting Dll4 have been shown to reduce tumour growth. As we know 
from retina and zebrafish studies inhibition of Dll4 leads to more sprouting and branching, 
and this also happens in murine xenograft tumour models. Interestingly, tumour growth is 
reduced when Dll4 is targeted [74,76,77]. The vasculature in such treated tumours shows 
more capillaries due to increased sprouting and branching, however the capillaries seem to 
function not effectively as the vascular network is not set up properly and many capillaries are 
not connected to the network. As a result the tumours are less well perfused than control 
tumours leading to impaired tumour growth: Increased capillarization – less perfusion. Even 
if many more trials need to be performed before anti-Dll4 therapies reach the clinic, this is a 
promising new therapeutic approach [81]. However, from a physiological point of view this 
underlines the essential role of a well diversified arterial network for sufficient organ 
perfusion. Thus angiogenesis alone is not enough and might also have adverse effects when 
considering new approaches for regenerative therapies.  
Jagged1 has also been shown to be expressed in tumours and to enhance neovascularization 
and tumour growth. In contrast to anti-Dll4 therapies a soluble Notch1 decoy receptor led to 
reduced tumour growth without increased vascularization. This indicates that the principle of 
ligand balance for controlling sprouting angiogenesis [78] might also hold true for tumour 
angiogenesis, but that roles of individual Notch receptors would be different. 
AV malformations occur when arterial identity is lost 
Normally, the arterial and venous system is connected by capillaries, and formation of this 
three step system depends on the specification of arterial and venous identity. Once this is 
lost, AV malformations form which indicates disturbed vascular identity. In loss of function 
Notch mutants, e.g. Notch1-/- or Dll4-/-, AV-malformations are readily detectable [40,46,47]. 
Interestingly AV malformations also occur in Ephrin-B2 and in EphB4 deficient mice [6,33], 
indicating that perturbation of the arterial differentiation cascade at any step leads to a 
defective vascular network. 
Notch1-/- embryos die in utero from severe vascular defects. Mice homozygous for a null 
mutation of the Notch4 gene do not exhibit an obvious mutant phenotype, presumably 
because of functional redundancy with the Notch1 gene [38]. However, Notch1/Notch4 
double mutants show a more severe vascular phenotype compared to Notch1-/- embryos, 
indicating that Notch1 and Notch4 are closely interrelated in a complex endothelial signaling 
network.  
At first glance, one could assume that Notch signaling functions as an on-off switch: Notch 
on – arterial identity, Notch off – default venous cell fate. However, Notch signaling needs to 
be finely tuned and precisely timed. For example, overexpression of Notch4 in EC leads to 
premature death at embryonic day E10 due to defective embryonic vasculature [82]. The 
phenotype of these mutants is very similar to the Notch1/Notch4 double knockout [38]. The 
similarity between a gain-of function and loss-of-function mutation in the same gene family 
demonstrates that appropriate and balanced levels of Notch signaling are critical for proper 
vascular development. AV malformations also occur in humans and altered Notch signaling 
has been detected in human brain AV malformations [83,84]. Furthermore, conditional 
overexpression of Notch4 in postnatal EC leads to AV malformations in mice [84,85], 
strongly suggesting that dysbalanced Notch signaling plays a causative role also in human AV 
malformations.  
Notch and vascular smooth muscle cell homeostasis 
Most studies on the role of Notch in the vascular system focused on EC in development and 
physiology. However Notch signaling is not only a master regulator of endothelial cell fate 
and function, but also plays a critical role for vascular SMC. SMC in human adults are not 
terminally differentiated but partially retain plasticity to respond to external cues. 
Consequently SMC shift between proliferation, synthesis and differentiation. When a vessel 
grows SMC change their phenotype from differentiation to a synthetic and proliferative 
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phenotype. Thus, genes regulating the SMC phenotype are of fundamental interest for 
understanding vascular growth. 
Initial reports suggested that Notch suppresses SMC differentiation in vitro via induction of 
Hey2 [86-88]. The exposure of SMC to cyclic mechanical strain represses Notch1 and Notch3 
expression and induces SMC differentiation markers [89,90]. These cells also show reduced 
proliferation and increased apoptosis rates. Overexpression of Notch1 or Notch3 intracellular 
domains in these cells restored normal levels of proliferation and apoptosis, suggesting that 
the effects of hemodynamic forces on SMC phenotype shifts are at least in part regulated via 
Notch. Neointima formation by vascular SMC is significantly impaired in Hey2-/- mice [91], 
and aortic SMC isolated from Hey2-/- mice show reduced proliferation compared to those 
from wildtype controls. SMC overexpressing Hey1 [92] or Hey2 [93] show higher 
proliferation rates with reduced levels of the cyclin-dependent kinase inhibitors p21 and p27 
respectively. Hey2 seems to be a direct transcriptional repressor of p27kip1 [93]. However, 
canonical Notch signaling activated by Jagged1 induces SMC differentiation [94,95]. Marker 
genes for SMC differentiation such as smooth muscle myosin heavy chain (SMMHC) [94] 
and smooth muscle alpha-actin (SMA) [96] were identified as direct Notch target genes.  
Mice in which Notch signaling is completely ablated specifically in vascular SMC are viable 
and fertile. They show vascular abnormalities in cerebrovascular patterning. After carotid 
ligation these mice die from stroke due to insufficient collateral blood flow in the circle of 
Willis [97]. This indicates that Notch in vascular SMC is not necessary for general vascular 
development but that detailed arterial patterning, and possibly adaptation to injury requires 
cell-autonomous Notch signaling in SMC. This is confirmed by data from Notch3 mutant 
mice. Notch3 is specifically expressed in arterial but not in venous SMC [98]. Notch3-/- mice 
are also viable and fertile but show severe arterial defects with dilated arteries and a thinned 
SMC layer compared to wildtype mice [99,100]. There are just few markers for arterial 
identity in SMC, such as smoothelin [101] and SM22a [102]. Interestingly, SMC of Notch3-/-
mutant mice have drastically reduced expression of these markers, suggesting together with 
morphological differences that these SMC have lost arterial identity. However, while SMC 
lose arterial identity in Notch3-/- mutant mice, EC do not: They still express all established 
arterial EC markers such as ephrin-B2 and Hes/Hey genes, demonstrating that loss of SMC 
arterial identity does not influence EC identity [99]. 
Regarding the results of experiments on Notch signaling in SMC it is likely that Notch acts 
context-dependent. One very remarkable feature of Notch signaling is that ligand-receptor 
interaction results in different effects depending on the context. This is mainly due to the fact 
that Notch signaling depends on intimate cell-cell contact. Thus, the following questions are 
essential: Which cell bears the ligand and which one the receptor? Which ligand and which 
receptor are present? Is more than one ligand involved? At which step of a given process will 
the signaling event take place? Most of these questions are not answered yet for vascular 
Notch signaling. This is especially important since many cells in the cardiovascular system 
carry both the ligand and the receptor. It is therefore critical to perform studies in mice with 
concise conditional knockout concepts to find out in which cell type under which condition a 
given member of the Notch family is important. 
Usually Notch signals in trans between neighboring cells. If these two cells are of the same 
type it is called a homotypic interaction, if not it is called a heterotypic interaction. However, 
Notch can also signal in cis, i.e. a ligand on a given cell interacts with a receptor on the same 
cell which is believed to be inhibitory [23,24]. In general, Notch signaling inside the arterial 
wall in vivo would occur between neighboring EC (trans, homotypic), from EC by filopodia 
through the basal membrane to SMC (trans, heterotypic) or from SMC to SMC (trans, 
homotypic) [103]. Regarding the expression profile of Notch ligands and receptors in the 
adult arterial wall (Fig. ?, Table 3), it is tempting to assume that such interactions take place, 
however very little is known about these processes. It has been shown that Jagged1 from EC 
activates Notch3 in SMC in vitro [104]. Deleting Jagged1 selectively in the endothelium 
recapitulates the global Jagged1-/- phenotype: Mutant embryos die around E10.5 from severe 
cardiovascular defects. Interestingly Notch1 activation and ephrin-B2 expression in the 
arterial endothelium were normal, suggesting that endothelial Jagged1 does not signal in trans 
to EC and that loss of arterial identity in the endothelium does not account for the phenotype. 
However markers of arterial differentiation like SMA and SM22a were not expressed in SMC 
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of mutant embryos anymore, indicating that loss of Jagged1 in the endothelium disturbs SMC 
differentiation [105]. These results would favour a model of trans heterotypic signaling from 
EC to SMC. Whether this happens directly or indirectly remains unclear. Future studies 
employing distinct cell-type specific gene targeting will hopefully decipher the exact role of 
Notch signaling for SMC homeostasis and growth. 
CADASIL 
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy 
(CADASIL) is an inherited disease which is thought to be caused by a mutation in the Notch3
gene. It is the most common genetic cause of stroke and vascular dementia in adults [106]. 
CADASIL patients suffer from various symptoms including mood disorders, cognitive 
decline, headaches, dementia or recurrent strokes, often resulting in premature death. 
Histopathological findings include degeneration of vascular SMC and accumulation of 
granular osmiophilic material (GOM) at the SMC basement membrane [107]. The 
accumulation is a typical and characteristic feature of CADASIL biopsy results. 
The mutations found in the Notch3 gene are located in the EGF-like repeats of the Notch3 
extracellular domain and do not lead to inactivation of the receptor. The mutations rather lead 
to accumulation of the Notch3 ectodomain in the cerebral microvasculature and constitute 
parts of the GOM deposition. Two mouse models of CADASIL exist, both of which carry 
Notch3 mutations found in patients. In one model, the endogenous murine Notch3 gene 
carries an Arg142Cys knock-in mutation [108]. However, these mice do not show CADASIL-
like symptoms or a related phenotype. The second model is a conditional mutant mouse 
carrying a human Notch3 cDNA with the Arg90Cys mutation in vascular smooth muscle cells 
[109]. These mice show classical histopathological features like Notch3 ectodomain 
accumulation and GOM deposits in arterioles, however a parenchymal brain damage is 
lacking. The cerebral vasoreactivity in these mice is impaired, suggesting that the introduced 
Notch3 mutation affects arterial function [110]. On the other hand, the introduced mutation 
does not impair Notch3 signaling in vivo [111]. Taken together, CADASIL seems not to be 
caused by impaired Notch3 signaling but by a novel mechanism which leads to Notch3 
protein accumulation. Whether the accumulated Notch3 protein acts as a decoy and locally 
inhibits Notch signaling or unspecifically disturbs SMC integrity remains unclear. Further 
insights from existing or novel mouse models will hopefully completely explain the disease 
mechanisms and lead to new therapeutic approaches in the future. 
Notch signaling and postnatal arteriogenesis 
The rescue of ischemic tissue critically depends on adequate perfusion. In postnatal life 
arteriogenesis, i.e. the growth of collateral arteries to conductance vessels, is sufficient to 
restore perfusion after disruption of blood flow (Fig. 0). To date much more is known about 
specific roles of Notch signaling for embryonic than for postnatal arteriogenesis. However the 
indispensable role of Notch signaling for both embryonic development of arteries and 
homeostasis of the arterial system in later life strongly suggest that Notch pathway members 
control postnatal arterial growth. Consequently very recent pivotal studies demonstrate an 
essential role of Notch signaling for postnatal arteriogenesis [43,112,113]. 
Notch1-/- mice die during embryogenesis from severe vascular defects, involving failure to 
remodel the primary vascular plexus [38]. Endothelial Notch1 ablation fully recapitulates this 
phenotype [39]. However global and endothelial-specific Notch1 heterozygous mice are 
viable. Limb necrosis after ischemia is strongly increased in these mice and blood flow 
recovery is impaired while VEGF-A upregulation is not altered compared to control mice 
[114]. This indicates that endothelial Notch1 is important for postnatal arterial growth. 
Furthermore this demonstrates that a genetic program which controls embryonic 
arteriogenesis is also essential for postnatal arterial growth. 
Postnatally the Notch ligand Dll1 is expressed selectively in the endothelium of medium and 
large arteries but not in veins or capillaries [43]. To test its role for postnatal arteriogenesis we 
employed a well established model of hind limb ischemia (Fig. 4), in which defined collateral 
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arteries in the mouse hind limb grow upon ligation of the femoral artery [115]. After ligation 
altered hemodynamic parameters such as fluid shear stress dynamically trigger initiation and 
maintenance of collateral arterial growth [116,117]. During growth of collateral arteries Dll1 
is strongly upregulated in the endothelium, and Notch signaling is activated as shown by the 
appearance of cleaved Notch and upregulation of Hes1, Hey1 and ephrin-B2. Dll1 
heterozygous mice are viable and fertile and do not show gross abnormalities of the vascular  
system. However, collateral arteries in these mice fail to grow upon femoral artery ligation, 
demonstrating that Dll1 is essential for postnatal arterial growth [43]. Limb necrosis and 
autoamputation is dramatically increased compared to wildtype controls. Induction of Notch 
target genes such as Hes1, Hey1 and ephrin-B2 in the vascular wall is lost in Dll1 
heterozygous mice. Since Dll1 is specifically expressed in the arterial endothelium, these 
results suggest that endothelial Dll1 is a critical mediator of a growth signaling cascade and 
that Dll1 haploinsufficiency impedes vascular Notch signaling. Interestingly, VEGF was 
upregulated in wildtype as well as in Dll1 heterozygous arteries during growth, recapitulating 
that VEGF is upstream of Notch. 

 0  Postnatal Arteriogenesis. Occlusion of a main artery leads to growth of collateral vessels which 
become conductance arteries. Dll1-mediated Notch signaling in the vascular wall is essential for collateral artery 
growth and rescue of downstream ischemic tissue.
Another study confirmed the involvement of Dll1 in growth of postnatal arteries [112]. In this 
study a model of carotid ligation was employed, in which ligation of the left carotid artery 
leads to increased blood flow and outward growth of the unligated carotid artery on the right 
side. Dll1 was strongly induced in the unligated artery, and this induction happened to occur 
shortly after ligation, indicating that Dll1 expression might respond to changes in blood flow. 
A very recent study investigated the vascular response to different flow conditions [113]. In 
human arterial endothelial cells pulsatile shear stress induced the expression of Hey1, Hey2, 
Hes1 and ephrin-B2. Dll1 and Dll4 induction was not statistically significant but showed a 
strong trend. Another study reported induction of Notch1 and Notch4 mRNA in human 
umbilical vein endothelial cells exposed to cyclic strain [118]. Notch3, which is primarily 
expressed in arterial SMC, was recently identified to be important for vascular 
mechanotransduction. Resistance arteries from Notch3 deficient mice contract normally upon 
stimulation with agents like phenylephrine or angiotensin. However shear stress induced 
vasodilation is abolished in these mice, indicating that Notch3 in SMC plays a role in the 
arterial response to changes in the blood flow pattern [119]. Together these results suggest a 
link between shear stress as an indispensable regulator of arteriogenesis and vascular Notch 
signaling. 
However, many questions are still unanswered: How is the spatial relationship between 
vascular wall cells regarding Notch signaling? Which receptors are activated during growth, 
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and which cells are the primary „receiver“ cells in this process? Is Notch signaling sufficient 
to induce arteriogenesis, maybe also in venous grafts? Ongoing studies will hopefully answer 
these and many more open questions in the near future. 
Specific roles of individual Notch ligands in the vascular system 
There is increasing evidence that given Notch ligand-receptor pairs exert specific effects, 
which suggests unique roles for individual ligands in the vasculature (Fig. ?). The amount of 
ligand expressed on a given cell is important for the signaling process and should be 
considered when analyzing genetically engineered mice: Low expression might not be 
sufficient to induce Notch signaling consistent with a threshold model of receptor activation 
[120]. The cleaved part of the intracellular domain of the four Notch receptors is supposed to 
be identical in terms of the molecular structure, however this does not necessarily reflect 
functional identity. Transgenic mice expressing activated forms of Notch1 or Notch3 in 
thymocytes display different phenotypes, indicating that the intracellular domains of the four 
Notch receptors exert different functions downstream [121,122]. This assumption was not 
specifically tested yet in the vascular system, but is likely to hold true in this context as well. 

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The expression of Dll4 precedes the expression of Dll1 in embryonic vessels [38,123,124], 
suggesting that the initial development of the arterial system depends on Dll4 and its 
maturation, diversification and growth might be controlled by Dll1. In EC-specific Dll1 
mutants the expression of arterial markers like ephrinB2 is lost and venous markers like 
Coup-TFII are upregulated despite the continuing expression of Dll4 [124]. Dll1 mediated 
Notch1 activation upregulates VEGF-R2 (KDR) and its coreceptor neuropilin-1, suggesting 
that Dll1 enhances the responsiveness of an arterial endothelial cell to VEGF-A stimulation. 
Dll1-/- mice die from severe hemorrhage at E11.5 [125], i.e. slightly later than Dll4-/- mice, 
however Dll+/- mice are viable and fertile [43] in contrast to Dll4 heterozygous mice. After 
birth Dll1 is selectively expressed in the arterial endothelium and an essential ligand for 
postnatal arteriogenesis [43]. Taken together Dll1 is not required for vasculogenesis and the 
initial specification of arterial identity in EC, but essential for arterial maturation, 
maintenance of arterial identity and postnatal growth of arteries (Fig. ?). 
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Dll3-/- mice die in utero from severe skeletal defects due to disorganized somite formation 
[126]. Dll3 mutations in humans have been linked to a disease called spondylocostal 
dysostosis [127]. A role of Dll3 for the vascular system has not been reported yet (Fig. ?). 
"0
Dll4 is the first Notch ligand to be expressed in the developing vasculature [38,128,129]. It 
controls arterial identity and is indispensable for arterial network formation (Fig. ?) 
[40,46,47]. As a result, Dll4-/- mice die at E10.5, and Dll4+/- are viable only under specific 
conditions (see Table 4). Dll4 expression decreases in the arterial endothelium during 
development and after birth Dll4 is detectable only in small but not in large arteries [43]. 
Whether Dll4 is necessary for arterial homeostasis after birth is unknown. Dll4 is expressed 
by endothelial tip cells and controls sprouting angiogenesis by activating Notch1 in adjacent 
stalk cells, in this context inhibiting endothelial sprouting [70]. Dll4 is strongly expressed in 
tumours and blockade of Dll4 in experimental tumour models leads to ineffective and 
uncoordinated vascular sprouting resulting in impaired tumour perfusion [74,76,77]. 
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In Jagged1-/- mice vasculogenesis is normal. However, the remodeling of the primary vascular 
plexus is severely impaired leading to intrauterine death at E10 [130]. The observed 
phenotype is not as severe as in Dll4 or Notch1 mutant embryos. Endothelial cell specific 
deletion of Jagged1 recapitulates the phenotype of global deletion and results in loss of 
arterial differentation of SMC, indicating a direct role of Jagged1 for SMC maturation 
[104,105]. Morphological abnormalities in Jagged1 mutant mice appear slightly later than in 
Dll4 or Notch1 mutant mice, indicating that this Notch ligand becomes important when initial 
vascular formation has started. Jagged1 promotes endothelial sprouting and opposes the 
actions of Dll4 in this context (Fig. ?) [78]. Mutations in the Jagged1 gene are associated with 
Alagille syndrome [131], an inherited human disease (see below). 
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Jagged 2 is expressed in the arterial endothelium and upregulated after experimental balloon 
injury [129,132]. Analysis of Jagged2 mutant mice suggests that Jagged2 plays an essential 
role during limb, craniofacial, and thymic development [133]. Whether or not there is a role 
of Jagged2 for the vascular system remains unknown (Fig. ?). 

Adult vascular homeostasis 
As described above Notch signaling critically controls arterial development and is essential 
for postnatal SMC physiology. It is therefore tempting to speculate that Notch is a general 
regulator of vascular homeostasis after birth. Hence, genes responsible for arterial identity 
might not only be marker genes but be functionally essential to sustain arterial environment 
and to prevent arterial disease. 
The postnatal ablation of RBPj in mice leads to spontaneous and disorganized angiogenesis 
[134]. Notch target genes are strongly downregulated, while VEGFR2 and proliferation rates 
are increased in Notch-signaling deficient mice. These findings suggest that Notch suppresses 
proliferation to maintain vascular homeostasis. However, the Cre deleter used in this study is 
rather unselective [135]. Since Notch acts highly context-dependent and most Notch mutants 
die in utero, inducible and specific gene targeting after birth is necessary to investigate the 
role of Notch signaling for the postnatal vascular system. The availability of specific 
inducible Cre deleter lines allows the selective ablation of Notch pathway members in EC and 
SMC on demand. The combination of such genetic approaches with suitable animal models of 
vascular adaptation and growth will clarify the role of Notch pathway members for adult 
vascular homeostasis. 
Other human cardiovascular disorders associated with defective Notch signaling 
The fundamental relevance of Notch signaling for vascular physiology is apparent through 
inherited (cardio-)vascular diseases caused by mutations in Notch pathway genes. Besides 
CADASIL, which was described above, two more diseases with cardiovascular abnormalities 
are linked to the Notch signaling pathway. 
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Alagille syndrome is a human disease with an autosomal dominant inheritance. It is 
characterized by abnormalities in heart, skeleton, liver, eye, kidney and some other organs 
[136]. In most cases of Alagille syndrome mutations in the Jagged1 gene are observed [131], 
however rarely mutations in the Notch2 gene were described [137]. Most Jagged1 mutations 
lead to null alleles, suggesting that Jagged1 haploinsufficiency is causative for the disease. 
However, data from mouse models demonstrates that Jagged1 mutations are not likely a 
sufficient explanation tor Alagille pathogenesis. Jagged1-/- mice die during embryogenesis. 
Jagged1 heterozygous mice develop eye defects similar to Alagille patients but lack other 
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abnormalities typical for the disease [130]. This indicates that Jagged1 deficiency alone can 
not explain Alagille disease. 
However, a combined mutant mouse model heterozygous for the Jagged1 null allele and a 
hypomorphic Notch2 allele reproduces the gross Alagille phenotype: These mice show nearly 
all developmental defects characteristic for the Alagille syndrome, e.g. growth retardation and 
developmental abnormalities in eye, heart, kidney and the biliary system [138]. Cardiac 
defects in Alagille patients comprise hypoplasia or stenosis of the pulmonary artery or the 
pulmonic valve or tetralogy of Fallot. Since Notch signaling has been shown to be required 
for the differentiation of cardiac neural crest cells into smooth muscle cells, it is likely that 
Notch signaling defects are directly involved in the cardiac defects in Allagille patients [95]. 
Taken together, pathogenesis of Alagille syndrome is complex and not yet fully understood 
but definitely involves a deficiency in Jagged1 mediated Notch signaling. 
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Bicuspid aortic valves occur in 1-2% of the population and are the most common congenital 
heart defect [139]. Bicuspid aortic valves predispose to aortic stenosis in adulthood. Aortic 
valve calcification is linked to RUNX2 which is regulated by Notch signaling [140]. 
Heterozygous Notch1 mutations were described in two independent families with autosomal 
dominant bicuspid aortic valves [140], and in 4% of patients with a sporadic bicuspid aortic 
valve Notch1 mutations can be found [141]. Even if bicuspid aortic valve therefore does not 
seem to be a monogenic disease, there is strong evidence that the malformation reflects 
defective epithelial-to-mesenchymal transformation associated with impaired Notch1 
signaling [142-144]. 
Conclusion 
The Notch signaling pathway is essential for arterial development and growth, both during 
development and after birth. Many different genetic approaches demonstrate the essential role 
of Notch ligands, receptors and target genes for arterial identity and remodeling. However, 
new genetic tools enable us to specify this role to distinct Notch pathway members in specific 
cellular environments. More selective gene targeting design is now required to specifically 
adress temporo-spatial contexts of arterial growth. This will not only elucidate the molecular 
and cellular mechanisms how Notch controls arterial development and growth but also 
identify specific roles of every ligand and receptor for distinct aspects of arterial physiology. 
Hopefully soon this will directly translate into new therapeutic approaches for cardiovascular 
disease.  
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Ephrin-B2 [6, 33, 34, 145] EphB4 [6, 33, 34] 
Dll1 [43, 113] Neuropilin-2 [146, 147] 
Dll4 [113, 129] COUP-TFII [59, 113] 
Jagged1 [129] Msr/Apj [148] 
Jagged2 [129] 
Notch1 [129] 
Notch4 [129] 
Bmx [149, 150] 
Neuropilin-1 [60, 146] 
Connexin 37 (Gja4), 
Connexin 40 (Gja5) 
[60, 113, 151, 152] 
Alk-1 [153] 
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Notch3 [98] 
Smoothelin [101] 
Sm22a [102] 
Ephrin-B2 [145] 
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VEGF, bFGF Dll1 Arterial EC Postnatal arteriogenesis [43] 
Foxc1, Foxc2 Dll4 Arterial EC Embryonic arteriogenesis [52, 53] 
VEGF-A Dll4 Arterial EC 
Arterial EC 
Arterial identity 
Sprouting Angiogenesis 
[45, 52] 
[71, 73] 
TNFa Dll4, Jagged1 Arterial EC Sprouting angiogenesis [78] 
Jagged1 Jagged1 Arterial SMC SMC maturation [104] 
Hypoxia Dll4 [154] 
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Dll1 Endothelium of middle and large arteries [43, 123, 129] 
Dll3 Not known to be expressed in the vascular system 
Dll4 Endothelium of small arteries, tumour vessels, tip cells of vascular 
sprouts. Absence in veins. Absence in large arteries. 
[38, 46, 47, 128, 129] 
Jagged1 Arterial endothelial and arterial smooth muscle cells [95, 104, 129, 155] 
Jagged2 Arterial EC [129, 156] 
Notch1 Arterial EC [129, 157, 158] 
Notch2 Not characterized yet 
Notch3 Arterial smooth muscle cells [98, 104] 
Notch4 Vascular EC [129, 159, 160] 

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? Comparison of Notch Ligands and Receptors. The vascular expression profile and the main functions 
in the vascular system are shown.
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Dll1+/lacZ 
(resulting in embryos 
heterozygous for Dll1) 
Defective postnatal arteriogenesis. Viable and fertile [43, 124, 125] 
Dll1lacZ/lacZ 
(embryos lack both Dll1 
alleles) 
Defective somitogenesis. 
Generalized hemorrhage from E10.5 
onward. 
Intrauterine death at 
E11.5 
[125, 161] 
Dll1lacZ/Dll1kineo
(a combination of a null 
allele and a hypomorphic 
allele) 
Normal formation of myotubes, but 
from E13 onward severe muscle 
hypotrophy 
Normal arterial wall structure but 
smaller lumen of large arteries. 
Increased capillary branching in the 
skin at E17.5 
Death at birth [124, 162] 
Dll1 
VE-Cadherin-CreERT2 x 
Dll1f/f 
(postnatal knockout of 
endothelial Dll1) 
Loss of arterial identity in EC. 
Normal arterial wall structure but 
smaller lumen of large arteries. 
Long term survival was 
not studied 
[124] 
Dll3 Dll3-/-2 Disorganised vertebrocostal 
skeleton, delayed somitogenesis. No 
observed vascular defects. 
Death between birth 
and postnatal day 10 
[126] 
Dll4+/lacZ 
(resulting in embryos 
lacking one Dll4 allele) 
Severity of phenotype varies. 
Reduced vitelline circulation, 
decreased yolk sac branching, 
variable degree of calibre reduction 
of the dorsal aorta. In cases of 
stronger constriction also calibre 
reduction of the posterior cardinal 
vein. Some animals show enlarged 
pericardial space. In adult mice 
capillary sprouting is increased. 
(Phenotype is background-
dependent) 
A proportion of 
embryos dies in utero. 
Surviving animals are 
viable and fertile 
[46, 71-75] Dll4 
Dll4lacZ/lacZ 
(resulting in embryos 
lacking both Dll4 alleles) 
Normal vasculogenesis, but later on 
severe vascular defects in the yolk 
sac and embryo proper due to 
missing maturation of the primary 
vascular plexus. Disorganized and 
fused vessels. Severe aortic 
constriction. Loss of arterial and 
gain of venous marker expression in 
the aorta. Strongly resembles the 
Notch1-/-/Notch4-/- phenotype. 
Intrauterine death 
between E9.5 and 10.5 
[40, 46, 47, 163] 
Jagged1-/- Normal initial vascular 
development, but later on vascular 
defects due to defective plexus 
maturation. Impaired embryonic 
hematopoiesis. 
Intrauterine death 
between E10.5 and 
E11.5 
[130, 164] 
Jagged1+/- Eye defects (coloboma), no 
observed vascular abnormalities 
Viable and fertile [130] 
Jagged1 
Tie2Cre x Jag1f/f Recapitulates the Jagged1-/-
phenotype 
Intrauterine death 
between E10.5 and 
E11.5 
[105] 
Jagged2 Jagged2-/- Syndactylia, defects in craniofacial 
morphogenesis and thymic 
development. No observed vascular 
abnormalities 
Perinatal death [133, 165] 
Notch1 Notch1-/- Defects in somitogenesis. Normal Intrauterine death [38, 166-168] 

2 Spondylocostal dysostosis is an inheritable human disease characterized by similar vertebrocostal defects. Dll3 
mutations are supposed to be causative for the disease.
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vasculogenesis, but severe vascular 
defects in the yolk sac and embryo 
proper due to defective plexus 
maturation. Enlarged pericardial 
sac, aortic constriction. 
around E10.5 
Tie2Cre x Notch1f/f Profound vascular defects 
recapitulating the general Notch1-/-
phenotype 
Intrauterine death at 
E10.5 
[39] 
Tie2Cre x Notch1+/f Impaired postnatal angio-
/arteriogenesis 
Viable and fertile [39, 114] 
Tie2-Cre x N1ICDtg 
(resulting in 
panendothelial 
overexpression of the 
intracellular domain of 
Notch1) 
Defective vascular remodeling, 
increased diameter of the aorta. AV-
malformations, which are 
morphologically different from 
Notch1 loss-of-function models 
Not studied yet  [169] 
Notch2del1/del1 
(targeted mutation 
resulting in a 
hypomorphic allele) 
Myocardial hypoplasia, edema, 
disturbed hyaloid vasculature in the 
eye, impaired glomerular 
development in the kidney 
Perinatal death [136] 
Notch2lacZ/lacZ 
(embryos lack both 
Notch2 alleles) 
Premature and increased apoptosis 
especially in neural tissue 
Intrauterine death at 
E10.5 
[170] 
Notch2 
Notch2+/lacZ 
(resulting in Notch2-
heterozygous embryos) 
No abnormalities reported Viable and fertile [170] 
Notch3 Notch3-/- Defective maturation and arterial 
identity of vascular SMC. Enlarged 
arteries with thinner SMC layer 
Viable and fertile [99, 100] 
Notch4-/- No obvious phenotype under normal 
conditions 
Viable and fertile [38] 
VEGF-R2Notch4tg 
(transgenic Notch4-
overexpression in 
embryonic EC) 
Disorganized vascular network, 
dilated blood vessels, AV-
malformations 
Intrauterine death at 
E9.5-10.5 
[82, 85] 
Notch4 
Tie2-tTANotch4tg 
(transgenic Notch4-
overexpression in 
postnatal EC) 
Profound vessel enlargement and 
AV-shunts, ectopic arterial marker 
expression 
Death within weeks 
after onset of transgenic 
expression 
[85] 
Notch1/ 
Notch4 
Notch1-/-/Notch4-/- Similar to Notch1-/-. 50% of Notch1-
/-/Notch4-/-embryos show a more 
severe phenotype than Notch1-/-
embryos.3
Intrauterine death 
between E9.5 and E10.5 
[38] 
RBPj-/- Defective neurogenesis, 
somitogenesis and vascular 
remodeling. Phenotype is more 
severe than in Dll4 or Notch1 
mutants, and resembles the Notch1-/-
/Notch4-/- phenotype 
Intrauterine death at 
E9.5 
[40, 171] 
Tie2-Cre x RBPjf/f 
(resulting in EC specific 
ablation of RBPj) 
Complete lack of vascular 
remodeling. Phenotype similar to 
that of Notch1-/- mutant mice. 
Intrauterine death at 
E9.5 
[40] 
RBPj
Mx-Cre x RBPjf/f Spontaneous angiogenesis in 
severeal organs, increased 
endothelial proliferation 
Postnatal gene targeting 
approach; it is unknown 
whether survival is 
affected 
[134] 
Hey1-/- No obvious phenotype Viable and fertile [49, 172] 
Hey2-/- Congenital heart defects Death in the first week 
after birth 
[173-176] 
Hey 
Hey1-/-/Hey2-/- Normal initial vasculogenesis, but 
loss of all further vascular 
remodeling. Enlarged pericardial 
sac, massive hemorrhage. 
Intrauterine death at 
E9.5 
[48, 49] 

3 The incomplete penetrance may be due to the fact that these mice were bred on a mixed background.
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HeyLlacZ/lacZ No obvious phenotype Viable and fertile [142] 
Hey1-/-/ HeyLlacZ/lacZ Congenital heart defects, similar to 
Hey2-/-
Death during the first 
postnatal days 
[142] 
Hes1-/- Severe neurogenesis defects; a role 
for the cardiovascular system has 
not been reported yet 
Death between E12.5 
and birth 
[177] 
Hes5-/- no obvious phenotype Viable and fertile [178, 179] 
Hes1-/-/Hes5-/- Similar to Hes1-/-, but more severe. 
Earlier lethality. 
Death around E10.5 [178, 179] 
Hes7+/lacZ 
(resulting in embryos 
heterozygous for Hes7) 
Adult mice appear nomal, but 43% 
have kinked tails 
Viable and fertile [180] 
Hes 
Hes7lacZ/lacZ 
(resulting in embryos 
lacking both Hes7 
alleles) 
Severe somitogenesis defects Perinatal death from 
respiratory failure due 
to chest abnormalities 
[180] 
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$ Collateral vessels grow in response to arterial narrowing and occlusion. Under favorable conditions 
collaterals can replace part of the function of the occluded artery (40% in the canine heart, more in the peripheral 
circulation of some mouse strains, but some degree of muscular atrophy persists). The molecular pathways are 
two-pronged: inflammatory with participation of factors of the innate immune system, and shear stress 
dependent, which latter is the initiating factor.  Blockade of inflammatory reactions leads to partial reductions of 
arteriogenesis. Only the inhibition of all NO production completely blocks collateral growth. Special NO donors 
are stimulants. A specific vascular smooth muscle mitogen induced by shear stress activated endothelium 
remains unknown. This holds true also for possible monocyte generated mitogens. 

Introduction 
The basics. Collateral vessels develop as a response to arterial occlusion. They are already 
universally present before occlusion as part of the arteriolar network feeding capillaries of 
heart, brain, intestines, kidneys and skeletal muscle [1-2]. As such they are constantly 
perfused and assume their role as “collaterals” only after arterial occlusion. Number and size 
of collateral vessels are genetically determined by the varying degree of pruning of the 
network of which they are a part during embryonal development [3], but genetic proof exists 
only for several mouse strains. The hearts of domestic pigs, rabbits, sheep and ponies exhibit 
collateral connections only at the capillary level [4]. Human hearts are endowed with 
anastomoses on all levels from arterioles to capillaries but number and size exhibit a bell-
shape distribution with a 30micrometer diameter in the top class [5-7].  
The shortest connections between pre- and post-occlusive branches of the arteriolar network 
(when present) enlarge by active growth, which is most impressive in the canine heart where 
the radius of grown mature sub-epicardially located vessels increases 10fold and in some 
cases more [1-2,8-9]. Human hearts exhibit only occasionally large epicardial collaterals. 
Most connections are located in the sub-endocardium and consist of large thin-walled micro-
vessels forming a network.  We have investigated the collateral circulation of pigs following 
gradual occlusion of the left circumflex coronary artery and found that although connections 
existed only at the capillary levels, infarcts could be prevented provided the time to occlusion 
was longer than necessary for the canine heart [10]. In the latter growth-enlarged collaterals 
carry blood into the distal part of the occluded artery, which serves, like in the normal state, as 
a distribution system for the blood flow to the tissues. The pressure in the distal stump of an 
occluded canine coronary artery is an indicator of the resistance of the collateral system 
provided the resistances of the micro-vascular system are equal [9]. That situation is reached 
by inducing maximal vasodilatation, which “clamps” the peripheral resistance to its lowest 
possible level. The higher the post-occlusive pressure (or peripheral coronary pressure, PCP) 
the lower the collateral resistance. Conversely, acutely increasing collateral flow lowers PCP, 
which is highest at no flow. 
In the porcine heart collateral flow is carried directly into the tissue by enlarged capillaries, 
and it cannot use the distal post-occlusive arterial distribution system. Pressure measurements 
at that point tend to be very low and the diagnostic significance remain questionable.  
Peripheral coronary pressure measurements in human patients have become routine in places 
with an interest in the coronary collateral circulation [11-13]. Pressures measured in an 
atherosclerotic occluded vessel that was opened by balloon angioplasty and then re-closed 
again with a balloon after placing a micro-manometer into the distal part of the artery, tend 
also to be very low, like in porcine hearts. In contrast to canine hearts, where the peripheral 
coronary pressure falls with increasing flow over the collateral vessels, it may rise 
occasionally in human patients after the vasodilatation of exercise or after chemical 
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vasodilators. This can be explained by assuming a rise of the arteriolar pressure in the 
adjacent normal myocardium, as it is typical for arteriolar pressure at vasodilatation and 
which is transmitted via collaterals to the point of pressure measurement. Groups of patients 
so tested exhibit a wide data scatter which is perhaps not only due to the degree of 
collateralization but also of the types of collateral, i.e., whether it had issued from pre-existent 
arterioles or from capillaries. 
Role of ischemia. Arterial occlusion leads to tissue ischemia but growing collaterals lie 
usually outside the ischemic region and cannot themselves become ischemic because they 
carry oxygenated arterial blood [5-6,14-15]. The nucleotide spectrum of black mice after 
femoral occlusion, obtained by magnetic resonance, remains normal when focused at the 
region where collaterals grow from pre-existing precursors [16]. Aortic occlusions in the in 
zebra fish gridlock mutation are salvaged by collaterals in a fully oxygenated medium [17].  
Physical forces 
The initial trigger for growth by mitosis is fluid shear stress (FSS), which is caused by the 
increased blood flow velocity within the interconnecting network, a consequence of the large 
difference between the upstream and the low downstream pressure, relative to the point of 
occlusion[1,18]. Stretch experiments in vitro showed that circumferential wall stress rather 
than fluid shear stress maybe the molding force acting via the transcription factor AP-1 [19]. 
However, AP-1 is also activated by fluid shear stress and whereas pressure derived forces act 
on both the endothelium as well as on the media, fluid shear stress acts exclusively on the 
endothelium, which is known to play a leading role in arteriogenesis. Increased FSS leads to 
endothelial activation seen first as cell swelling, caused by loss of osmotic control brought 
about by activity changes of ion channels (Cl-, K+, Ca++) [3,20-21]. The discussion about the 
role of FSS and the other stresses oscillates back and forth since about 100 years but the 
stronger evidence is clearly in favor of FSS since Guzman and our group could show that the 
high flows and low pressures observed in arterio-venous shunts resulting in increased 
arteriogenesis can only be explained by increased FSS [22] (see chapter 5). 
Endothelial cells change phenotype into a synthetic and proliferative one with synthesis of 
cytokines (MCP-1) [23] and adhesion molecules (ICAM-1, VICAM-1) [1]. Adhesion and 
invasion of monocytes follow and endothelial mitoses become visible at day 2 [9]. FSS, only 
a weak force compared to pressure-related forces acting on the vascular wall, is able to 
activate the IIS as we have recently shown [24-25].  
The cell cycle time of smooth muscle cells from the initial stimulus to completion of mitosis 
is about 22 hours [8]. Interventions aimed at stimulation of collateral growth must consider 
these constraints. Since myocardium dies within about one hour after an acute coronary 
occlusion, growth factor therapy arrives too late even if applied at the moment of occlusion. 
However, slowly progressing experimental coronary stenosis is tolerated without infarction 
when the time to occlusion does not fall below 3 - 6 days depending on species [26]. Un-
stimulated skeletal muscle has a longer ischemic tolerance and acute femoral occlusion is 
tolerated without tissue damage in some species of mammals like rabbits, rats and certain 
mouse strains. 
The 

 of the media change from a contractile to a synthetic phenotype by 
altering expression of SM-actin binding genes, like abra, thymosin-beta 4, smoothelin, destrin 
and cofilin and start to divide [27] (see chapter 5). Meanwhile the %
 and 
the expression of matrix-metallo-proteinases (MMPs) had led to the digestion of matrix and 
of the internal elastic lamina, provisions for the radial enlargement of the vessel [2]. Most 
monocytes/bone marrow derived cells are recruited from the perivascular tissue and are 
attracted by the chemokine MCP-1 that is strongly expressed in the smooth muscle cells of 
pre-existent collaterals in response to a signal emanating form the fluid shear stressed 
endothelium. Radial enlargement is only possible by creating new extra-vascular space, a task 
of invading T-cells and NK-cells [28-29].  
Reduction of the number of monocytes by cytostatics (5-fluoro-uracil) or by studying animals 
with low monocyte counts (osteopetrosis) or knock-down with nano lipid-particles containing 
bisphophonates inhibits- and infusion of monocytes stimulates collateral growth [20, 30]. 
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Monocytes do not undergo a metaplastic change into endothelial or smooth muscle cells [31]. 
They serve as producers of cytokines, growth factors and NO [32].  
The role of NO
We noticed that excessive growth of collaterals under high FSS created by an arterio-venous 
shunt was inhibited by L-NAME [1], which is a non-specific inhibitor that, depending on 
dose, inhibits all forms of NOS. We showed recently that genetic targeting of eNOS did not 
inhibit collateral growth [33]. It inhibited blood flow recovery to the paw skin of the affected 
hind limb but this was caused by vaso-spasm, which could be unmasked by test injections of 
NO-donors. Deep muscle blood flow, measured by Magnetic Resonance Imaging remained 
normal compared to wild type animals [16,34]. Only the combined inhibition (eNOS 
knockouts treated with the iNOS-specific L-NIL) completely blocks collateral growth [32]. 
Which suggests that one isoform can substitute for the other. It is known that low activity or 
absence of constitutive NOS induces iNOS, which must have been the case in eNOS targeted 
mice that showed almost normal arteriogenesis [35]. Our data would not exclude the 
possibility that NO from eNOS is rapidly exhausted by persisting high shear stress during the 
earliest stages of collateral growth. This would favor adhesion of monocytes to the activated 
endothelium, which, with normal eNOS activity, would not occur. Monocyte derived iNOS 
and increased transcription and translation of eNOS would, at later stages, boost NO 
production. Since early exhaustion of NO availability is imaginable we tested the effects of 
NO donors and found that the close-collateral intra-arterial infusion of detaNONOate is a 
strong stimulant of arteriogenesis [32]. This property was not shared by the classical NO 
donors glyceryltrinitrate and Sin-1, the latter being a significant suppressor of collateral 
growth probably because of its ability to produce peroxinitrite. 
The role of the innate immune system  
Monocytes, accumulating close to growing collaterals, stained positive for TNF alpha [23, 
36], TGF-beta, FGF-2 [37] and iNOS. The changes in the tissue concentrations of the factors 
resp. cells are symptoms for the activation of the innate immune system (IIS) and LPS, the 
classical activator of the IIS, indeed over-stimulates collateral growth [23]. Genetic targeting 
of TNF-alpha and its receptor partially inhibits arteriogenesis [38]. These findings strongly 
suggest that increased fluid shear stress, the primary trigger for collateral artery growth, is 
also a stimulant for the IIS, which is important for regeneration via collateral vessels. This in 
line with our observation that Toll-like receptors, initiators of the IIS, are up-regulated in the 
early stages of collateral growth (Troidl, unpublished). The observation that transplanted 
human hearts under full immune-suppressive medication are able to grow collaterals let the 
role of the IIS in arteriogenesis appear in a more complex light [11].
The role of VEGF
VEGF plays an important role in angiogenesis but its role in arteriogenesis is less clear. 
Smooth muscle cells play a key role in arteriogenesis if only because of their tissue mass, 
much larger than that of ECs. Endothelial mitosis is clearly dependent on the presence of 
VEGF and the role of the endothelium in directing the growth of medial smooth muscle is 
also undisputed. However, VEGF is not a SMC mitogen and hence cannot play a direct role 
in SMC mitosis. VEGF mRNA is not detectable (neither by in-situ hybridization nor by 
micro-array) in high fluid shear stressed collateral vessels [39]. Furthermore it was never 
shown that VEGF is released under in vivo conditions from fluid shear stressed endothelium. 
VEGF protein infusions over 7 days into the peripheral collateral circulation of rabbits did not 
stimulate the development of collateral vessels [40]. This contradicts earlier pharmacological 
studies, where massive single doses, leading also to edema, had a positive effect upon 
restitution of lower leg blood flow in rabbits. However interesting, this does not necessarily 
suggest a role of VEGF in the patho-physiological process of arteriogenesis. VEGF is up-
regulated by hypoxia via the transcription factor HIF. However, it is virtually impossible that 
the endothelium of growing collaterals becomes hypoxic because it is constantly bathed in 
oxygenated arterial blood. Often collateral vessels run through tissue that does not become 
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ischemic itself after femoral occlusion like the upper limb muscles in the C57BL/6 mouse 
strain that develop to a much greater extent than collaterals of the BALB/C mouse where 
ischemia after femoral occlusion is extending to the upper limb but results in a far inferior 
degree of collateralization [16]. It is likely that VEGF production may be started by shear 
stress or transgenically overexpressed NOS [41], although most reports emphasize the other 
way round, which is difficult to reconcile with the fact that any change in fluid shear stress 
results in an instantaneous change in the level of NO. Studies in cultured endothelial and 
smooth muscle cells exposed to VEGF produce NO only after about 30 minutes [42]. The 
relationship between VEGF and NO may be that of a positive feedback. Studies with VEGF 
receptor antagonists showed that arteriogenesis is even more inhibited than angiogenesis [43]. 
In this study the collateral blood flow was significantly more impeded than calf blood flow. 
This is difficult to understand because collateral flow cannot change independently from 
peripheral flow since they are connected in series. In order to study collateral flow proper 
without interference from the periphery we created a model where the distal stump of the 
occluded artery, the collecting point of the collateral flow, was connected to the 
accompanying vein [24]. In spite of the enormous growth of collaterals in this high flow 
model, the peripheral flow, upon closure of the shunt, remains unaltered and only the pressure 
gradient along the collaterals decreases thereby increasing conductance [24]. This is not 
surprising because it is the peripheral flow, which is a determinant of collateral flow in the 
absence of additional angiogenesis. 

< The figure depicts the endothelial cell deformed by fluid shear stress and secretes NO which in turn 
may induce VEGF (never convincingly described under in vivo conditions) leading to endothelial mitosis. The 
secretion of MCP-1 leads to the attraction of monocytes, which participate in the remodeling of the arteriolar 
structure which leads to the phenotype change of the smooth muscle of the media which eventually enter the cell 
cycle. Actin binding proteins play a key role. Among the transcription factors Egr-1 plays an important role, the 
role of CARP is still unclear. Although the smooth muscle cells exhibit an inducible FGF receptor the role of the 
FGF-family remains unclear because genetic targeting does not interfere with arteriogenesis. A specific SMC 
mitogen was so far not identified. 
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The quest for the elusive SMC mitogen 
From many studies it has become certain that the endothelium plays a dominant role in 
arteriogenesis. In order to fulfill this role it has to condition the smooth muscle cells of the 
media to de-differentiate and to start the cell cycle and proceed to mitosis. Since direct cell-to-
cell contacts between ECs and SMCs do not exist in preformed arterioles only a diffusible 
mitogen appears possible.
The hypothetical mitogen is produced and secreted by the endothelium, must overcome the 
internal elastic lamina and the extra-cellular matrix to dock on to a receptor on the SMC 
surface. An alternative would be that adhering monocytes provide the growth factor. 
Diffusible factors secreted by ECs are NO, MCP-1, endothelin 1, VEGF and, perhaps, FGF5 
(FGF-1 and -2 are not secreted growth factors). Because MCP-1 is also produced and secreted 
by SMCs in growing collaterals, some authors believed and showed evidence for a SMC 
mitogenic role of MCP-1 [44]. However, the signaling chain of this chemokine does not 
directly lead towards canonical mitogenic processes. 
A natural candidate for the SMC mitogen, necessary for structural collateral enlargement, is 
FGF. FGF-1 and -2 are present in heart and skeletal muscle and FGF-2 is strongly expressed 
in activated and adherent monocytes [37]. Infusion of FGF-2 increases growth of canine 
collateral vessels after coronary artery stenosis [45]. Blockade of the FGF receptor with PAS 
inhibits collateral growth [46]. Transgenic over-expression of FGF increases coronary blood 
flow and arteriolar branching [47]. However, targeted disruption of the FGF-1 and -2 genes 
and their double knockout does not interfere with arteriogenesis. Apparently the system is 
highly safeguarded and other factors substitute for the loss of FGF. 
Another natural candidate is PDGF, the classical smooth muscle mitogen. However, it never 
showed up in our screens like differential cloning or micro-arrays with RNA from growing 
collaterals. 
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$ Fluid shear stress (FSS), caused by a pressure gradient between the high pre-occlusive and the very 
low post-occlusive regions that are interconnected by collateral vessels, is the widely accepted initial trigger of 
arteriogenesis. Deformation and activation of endothelial cells induces MCP-1 synthesis and leads to attraction 
of monocytes and T-cells. Those mononuclear cells then release proteases and growth factors, which digest the 
extra-cellular scaffold and provide space for the enlargement of the collateral artery. The increase in tissue mass 
is carried mainly by proliferation of the smooth muscle cells (SMC).
Chronically elevated Fluid Shear stress (FSS) leads to an extreme arteriogenic response resulting in a marked 
increase in size and number of collateral arteries. Pharmacological studies and gene expression profiling 
approaches were combined for the elucidation of the pathways involved in that strongly stimulated growth 
process, that comprises the FSS-sensing endothelium, the signal transmission from the ECs to the media and the 
SMC proliferation / outward remodeling.  
We could demonstrate that Ca++ signaling plays a crucial role and represents a very early event in FSS-induced 
collateral growth. Further downstream, the occurrence of highly increased expression of actin-binding Rho 
activating protein (Abra) in growing collaterals provides link, which accounts for the remodeling during the 
arteriogenic process.  
Introduction: 
Even though several chemical or physical stimuli are discussed for arteriogenesis, the most 
drastic stimulation of collateral growth is achieved by an exclusive increase of FSS [1]. This 
was realized by adapting the established model of femoral artery ligature (FAL) in rats. We 
created an arterio-venous (AV)-shunt to drain most of the collateral flow into the venous 
system [2,3] thereby re-establishing a method invented by Holman in 1949 [4]. As a 
consequence, this model prevented an early growth induced decline of the FSS and resulted in 
a long lasting enlargement of collateral vessels. These vessels completely restored (and 
overshot) physiologic function of the occluded artery demonstrating that no structural 
restraints are the cause for an incomplete natural response (Fig8<). Furthermore it allowed a 
detailed investigation of FSS-driven pathways and contributed to the elucidation of the 
mechanisms, which translate the physical stimulus into a growth response. 
There are several possibilities to completely block arteriogenesis giving the first hints on the 
signal transduction pathways, which are involved. Inhibition of NO production as well as 
inhibition of the Rho pathway completely blocked the collateral growth. 
Endothelial FSS-sensitive Ca2+ channel Trpv4 and Ca2+ signaling 
TRPV4 – initial sensor of fluid shear stress during arteriogenesis 
FSS triggered arteriogenesis leads to vast remodeling processes of the collateral network. 
Even though many underlying subcellular mechanisms have been identified over the last 
years [3,5-7], little is known about the early and initial trigger, which translates the physical 
force into an intracellular remodeling response. All mechanisms have in common that 
mechanical forces first are excerted to the inner lining of the vascular wall, the endothelium. 
Therefore, target genes, which are known to be mechanical stress (e.g. shear stress) sensitive, 
are important candidates in the context of arteriogenesis. 
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Tzima et al. showed that platelet/endothelial cell adhesion molecule (PECAM-1), vascular 
endothelial cell cadherin (VE-Cadherin) and kinase insert domain receptor (a type III 
receptor tyrosine kinase) (VEGFR2) comprise a mechanosensory complex transducing FSS 
into an intracellular signal [8]. Whereas PECAM-1 directly transmits mechanical force, 
vascular endothelial cell cadherin functions as the adaptor, which subsequently leads to 
activation of phosphatidylinositol-3-OH kinase via VEGFR2. Their observation was mainly 
based on flow-culture experiments using cultivated endothelial cells lacking VE-cadherin and 
PECAM-1 expression, which showed no nuclear factor kappa-B activation and a decreased 
inflammatory response in regions of disturbed blood flow. However, in a model where FSS is 
chronically elevated in the collateral network (AV-shunt) a genome wide screening of mRNA 
derived from collaterals showed an significant upregulation of the transient receptor potential 
cation channel, subfamily V, member 4 (Trpv4) as a possible mediator of physical stimuli to 
intracellular signals [9]. 

 < Angiographies of the rat hind limb 14d after the indicated treatment. Ligature depicts the natural 
response after femoral artery occlusion whereas after shunt treatment the size and number of the visible 
collateral arteries is increased. From Ref 3. 
The vanilloid subfamily of Transient Receptor Potential (TRPV) cation channels have been 
implicated into a broad range of fundamentally physiological functions [10]. At first 
described by Strotmann et al. [11], Liedtke et al. [12] and Nilius et al. [13], TRPV4 is known 
to be a transducer of mechanical, osmotic and thermal stimuli [14-18]. In endothelial cells of 
the vasculature, TRPV4 is assigned an important function in regulating vasomotion [19] and, 
upon dysfunction, is involved in several vascular and cardiovascular pathologies [20,21]. 
Upon channel activation, three Ca2+-dependent mechanisms are considered to play a role in 
transducing TRPV4-signaling across the internal elastic lamina in order to trigger 
vasodilatation of the smooth muscle cell layer: (1) the endothelial derived hyperpolarisation 
factor (EDHF) via opening of Ca2+-activated K+-channels, which represents an 
electrochemical stimulus [22]. (2) Prostacyclin (PGI2) synthesis by cyclooxigenase-1, which 
requires Ca2+-dependent release of arachnidonic acid [15,23]. And (3) nitric oxide (NO) 
derived from the Ca2+/calmodulin-dependent activated endothelial nitric oxide synthase
(eNOS) [24]. In the context of arteriogenesis, it is known that eNOS-antagonsists L-NAME 
and L-NNA show a strong antiarteriogenic response [3,25]. Therefore, one can speculate that 
TRPV4-induced growth of smooth muscle cells, a crucial process during collateral formation, 
acts through NO because known NO-inhibitors impair arteriogenesis [3]. 
mRNA transcription of this Ca2+-channel is constantly up-regulated in FSS-induced 
collaterals after AV-shunt treatment [9] (Fig.=and,). In contrast, after FAL without AV-
shunt, TRPV4 transcriptional levels are only transiently up-regulated until day 5 and drop to 
control levels after day 7. The chronic up-regulation (up to 14d) of TRPV4 mRNA abundance 
is followed by active proliferation of vascular cells, which could be demonstrated by 
increased numbers of Ki67 positive nuclei in the vascular wall (Fig. =) and enhanced 
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arteriole density. In addition, administrating 4-Phorbol-12,13-didecanoate (4PDD) via an 
osmotic minipump proximal to the ligature without chronically elevated FSS (no AV-shunt) 
leads to increased proliferative activity of collaterals and significantly improved 
hemodynamics in the area of impaired blood flow (Fig. ="and ). 

= (A) Time course of mRNA transcription of Trpv4 in rat collaterals after ligature or shunt treatment 
using qRT-PCR. Relative numbers of transcripts were measured in fold changes (FC) vs. mRNA transcription of 
untreated control collaterals (=1; sham, red line). Note that after FAL without AV-shunt TRPV4-transcription 
drops to sham levels after 5d. In shunt treated rats Trpv4 in constantly up-regulated after FAL. (Values are given 
in mean +/- s.e.m.; n=5; *p<0.05, **p<0.01 significant vs. sham). (B) Immunofluorescence confocal microscopy 
of collateral vessels in rats was performed with antibodies to Trpv4 (green) and the endothelial marker CD31 
(red) 7d after the indicated treatments. Double labeling demonstrated unchanged staining of the media but highly 
increased staining of the endothelium of shunt collaterals (arrows). In the left panel an immunoabsorption using 
Trpv4 peptide which was added before immunoprecipitation was performed in order to test antibody specificity. 
Nuclei were counterstained with Draq5 (blue). Scale bars: 40 µm. (C) Representative pictures of Ki-67 stained 
collateral arteries. Vessels were labeled with Ki-67 (purple). 4αPDD significantly stimulates proliferation in 
collateral arteries. Nuclei were counterstained with Draq5 (blue). (Lu = vessel lumen) Scale bars: 50 µm. (D) 
Immunofluorescence confocal microscopy of collateral vessels of rats 7d after the indicated Trpv4 modulation 
using antibodies against Trpv4 (green) and endothelial marker CD31 (red). 4αPDD treatment increased Trpv4 
expression in the endothelium compared to sham treatment. Nuclei were counterstained with Draq5 (blue). Scale 
bars: 30 µm. (E) Maximum collateral conductances (CCmax) in rabbit hind limbs after indicated treatment. 
4αPDD and shunt treatment significantly increased CCmax compared to minipump-solvent controls (MP 
control) and reaches 72.6 % of the conductance of a shunt treated rabbit. (Values are given in mean +/- s.e.m.). 
From Ref 9. 
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TRPV4 mediated calcium signaling in Arteriogenesis 
It has been shown extensively that activation of TRPV4 leads to increased cytosolic calcium 
levels [10,12,16,17,26]. Although TRPV4 triggers vasodilatation when a fast Ca2+-transient 
across the cell membrane leads to depolarization of the endothelium [16,23,27], TRP channels 
tend to have low conductances and can, therefore, also operate for a much longer time period 
without overwhelming the cell with Ca2+ [28]. Furthermore, it is known that calcium regulates 
many important cellular functions, including synaptic plasticity, fertilization, immune 
response, secretion, and proliferation [29-31]. In fact, it was recently shown that TRPV4-
mediated cytosolic alterations of Ca2+ levels contribute to transcriptional regulation via 
Calcineurin (CaN) and nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 
1 (NFATc1), thereby inducing osteoclast differentiation [32,33]. 
In line with these results NFATc1 and CaN mRNAs were strongly upregulated after TRPV4 
activation in growing collateral vessels. Immunohistochemistry proved increased fluorescence 
signals of NFATc1 within the nuclei of growing collaterals (Fig.>2) [34], which is known 
to translocate to the nucleus upon calcium-dependent dephosphorylation [35]. Our 
observation that NFATc1 activation depends on a constantly elevated extracellular Ca2+
influx via TRPV4 is supported by Rinne et al. [36], who reported that only a long lasting 
extracellular Ca2+ influx leads to NFAT activation and translocation, whereas even large 
amplitude Ca2+ signals generated by intracellular Ca2+ release were essentially ineffective.  
Besides NFATc1, two other major and directly Ca2+-dependent transcriptional regulators have 
been described [37]. The transcriptional repressor Kv channel interacting protein 3, calsenilin
(KCNIP3, also known as CSEN or DREAM) translocates out of the nucleus upon Ca2+-
binding, thereby de-repressing its target gene promoters [38]. Overall, CSEN mRNA 
abundance did not change after TRPV4 activation, but immunoblotting showed that CSEN 
translocates from the nucleus to the cytoplasm (Fig. > " and ) [34]. Previously, it was 
demonstrated that de-repression of CSEN leads to activation of activator protein 1 (AP1) - 
and CREB-dependent transcription in the context of pain modulation [39]. C-JUN and FOS, 
which form the AP1-transcriptional complex, are up-regulated on the protein level in the 
nuclei of vascular and perivascular cells in growing collaterals (data not shown) [34]. 
Demicheva et al. demonstrated the important role of activated AP-1 during arteriogenesis 
[40]. Even though they postulate that cyclic stretch and not FS, which was shown by Miyagi 
et al. [41], triggers AP-1, they demonstrate that activated AP-1 triggers MCP1 transcription 
which subsequently induces the homing of monocytes, a crucial process during arteriogenesis. 
In conclusion, TRPV4 activation followed by Ca2+-mediated subcellular mechanisms plays a 
crucial role in arteriogenesis by transmitting the physical stimulus (FSS) into an active 
intracellular growth response thereby representing a very early event in vascular remodeling. 
In endothelial cells, a link between increased cytosolic Calcium levels and Ca2+-mediated 
transcriptional signaling can be demonstrated (Fig. 0). The signal-transmission between 
endothelial and smooth muscle cells is still under debate. Cell-culture experiments showed 
that cytokine release does not account for the transfer mechanism [9]. Small diffusible 
molecules like NO, which are known to pass easily through the internal elastic lamina, are 
most likely the second messengers between endothelial and smooth muscle cells. 
Signaling pathways in the media 
Despite the fact that structural changes occur in all layers of the arterial wall, the hot spot of 
remodeling is the media. The bulk of tissue production (up to 50-fold increase in tissue mass) 
proceeds in the smooth muscle cells, which transform their phenotype from a contractile into 
a synthetic and proliferative one. This process is further characterized by the recapitulation of 
an embryonic expression pattern of intracellular contractile, cytoskeletal and extracellular 
matrix proteins. 
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
>  (A) qRT-PCR using NFATc1 specific primers. NFAT mRNA abundance was strongly upregulated 
after 4αPDD and AV-shunt treatment in collaterals isolated from the hind limb of pigs. (B) 
Immunohistochemistry using NFATc1 specific antibodies (red). Immunohistochemistry shows decreased 
staining of NFATc1 (red) in the cytoplasm and increased fluorescence signals of NFATc1 in nuclei (purple) of 
vascular cells after 4αPDD and AV-shunt treatment. (Scale bar, 30 µm). (C) qRT-PCR using calcineurin (CaN) 
specific antibodies. The mRNA abundance of CaN, an upstream modulator of NFATc1, was also significantly 
upregulated after 4αPDD and AV-shunt treatment. (D) qRT-PCR using CSEN-specific primers. No significant 
change in mRNA abundance after treatment with ligature-only, 4αPDD, or AV-shunt was observed. (E) Western 
blot analysis of cytoplasmic and nucleic protein lysates using CSEN specific antibodies. The nucleic protein 
fraction showed increased amounts of CSEN protein after 4αPDD treatment, which was even stronger after AV-
shunt surgery. From Ref 34. 
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

 0 Schematic diagram of FSS induced calcium signaling during arteriogenesis. Whereas short-term 
increase of TRPV4-induced cytosolic Ca2+-levels leads to vasodilatation, an increase over a longer period of 
time triggers calcium-dependent signaling via CaN, NFAT, CSEN, AP-1 and initiates remodeling and growth of 
the preformed collateral arterioles.  
Phenotypic modulation of SMCs 
The fact that vascular SMC are not terminally differentiated and retain the ability to modulate 
their phenotype to changing environmental cues likely evolved as a key mechanism to allow 
repair of vascular injury and adaptation of SMC contractile mass to match functional 
demands. Vascular remodeling during collateral growth requires proliferation of smooth 
muscle cells (SMC), a process which is on the other hand strongly associated with vascular 
disease states. 
The application of chronically elevated FSS is obviously sufficient to determine an expression 
pattern leading to appropriate collateral growth in vivo. The search for flow dependent genes 
in endothelial cells under static or flow conditions in vitro will not adequately represent the 
complex situation. A gene expression pattern of FSS-stimulated growing collaterals, which 
were dissected from the surrounding muscle, is expected to reflect the unique arteriogenic 
response (Fig. ?). This profiling revealed down-regulation of genes with the highest 
specificity for SMCs, whereas those genes, which are expressed in all three muscle types 
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during development, are either unchanged or up-regulated. Chronically elevated FSS 
coincides with a prolongation of the dedifferentiated state of smooth muscle cells (Fig.?,2).
Differentiation markers smoothelin (Smtn, 0.4-fold) and smooth muscle myosin (Myh11, 0.5-
fold) are significantly downregulated in FSS-stimulated growing collaterals. In contrast, a re-
expression of cardiac, fetal or skeletal isoforms of proteins was observed (Acta1 12.2-fold; 
Actc1 6.1-fold.; Tpm1 12.0-fold; Tuba1 2.4-fold; Myh6/7 9.4-fold; Desmin 4.6-fold).  

 ? A: Superficial adductor muscle collateral arteries connecting the A. saphena with the A. femoralis 
visualized under the stereo-microscope. Midzones of these collaterals were dissected from the surrounding 
muscle and subjected to RNA isolation. B-E: Immmunostaining showing the de-differentiated state of FSS-
stimulated collaterals. red: Smoothelin, green: α-smooth muscle actin, blue: nuclei. D+E merge 

The transcriptional control of these events is still under investigation. Differentiated SMC are 
defined by an array of contractile and cytoskeletal proteins as well as transcription factors and 
signal transducers. A partial transcriptome of a smooth muscle cells is reviewed in [42]. A 
large part of SMC restricted genes contain one or more CArG elements representing binding 
sites for serum response factor (SRF). Even though SRF is expressed in all cell lineages it 
only activates transcription of SMC-restricted contractile genes in SMC by recruiting the 
potent transcriptional co-activator myocardin, which is exclusively expressed in SMC and 
cardiomyocytes. The paradoxon of SRF’s ability to simultaneously activate transcription of 
genes involved in opposing cellular processes such as differentiation and proliferation reflects 
the complex network of molecular pathways underlying arteriogenesis.  
The transcription factor early growth response 1 (Egr-1), which we found upregulated during 
collateral artery growth [43], participates in this ensemble of signal transduction [44]. Five 
serum response elements (SRE) with adjacent binding sites for the transcriptional co-enhancer 
Elk-1 (nuclear target of the Raf/MEK/ERK cascade) have been identified on the Egr-1 
promoter [45]. It has further been shown that SRF is involved in the transcriptional regulation 
of Egr-1 [46] and that FSS induces the mRNA of Egr-1 in endothelial cells (EC) in vitro via
the Raf/MEK/ERK pathway [47]. Egr-1 is a key regulator in growth processes [48] 
interconnecting upstream growth factor (GF) signals in ECs [49] with Egr-1 mediated 
upregulation of downstream GFs, for instance in response to FSS [50]. Furthermore, Egr-1 
controls cell cycle progression via cyclin D1/E or cell division cycle 20 gene (cdc20), all of 
them being among the identified Egr-1 in vitro downstream genes [51,52]. SMC proliferation 
and phenotype switch, the two essential processes in arteriogenesis, are strongly dependent on 
downregulation of the transcriptional repressor splicing factor-1 (SF-1) [53] and SMC 
proliferation requires the presence and accurate function of Egr-1 [54]. In this regard, recent 
in vitro data indicate that Egr-1 is responsible for this downregulation in response to GF 
stimulation [53,55]. As stated above, myocardin co-enhances SRF mediated transcription of 
SMC-restricted contractile genes, maybe alternating with Elk-1 related gene (Egr-1) 
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transcription. Both co-enhancers translocate into the nucleus depending on the signal 
transduction cascade being activated upstream and the process involved. So it appears that it 
is not SRF but rather the co-enhancers myocardin and Elk-1 recruiting and competing for 
SRF within the nucleus.  
Irrespective from the transcriptional control, the cytoskeletal integrity as well as the actin 
polymerization status itself could also account for structural changes. Changes in actin 
dynamics are hallmarks for arteriogenesis: The phenotypic transition in smooth muscle cells 
during arteriogenesis from the contractile to the synthetic and proliferative state is 
characterized by the lack of actin filaments, which is a result of down regulation of actin 
transcription as well as the degree of actin polymerization. In our experiments of chronically 
elevated FSS we prolonged the dedifferentiated state of smooth muscle cells that is 
characterized by differential expression of the actin-(de)polymerizing proteins (destrin, 
cofilin1, cofilin2, and transgelin2) [2]. A specific staining of F-actin and G-actin supports this 
observation: F-actin is more fragmented whereas G-actin accumulates in shunt vessels 
compared to sham treated collaterals [56]. Disruption of actin cytoskeleton mediates the loss 
of tensile stress induced early phenotypic modulation of VSMC in organ culture [57] and this 
is accompanied by accelerated actin cytoskeleton dynamics and down-regulation of 
myocardin and SRF. Tightly coupled with the changes of actin polymerization is the Rho 
signaling pathway. We knew from previous studies that the inhibition of Rho-kinase by 
Fasudil completely blocked the effect of FSS on collateral growth [3]. 
A co-transcriptional factor, which exhibits strong up-regulation in rabbit and mice was the 
cardiac ankyrin repeat protein carp (ANKRD1) [58]. Apart from its ability to regulate growth 
factor expression during embryonic development its role during arteriogenesis in the adult 
organism remains unclear. Targeted deletion of ANKRD1 did not show a delay in blood flow 
recovery after femoral artery occlusion and adenoviral over-expression did not improve 
collateral growth. 
A common initiator: Abra 
In a genome-wide screening of mRNA abundance in growing collaterals of rats we identified 
actin-binding Rho activating protein (Abra). Abra (also known as Stars) is a muscle specific 
actin-binding protein capable of stimulating SRF-dependent transcription through a 
mechanism involving RhoA and actin polymerization [59]. In cardiac tissue Abra mRNA is 
up-regulated in response to pressure overload [59,60]. Recently it was shown that Abra is 
involved in human skeletal muscle hypertrophy and atrophy [61]. Forced overexpression of 
Abra in mouse heart tissue results in an increased sensitivity to biomechanical stress stimuli 
leading to cardiac hypertrophy [62]. However, its role in blood vessels has not been 
determined. In light of the requirement of Rho signaling during arteriogenesis, we 
hypothesized that a fluid shear stress induced up-regulation of Abra initiates collateral 
remodeling. And indeed, adenoviral gene transfer of Abra improved arteriogenesis, thereby 
partially substituting for FSS. Cell culture studies demonstrated an Abra-triggered 
proliferation of smooth muscle cells through a mechanism that requires Rho signaling [56].
The well-established abilities of Abra to activate Rho signaling, to influence actin dynamics 
as well as cytoskeletal integrity, and to initiate SRF-dependent gene transcription [59] provide 
potential mechanisms to account for the improvement of collateral growth. We know from 
previous studies that the Rho-pathway is involved in flow-related remodeling of small arteries 
[63] and in particular in arteriogenesis [3] because the Rho kinase blocker Fasudil abolished 
the beneficial effect of shunt treatment in rabbits. Increased RhoA expression in FSS-
stimulated collaterals as well as in Ad_Abra treated collaterals support a causal connection of 
Abra and RhoA in arteriogenesis. However, Abra promotes the formation of F-actin and Rho 
activation leads to actin polymerization. This apparent contradiction corresponds with and 
extends previous findings derived from forced Abra overexpression in the heart. Increased 
expression of Abra in response to stress stimuli – FSS in our model – may initially serve as a 
compensatory response to increased actin content to maintain cytoskeletal integrity and 
sustain arterial function [62]. But excessive expression leads to adaptation, which results in 
adverse cardiac remodeling in mouse models of cardiac hypertrophy [62] or, as we could 
demonstrate in rat and rabbit models of FAL, to beneficial collateral growth. Interestingly, 
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Abra over-expression in both models is accompanied by activation of SRF-dependent fetal 
cardiac genes [62]. Abra initiates SRF dependent transcription. Apart from previous findings 
of SRF-dependent transcription during arteriogenesis (reviewed in [64]), we were able to 
demonstrate that SRF itself is up-regulated under conditions of high FSS. RhoA-dependent 
regulation of the actin cytoskeleton selectively regulates SMC differentiation marker gene 
expression by modulating SRF dependent transcription [65]. 
In summary, the “Arteriogenesis” pathway, which remodels a preexistent arteriole into an 
artery, originates at the shear stressed endothelium and induces a multitude of morphological, 
biochemical and molecular changes in endothelial and smooth muscle cells. We have 
discovered essential pathways, which contribute to FSS-sensing as well as to smooth muscle 
proliferation, but the fundamental event that initiates the mitogenic stimulation and 
distinguishes the arteriogenic outward remodeling from the negative atherosclerotic inward 
remodeling has not been unraveled. 
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$  Flow-mediated remodeling is a fundamentally important phenomenon which occurs throughout the 
arterial vasculature including the small mesenteric arteries. The accessibility of the mesenteric vasculature 
facilitates the use of intravital techniques, and hemodynamic measurements are possible as well as direct 
assessment of peri-arterial NO and H2O2 concentrations. The mesenteric arterial branching pattern provides the 
ability to place ligations and make graded flow alterations in specific vessels, unlike other organs with a more 
complex vascular network. Such studies with the mesenteric model have established that the magnitude and rate 
of luminal expansion, as well as cell proliferation, depend upon shear level and that outward remodeling is 
associated with increased MMP2 expression/activation. Animal models of chronic oxidative stress demonstrate 
profound suppression of flow-mediated outward remodeling that is associated with abnormal flow-related 
protein expression, including eNOS. Anti-oxidant therapies restore the capacity for flow-mediated remodeling 
and NOS inhibition prevents their beneficial effect.  However, direct measurements of NO reveal that peri-
arterial NO is not decreased in these models but rather increased by elevated H2O2. Thus, the beneficial effect of 
anti-oxidant therapies may result from some mechanism other than improving bioavailable NO, such as reversal 
of an oxidant dependent, NO-insensitive state. Additional studies are warranted to investigate the mechanisms 
mediating the collateral growth impairment which occurs in humans as well as animals, as the results could 
facilitate development of novel therapies. The unique advantages of the mesenteric model may be useful in 
further elucidating these mechanisms and evaluating potential therapies. 
Importance of flow-mediated remodeling 
Vascular remodeling refers to structural changes within the vascular wall that are not due to 
active smooth muscle constriction or dilation.  Blood flow and wall shear stress have long 
been known to be important for luminal expansion of vascular structures during embryonic 
development and early postnatal growth.  Even in mature animals where low rates of cell 
turnover indicate that major vascular structures are extremely stable [1-2],  individual conduit 
and resistance arteries are known to undergo remarkable changes in luminal and wall 
dimensions in response to altered hemodynamic forces.  Such changes in vascular structure 
are known to occur during menstrual cycles, pregnancy, muscle disuse and exercise training, 
weight gain, and in various disease states.  Significant evidence exists that luminal diameters 
of large through small arteries and arterioles are determined by wall shear stress.  Chronic 
alterations in shear forces are associated with structural luminal expansion or retraction 
appropriate to restore wall shear forces [2-4]. Flow-mediated remodeling occurs in the aorta 
[5], carotid [3,6-7], iliac [4], middle cerebral, basilar [8], radial [9], ulnar [10] and uterine 
[11] arteries and skeletal muscle arterioles [12] and thus appears to be universal throughout 
the arterial system. Although it is widely recognized that wall shear stress is one of the 
hemodynamic forces that are fundamentally important in the regulation of vascular structure 
and matching perfusion with metabolic need, controversies exist to this date in the specific 
stimuli, sensors, mediators and remodeling processes involved [13].   
One area where our knowledge is specifically limited and additional investigation needed is 
the impact of various pathological and disease states on flow-dependent remodeling. Langille 
[1] has reviewed the potential role of flow-related remodeling in atherosclerosis, intimal 
proliferation, and post-stenotic dilatation and provided evidence that flow-mediated outward 
remodeling is suppressed with normal maturation and aging [14]. An additional condition 
where flow-dependent remodeling is considered to have major significance is the 
enlargement of pre-existing vessels which form collateral pathways in arterial occlusive 
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 < Chronic alterations in shear stress stimulate 
vascular remodeling through multiple mechanisms and 
pathways associated with matrix degradation and 
deposition; cellular hypertrophy, hyperplasia, 
recruitment and apoptosis; and changes in molecular 
expression and activation.  Shear stress alters the 
production of ROS and NO which may influence all of 
these processes.  Vascular disease and risk factors also 
influence ROS and NO levels and impact the remodeling 
process. 
disease.  Human and pre-clinical studies have shown that the vasculature is capable of full 
compensation for major arterial occlusion in the peripheral circulation through collateral 
growth, but also indicate a profound impairment of collateral growth in the presence of risk 
factors for vascular disease, especially aging (reviewed by Ziegler et al. [15]). Abnormal 
levels of nitric oxide (NO) and reactive oxygen species (ROS) are associated with vascular 
risk factors and may contribute to impaired collateral growth, but the role of these reactive 
molecules is controversial, even in the context of successful collateral growth.  Because ROS 
and NO mediate many signaling events, transcription factor activation, gene expression, 
MMP activation, and cell growth (Fig. <), understanding their role in flow-mediated 
remodeling is fundamentally important. 
The most common site of peripheral arterial occlusion is the lower extremity.  Current animal 
models of arterial occlusion and 
collateral growth in the hindlimb have 
limitations in the ability to measure 
hemodynamic forces and identify 
primary collaterals for morphometric 
and biochemical analyses.  Such 
measurements are fundamentally 
important in determining mechanisms 
responsible for flow-mediated 
remodeling and its impairment.  In this 
chapter, we review studies performed in 
simpler models in which the arterial 
flow through small resistance arteries 
can be varied, hemodynamic 
measurements are possible, and 
isolation of the experimental and 
control arteries more easily performed.  
In addition, direct measurement of NO 
and ROS are possible with existing 
technology for intravital studies.   
Development of the Mesenteric Model        
The mesenteric model of arterial 
occlusion and collateral growth was 
originally developed after initial studies 
in the rat hindlimb convinced us that the 
questions we wanted to investigate 
could be addressed more directly and clearly in a different model. 
Studies of the microvasculature in tissues distal to the site of arterial occlusion are 
controversial.  While many studies report angiogenesis, this does not occur in all animal 
models [16] and may depend upon the specific time investigated [17].  In addition, evidence 
from humans with peripheral arterial occlusive disease suggests that there is a 
decompensation or regression of small arteries and arterioles [18-19].  Very few studies have 
assessed the hemodynamic significance of collateral versus microvascular adaptations.  In 
1994 and 1995, we reported three studies in the rat which investigated the role of collateral 
and distal microvascular resistances after abrupt femoral artery occlusion. We had begun with 
the hypothesis that microvascular adaptations would be an important component of vascular 
compensation to arterial occlusion, and that microvascular resistance distal to the occlusion 
site would be decreased by an increase in arteriolar diameters and numbers.  This hypothesis 
was based upon the knowledge that small arteries and large arterioles normally have the 
major role in the regulation of vascular resistance and tissue perfusion in the peripheral 
circulation [20-23].  Our first reported study found that the initial compensation to abrupt 
femoral artery occlusion occurred in collateral vessels rather than the distal microcirculation 
[24]. Within seconds, both arterial inflow and distal pressure began a recovery from the nadir 
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 =  Resistances of the collateral circulation 
and distal microvasculature (mmHg*(ml/min)-1) 
after rat femoral artery ligation. The figure shows 
distal microvascular resistance remains unchanged 
as collateral resistance progressively decreases 
after femoral artery occlusion.  From Ziegler et al. 
[15], based on our published studies [38,39].  
which occurs immediately after abrupt arterial occlusion.  The increase in distal pressure 
indicated a greater decrease in collateral than distal microvascular resistance.  Administration 
of nitric oxide synthase inhibitors prevented 
the recovery and suggested that the 
compensation was largely due to NO 
mediated dilation of collateral arteries, 
presumably in response to elevated blood 
flow and shear stress.  Subsequent studies at 
1 and 8 weeks post-occlusion indicated 
progressive compensation as hindlimb 
vascular resistance decreased.  This decrease 
occurred entirely in the collateral circuit 
rather than the distal microcirculation (Fig. 
=).  These data are consistent with early 
responses to femoral occlusion reported for 
the canine hindlimb [25] and human lower 
extremity [26] and also for chronic 
adaptations in the canine and murine 
hindlimbs [27-28].  
At this point, we were interested in 
investigating the role of hemodynamic 
forces and metabolic factors in the vascular 
remodeling processes which resulted in 
rapid decreases in collateral resistance without apparent compensation in the distal 
microvasculature.  We were unable to develop a viable experimental approach to investigate 
these areas in the hindlimb. Microscopic computed tomography was not available and 
assessing changes in microvascular diameters, lengths, and numbers would be difficult due to 
the complex branching patterns and three-dimensional arrangement in multiple calf muscles. 
Longland’s work [29] had not only demonstrated the existence of multiple collateral 
pathways in the hindlimb but also observed that many begin to enlarge, but that subsequently 
most undergo regression.  These hindlimb collaterals are embedded within and between 
muscles, so even if we could identify them, their anatomical location would prevent in vivo 
measurements of pressure and flow to assess hemodynamic stimuli.  In addition, we would 
not be able to determine with certainty if a given vessel were in the process of luminal 
expansion or regression. These limitations led us to consider alternative models. Our previous 
work had demonstrated the utility of the rat terminal ileum for evaluation of adaptations in 
the microvascular network that occurred during juvenile growth and maturation [30-32]. The 
entire intestinal vasculature could be visualized from small feed arteries to small arterioles 
and even muscle layer capillaries.  Comparisons made of exactly the same tissue regions and 
vessels at multiple times demonstrated a decrease in vascular density occurred during rapid 
post-natal growth which was due entirely to tissue expansion rather than a loss of 
microvessels. With this preparation, the gain and loss of individual arterioles between 
observations can be determined as well as changes in diameter. In addition, the small 
mesenteric arteries are readily accessible for in vivo measurements including pressure and 
flow.

Characteristics of the model and comparison to the hindlimb 
Because of the advantages indicated above, we began to develop models of mesenteric artery 
occlusion.  Our initial results indicated that arterial ligations could be made without bowel 
infarction and that significant adaptations were observed in both arterioles and small arteries 
as shown in Fig. > and 0, respectively.  We further developed and characterized the model in 
which the small ileal arteries experienced increased blood flow and underwent enlargement, 
as this branching order between a major artery (superior mesenteric artery) and the distal feed 
arteries is similar to the branching order of arteries which function as primary collaterals in 
the human leg [33-35] (as shown in Fig. ? and reviewed by Ziegler et al. [15]).  In addition, 
these vessels are more easily isolated than the microvessels embedded in tissue and provide 
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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 0  Small arterial collateral in mesentery.  Occlusion of adjacent 
arteries (Fig. @) resulted in increased blood flow in the patent arteries 
which functioned as collaterals for the intestinal regions originally perfused 
by the occluded vessels.  One such collateral ileal artery is shown initially 
after ligation and 7 days later.  Calipers placed in the micrographs at the 
exact location illustrate vascular enlargement from Day 0 to 7. Both 
photographs were taken at the same magnification.  The ability for repeated 
diameter measurements is a significant advantage of the mesenteric model.  
"%D"%A
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>  Arteriolar collaterals in the intestinal wall.  Numbers 1-5 near 
the bottom of the micrographs identify 1st order arterioles arising from the 
marginal artery.  Marginal artery ligations were made between arterioles 1 
& 2 and 4 & 5 at sites indicated by arrowheads.  Photomicrographs were 
made under maximal dilation after ligation (Day 0) and 1 week later (Day 
7).  Interconnecting arterioles which span the occlusion to form collaterals 
and would be expected to experience increased flow are identified in 
capital letters and are enlarged (A-D).  Arcading arterioles which would not 
form collateral pathways are identified in lower case letters and are not 
enlarged.   
greater amounts of tissue 
for biochemical analyses. 
A schematic representing 
this model is presented 
in Fig. @.  The major 
characteristics of this 
model, including 
hemodynamic alterations 
and the early adaptations 
in the collateral arteries 
which experienced 
elevated flow, and the 
distal microvasculature 
were reported in 1996 
[36].  These results are 
reviewed below and also 
compared to the 
hindlimb.  
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A clinically significant 
arterial stenosis or 
occlusion in the 
peripheral circulation is 
typically manifested by a 
reduced arterial pressure 
distal to the site of 
occlusion or stenosis 
[37].  In our model of 
ileal artery ligation, 
arterial pressure at the 
center of the collateral-
dependent region was 
substantially reduced to 
about 30 mmHg by 
arterial ligation and then 
gradually recovered [36], 
similar to the distal 
pressures measured after 
femoral artery occlusion 
in the rat hindlimb [38-
39].    
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Tissue perfusion 
assessed by microspheres 
indicated that intestinal 
blood flow at the center 
of the collateral 
dependent region was similar to control regions at rest, but was significantly decreased with 
maximal dilation [36].  This is similar to what is observed in human claudicants and some 
rodent models of single vessel occlusion where flow reserve is eliminated but resting 
perfusion is normal [40].  
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?   Lower extremity human angiograms from Ziegler et al [15] demonstrate natural collateral 
development subsequent to focal arterial occlusion.  Collateral vessels are observed bypassing the site of 
a superficial femoral artery occlusion (A) and a popliteal artery occlusion (B).  The occlusion is bounded 
by asterisks.  Arrows and arrowheads identify collateral arteries with minimal and significant tortuosity, 
respectively.  The collaterals providing distal reconstitution arise from small pre-existing geniculate 
arteries, consistent with published reports [33-35].  
Collateral and microvascular adaptations  
Distal arterial pressure increased ~30% during the first week post-occlusion [36]. This 
increase in distal arterial pressure is consistent with what is observed after occlusion of the 
femoral, carotid, and coronary arteries [41] and indicates a greater compensation in the 
collateral arteries than the distal microcirculation.   Evaluation of the arteriolar network for 
arteriolar numbers and diameters at the center of the collateral dependent region (Fig. @) 
indicated no significant changes within the first week after occlusion [36].  During this same 
time, there was ~30% diameter increase in the mesenteric collateral vessels which experience 
elevated flow.   These results are consistent with the measurements of collateral and distal 
microvascular resistances in the rat and cat hindlimbs after femoral artery occlusion [27,38].  
+
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When we began our studies with the rat mesentery, shear stress had been shown to regulate 
luminal dimensions in conduit arteries and to impact wall structure in these same vessels, but 
there were no studies available on remodeling in small resistance arteries under known 
alterations in wall shear forces.  For these vessels, the stimulus level necessary to initiate 
structural outward remodeling and the degree of luminal expansion that would result from a 
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@  Mesenteric artery occlusion model.  These sketches from Unthank et al.[36]  represent the 
model used to assess collateral and microvascular adaptations.  In A, the collateral pathway is shown 
by thick black lines and sites of occlusion, diameter, and flow measurement are indicated for collateral 
and control vessels.  Pilot studies indicated elevated flow occurred only in the ileal arteries 
immediately adjacent to the ligated arteries.  For each animal, micrographs and video recordings were 
made similar to the sketches shown in B and C to identify changes in the number of first- through 
third-order arterioles and arteriolar diameters under maximal dilation at both the initial and final times 
of observation. 
given increase in shear stress were unknown.  Neither was the impact of shear level on the 
specific nature of the remodeling process known.   
We performed morphometric analysis of arterial cross-sections to obtain insight into the 
remodeling processes involved.  Figure A shows representative cross-sections of control and 
collateral arteries from the same animal.  In Figure B, data from our published work is 
summarized to show changes in luminal and medial areas of the experimental artery which 
experienced chronically elevated blood flow. The results demonstrate that luminal and medial 
cross-sectional areas relative to same animal controls are significantly increased at 1-12 
weeks post-occlusion and that most of the increase occurs during the first week. This 
indicates that, even at the most rapid phase of flow-related luminal expansion in these small 
resistance vessels, the remodeling process is hypertrophic and there is an increase in wall 
components.  Medial thickness was also increased [2] such that the relationship between 
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B   Percent increase in cross-sectional luminal 
and medial areas of collateral vessels experiencing 
elevated flow relative to same animal controls at 1, 4, 
and 12 weeks post-occlusion.  Data from Unthank et 
al. [2, 46].
                            Control                                                           Collateral 

A  Representative cross-sections of control and collateral ileal arteries at one week post-ligation.  
Vessels were perfusion fixed at the mean systemic arterial pressure and embedded in plastic due to the 
superior histology and nuclear numbers and densities.  The most remarkable difference between the control 
and collateral arteries was the increase in intimal cell nuclei (arrows identify single intimal nuclei in each 
image). 
medial thickness and luminal radius remains unchanged. This suggests that the specific 
remodeling response was acting not only to restore normal wall shear forces but also to 
preserve circumferential wall stress, even during the early and rapid phase of luminal 
expansion. 
The medial layer hypertrophy is similar to 
other reports of flow-mediated outward 
remodeling [6,8,42-43]. The rapid luminal 
expansion is consistent with the increased 
collateral diameter and swift improvement 
in perfusion observed in the rodent 
hindlimb [44].  It is also consistent with 
reports from humans indicating significant 
collateral growth can occur within days to 
weeks after either abrupt arterial ligation 
in wounded limbs or atherosclerotic 
occlusion [35, 45]. 
4

To obtain insight regarding the 
mechanisms involved in the hypertrophic 
remodeling response, we determined 
intimal and medial cell numbers and 
densities by nuclear counts in arterial 
cross-sections [2, 46].   
Endothelial cell response.  The most apparent and dramatic aspect of the mesenteric collateral 
arterial remodeling was the response observed within the intima (Fig. A).  Examination of 
arterial cross-sections, longitudinal sections, and whole vessel imaging revealed a remarkable 
increase in the number of intimal nuclei.  The nuclei were uniform in size and shape with the 
longitudinal axis oriented parallel to the axis of flow, consistent with an endothelial 
phenotype.  As illustrated in Figure C, after 1 wk of elevated flow there was almost a 100% 
increase in the intimal cell nuclei as percent of same animal control vessel.  This was reduced 
slightly at 4 wks and significantly at 12 weeks.  Intimal cell density (nuclei per 100 µm 
luminal perimeter) was increased 60% at 1 wk, remained elevated at 4 wks, but was reduced 
and similar to control vessels at 12 weeks [2,46]. Endothelial cell proliferation and 
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 <D  Representative cross sections 
demonstrate typical luminal expansion and 
increased endothelial cell numbers in mouse 
hindlimb collateral arteries compared with control 
arteries at 14 days after femoral artery ligation.  
Arrows identify some of the intimal nuclei.  The 
asterisk identifies the presence of Microfil in the 
lumen.  From Distasi et al. [44]. 
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 <<  Arterial cross-sections 4 wks after 
femoral artery ligation in the porcine hindlimb.  
Note the remarkable collateral intimal response.  
All intimal cells displayed positive 
immunoreactivity for von Willebrand factor.  
Arrows identify endothelial nuclei.  From Ziegler 
et al. [15].
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 C   Number of intimal nuclei in cross-sections of 
control and collateral arteries at 1, 4, and 12 weeks after 
abrupt flow elevation by occlusion of adjacent ileal 
arteries.Data from Unthank et al. [2,46].
recruitment occurs in conduit arteries 
exposed to chronically elevated shear 
and precedes the luminal expansion 
[47-48].  As shown in Fig. <D and <<, 
this response observed in mesenteric 
collaterals is similar in nature to what 
we have observed and reported for 
primary collaterals in the murine and 
porcine hindlimbs [15,44]. 
Smooth muscle cell response.  Unlike 
the response observed in the intima, 
medial cell nuclear number was not 
significantly increased at one week 
(Fig. <=) post-occlusion despite a 
>50% increase in medial area.  
Consequently, medial cell density was 
decreased ~30% [2].  By 4 wks 
however, there was an 80% increase in 
the number of medial nuclei in arterial 
cross- sections, and medial cell density 
was slightly increased relative to 
control arteries [2].  At 12weeks the absolute number of medial nuclei compared compared to 
controls was increased 35% and medial cell density was slightly reduced [46].  Our results 
demonstrating smooth muscle cell hyperplasia at 4 weeks after chronic flow elevation in 
mesenteric collateral arteries are consistent with studies of flow-mediated outward 
remodeling in a similar rat mesenteric model and in carotid and basilar arteries [8,42-43].  
Our data, however, suggest that smooth muscle cell hypertrophy both precedes and follows 
the hyperplastic response. 

Matrix metalloproteinase (MMP) expression/activity.  The expression and activation of 
MMP-2 and MMP-9 were investigated to determine their potential role in the remodeling of 
small resistance arteries subjected to a degree of wall shear stress elevation that might occur 
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<>   Expression of MMP-2 and MMP-9.  Arteries were harvested at 2, 4, or 7 days after ligation 
surgery and MMP expression analyzed by zymography. A: representative gelatin zymographs showing 
MMP-2 to be present in latent (72-kDa) and active (62-kDa) forms and MMP-9 present in latent (92-kDa) 
form and in high-molecular-weight form corresponding to dimerized latent MMP-9 (*). S, sham operated; 
C, control artery; E, experimental collateral artery. B: densitometric analysis of MMP-2 protein shows total 
MMP-2 protein to be significantly increased in collateral compared with time-matched control arteries at 4 
and 7 days. C: percentage of MMP-2 in active (62-kDa) form 2, 4, and 7 days after ligation surgery. 
Percentage of active MMP-2 increased significantly compared with control arteries at 4 days. *: P 0.05 vs. 
time-matched control (n = 4).  From Haas et al. [49]. 
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 <=   Number of medial nuclei in cross-
sections of control and collateral arteries at 1, 4, and 
12 weeks after abrupt flow elevation by occlusion of 
adjacent arteries. Data from Unthank et al. [2,46].
under physiological conditions and after 
major arterial occlusion [49]. The 
expression of latent and active forms of 
MMP-2 and –9 are shown in Figure <>. 
MMP-2 expression was significantly 
elevated in collaterals at days 4 and 7 and 
percent of the activated form increased 
~4X by day 4. No difference in MMP-9 
expression between controls and collaterals 
was detected during the first week after 
chronic flow elevation.  The increase in 
MMP-2 was confirmed by 
immunofluorescence (Fig. <0) which also 
demonstrated increased expression of the 
MT1-MMP, a key physiological regulator 
of MMP-2. The increases in MMP-2 and 
MT1-MMP primarily occurred in the 
media, where increases in phosphorylated c-Jun and Egr-1(transcriptional activators of 
MMP-2 and MT1-MMP, respectively) were also observed [49].  Treatment with the general 
MMP inhibitor doxycycline suppressed MMP-2 expression and activation and prevented 
significant increases in luminal diameter, but not medial area or intimal cell number.   
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 <0  Immunolocalization of MMP-2 and MT1-MMP in control and collateral arteries.  
Representative images are shown for control (A and D) and collateral (B and E) arteries immunostained 
for MMP-2 (A and B) or MT1-MMP (D and E) 4 days after ligation. Sections were counterstained with 
diamidino-2-phenylindole (DAPI, blue) to visualize nuclei. A: diffuse staining of MMP-2 within smooth 
muscle layers of control arteries. B: intense staining of MMP-2 in collateral arteries. Immunostaining 
appeared predominantly in smooth muscle layers, with intermittent endothelial staining. D: weak staining 
of MT1-MMP, the activator of MMP-2, in control arteries. E: in collateral arteries, localization of MT1-
MMP, with intense staining, to smooth muscle layer, with intermittent labeling of endothelial cell layer 
and adventitia. Arrows, staining within smooth muscle layers; solid arrowheads, endothelial cell staining; 
open arrowheads, adventitial cells. L, lumen. Magnification 400X.  C and F: pixel intensities (arbitrary 
units) for MMP-2 and MT1-MMP. *: P  0.05 vs. control. From Haas et al. [49]. 
In a different rat mesenteric model, Dumont et al. [50] observed an increase in MMP-9 but 
not MMP-2 expression at 4 days after abrupt flow elevation.  Expression was assessed by 
immunostaining rather than gelatin zymography and the percent of activation was not 
evaluated.  The magnitude of flow and shear stress elevation were not reported.   In larger 
carotid arteries where flow and shear stress were increased to levels comparable to our model 
by creation of an arteriovenous fistula, Tronc et al [51] observed an increase in the active 
form of MMP-2 but not MMP-9, consistent with our observation.  
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The above data suggested to us that a number of events occur transiently rather than 
progressively throughout the period of luminal expansion.  MMP-2 production and 
activation, endothelial cell proliferation/recruitment, and medial layer expansion due to 
smooth muscle cell hypertrophy occur during the first week following model creation when 
shear forces are at their highest. As the shear level is returned toward normal levels, between 
1 and 4 wk, the rate of luminal expansion is decreased and smooth muscle cell hyperplasia is 
observed [46,48]. These observations led to the formulation of two hypotheses: 1) both the 
rate and magnitude of luminal expansion are dependent on the degree of initial shear 
elevation, and 2) specific remodeling events within the arterial wall layers occur in a 
temporal sequence dependent upon the level of shear alteration.  Based upon the studies 
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<@  Arterial flow and wall shear rate for the different vessel types from Fig. <?.  A significant 
linear relationship existed between prefusion territory and both flow and wall shear rate.  From Tuttle et 
al. [53]. 


 <?   Schematic of multiple shear level mesenteric model.  The 
normal perfusion territory for the arteries of interest was assumed to be the 
mid-point between it and the adjacent artery on each side as indicated by 
vertical dashed lines.  This perfusion territory was reduced by 50% or 
increased to 200% or 400% of the original by ligations placed on ileal and 
marginal arteries.  Altered perfusion territories are shown by blue dotted 
horizontal lines with arrows.  Modified from Tuttle et al. [53]. 
available at the time [7,42], we presumed the shear-related events were also linked to 
increased eNOS expression and NO production. 
We obtained initial 
results related to the 
impact of wall shear 
level on cell 
proliferation in a 
simple modification of 
our model [52].  
However, the 
interpretation of this 
data was confounded 
by the involvement of 
different branching 
orders.   To more 
clearly investigate the 
effect of the magnitude 
of change in blood 
flow and wall shear 
force with abrupt 
occlusion, we 
developed a new model 
[53] as shown in Fig. 
<?. Ligations were 
selectively placed on 
ileal and marginal arteries to vary the length of bowel and number of microvascular units 
perfused by individual mesenteric arteries to ~50, 200, and 400% of their control condition as 
illustrated.   With this approach, we were able to create three levels of altered arterial blood 
flows and shear forces in identical branching order arteries within the same animal as shown 
in Figs. <? and <@. Luminal dimensions, wall areas, nuclear densities, and endothelial nitric 
oxide synthase (eNOS) expression were measured to investigate how the level of altered 
shear impacts the rate of remodeling, wall expansion and composition, and endothelial gene 
expression.   
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 <A   Rate of diameter change for each vessel 
type calculated as percent change in diameter divided 
by number of days after model creation.  Blue, gray, 
green, and red bars represent vessel types 50, 100, 200, 
and 400%, respectively.  From Tuttle et al. [53].
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2 Day Group 7 Day Group Vessel 
Type D0 D2 D0 D7 
50% 383±7.9 348±8.6* 377±15.6 339±16.1* 
100% 350±10.2 357±6.2 342±14.5 348±11.3 
200% 352±11.4 359±8.5 341±12.3 397±12.3* 
400% 368±14.3 402±14.4* 346±14.9 457±18.0* 
Values are means ± SE (in µm) for the 50%, 100%, 200%, 
and 400% vessel types for the 2-day group (n = 7) and the 
7-day group (n = 10). *P 0.05 vs. D0 within vessel type. 
D0, Day 0; D2, Day 2; D7, Day 7.  From Tuttle et al. [53]. 
Impact of shear level on magnitude and rate of luminal expansion 
In vivo diameters of the various vessel 
types obtained under maximally dilated 
conditions are reported in Table 1.  
Diameters of all vessel types were similar 
at the time of model creation (D0).  No 
change occurred in the diameter of the 
control (100%) arteries at either 2 or 7 days 
(D2, D7) after arterial ligation. The 50% 
arteries had a reduced luminal diameter at 
2 days which was not further decreased at 
1 wk. Consequently, the greatest rate of 
change in diameter of the 50% arteries 
occurred during the first 2 days (Fig. <A). The highest flow (400%) arteries also were 
characterized by a significant diameter change at 2 days and the rate of diameter change was 
similar from D0 to D2 and D0 to D7 
(Fig. <A). The 200% arteries did not 
experience a significant increase in 
diameter until day 7 (Table 1), and the 
rate of diameter change in these vessels 
was greater after day 2 (Fig. <A). Both 
the magnitude (Table 1) and the rate (Fig. 
<A) of diameter change were greater in 
the 400% than 200% vessels.   
It is interesting to note that while the 
magnitude of the change in flow and wall 
shear were similar in the 50% and 200% 
vessels (Fig. <@); the rate of change at 
day 2 was much greater in the 50% 
vessels.  This could indicate that 
resistance vessels are more sensitive to 
and respond more rapidly to decreases in 
wall shear forces than increases as 
observed by in rabbit carotid arteries 
[54].  This may explain the rapid 
regression of collaterals after installation 
of a bypass graft or stent [55-56]. 
Impact of shear level on wall areas and 
nuclear densities  
Wall areas were determined from arterial cross-sections as in previous studies.  At 2 and 7 
days post-occlusion, intimal and medial areas (Fig. <B) were altered from control arteries 
only in the 400% arteries where they were increased. Brownlee and Langille [54] reported 
that a 60% increase in carotid artery flow did not result in luminal or medial expansion in 
mature rabbits and proposed that a threshold may exist for shear stress below which the 
vessels are unresponsive.  Langille [14,57] also observed that with inward carotid artery 
remodeling associated with a reduction in flow, no change occurred in the major wall 
components. 
Cell densities were determined from whole vessel imaging of intimal, medial, and adventitial 
nuclei as developed by Arribas and McGrath [58-59]. Intimal and adventitial cell densities 
(Fig. <C) were only altered in the 400% where they were increased.   Immunostaining for the 
cell proliferation marker Ki-67 demonstrated significant nuclear reactivity at day 2 (Fig. =D), 
suggesting that the increase in intimal and adventitial cell densities were primarily due to 
proliferation rather than recruitment.   Sho et al. [48] observed a similar endothelial response 
in carotid arteries exposed to elevated flow.  Their kinetic analysis indicated that the 
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<C   Number of intimal and adventitial cells per unit area determined from whole vessel imaging. 
Blue, gray, green, and red bars represent vessel types 50, 100, 200, and 400%, respectively. Significant 
increases were observed only in the 400% vessels. From Tuttle et al.  [53]. 
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<B Intimal and medial cross-sectional area for each vessel type. Blue, gray, green, and red bars 
represent vessel types 50, 100, 200, and 400%, respectively.   Significant increases were observed only in 
the 400% vessels.  From Tuttle et al. [53].  
increased endothelial cell density was primarily mediated by a proliferative response which 
mostly occurred before 3 days [48]. Consistent with the preservation of cell density in 
reduced flow vessels,  Langille et al. [14] demonstrated that endothelial cell density is 
preserved by cell loss during inward remodeling associated with reduced flow in carotid 
arteries of mature rabbits.  
It is important to note that while increases in wall areas and cell densities in the 400% arteries 
were already apparent at 2 days (Fig. <B and <C) when luminal diameter had only increased 
about 10% (Table 1), no increases had occurred by 7 days in the 200% arteries which had a 
luminal expansion of 17%.  Also, wall areas and nuclear densities were not altered in the 50% 
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=D  Representative micrographs of 200% and 400% arteries with immunohistochemical 
staining for the cell proliferation marker Ki-67 at 2 days after arterial ligation.  The results are 
consistent with the increase in intimal and adventitial cell density observed in the 400% but not 
200% vessels and indicate a proliferative response is primarily responsible. 
vessels which had a rate of expansion similar in magnitude to the 400% arteries.  Whereas 
previous studies have demonstrated that changes in wall areas and cell densities are altered by 
an increase or decrease in blood flow, this was the first study to demonstrate that these 
specific remodeling events associated with flow-mediated luminal expansion are dependent 
upon the initial stimulus level.  With either a reduction or moderate elevation in flow the 
remodeling was eutrophic in nature, but hypertrophic in the vessels experiencing greater flow 
elevation. These data suggest that enlarging collateral vessels located in the same animal 
could exhibit markedly different histological and morphometric characteristics depending 
upon the specific hemodynamic stimuli to which they are exposed. 
Effect of shear level on endothelial gene expression  
Because studies had suggested that increased eNOS expression was associated with 
successful flow-mediated luminal expansion [7] and that NOS inhibition prevented flow-
mediated outward remodeling [42], we evaluated eNOS expression in the various arteries by 
quantitative immunohistochemistry.  eNOS staining was present only within the endothelium 
and varied with flow condition as illustrated in Fig. =<.  eNOS content normalized to luminal 
circumference was greater in the 400% than in the 100% arteries at both day 2 and day 7.   
Assessment of eNOS expression by Western blotting in 100% and 400% arteries indicated a 
3.7 fold increase at day 2 [53]. As this increase in eNOS content was much greater than the 
increase in endothelial cell density (~30%), the increased eNOS content is primarily the result 
of increased cellular expression rather than elevated cellular density.  
Studies by others using a similar mesenteric model confirm our results demonstrating 
increased eNOS expression and provide additional evidence of the importance of eNOS 
derived NO in the flow-mediated response. eNOS expression determined by Western blotting 
was increased ~50-100% from 4-7 days after flow elevation [50,60]. Both studies 
demonstrated the suppression of flow-mediated outward remodeling by the NOS inhibitor L-
NAME in rat mesenteric arteries.  In addition, Dumont et al. [50] observed suppression of 
outward but not inward flow-mediated remodeling in mesenteric arteries of eNOS deficient 
mice. However, not all studies are consistent with a significant role for eNOS derived NO in 
flow-mediated outward remodeling.  L-NAME inhibits all NOS isoforms and Mees et al. [61] 
have presented data suggesting that collateral development in the mouse hindlimb is 
dependent upon iNOS rather than eNOS.  
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 =<  Endothelial nitric oxide synthase (eNOS) staining and average content in 
mesenteric arteries (n = 8) are shown in the micrographs (A, representative images from the 2-
day group) and plot (B). Specific eNOS staining is localized to the endothelium within the 
mesenteric arteries. A significant increase in eNOS (B) content was observed between the 400% 
and 100% arteries both 2 and 7 days postligation and was confirmed with Western blotting (C).
From Tuttle et al. [53]. 
Together, our data from the multiple shear level model provide compelling support for the 
hypothesis that specific wall remodeling events, including the magnitude and rate of luminal 
expansion, cross-sectional wall areas, and cell proliferation, are dependent on the level of the 
shear stimulus.
Impact of risk factors on flow-mediated collateral growth 
It has been known since the last century that advancing age and vascular risk factors suppress 
the capacity of the human circulation to compensate for abrupt occlusion of a major 
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Luminal area (µm2)  43,500 ± 11,200 68,900 ± 6400* 31,900 ± 4560 40,800 ± 3600*† 
Medial area (µm2) 19,000 ± 3550 25,500 ± 2670 23,200 ± 1260 29,700 ± 2050† 
#Medial nuclei 31 ± 6 30 ± 2 37 ± 2 39 ± 3† 
#Intimal nuclei 20 ± 2 35 ± 3* 28 ± 2† 35 ± 3* 
   
*, †:P 0.05 collateral vs control, SHR vs WKY. From Tuttle et al.[74]. 
peripheral artery (see review by Ziegler et al. [15]).  Animal studies also support this 
observation regarding collateral growth and even juvenile maturation can impact the capacity 
for flow-mediated remodeling [7,54].  Yet few investigations have addressed the specific 
abnormalities and potential mechanisms until recently.  Vascular remodeling is a complex 
process and impairments could result from one or more deficiencies in signal transduction; 
transcription factor activation; gene transcription and translation; cellular proliferation, 
growth and recruitment; and abnormal expression or activation of receptors and matrix 
metalloproteases and their inhibitors.  Having completed the above studies in young healthy 
animals, we undertook the investigation of mechanisms involved in collateral growth 
impairment which occurs in the presence of risk factors.  We performed studies in both the 
spontaneously hypertensive rat (SHR) and in aged, normotensive rats.  The SHR is a genetic 
model of essential hypertension and is also characterized by endothelial dysfunction, elevated 
oxidative stress, an activated renin angiotensin system, and metabolic abnormalities.  
Multiple studies with SHR have documented suppressed compensation to arterial occlusion 
[62-74].  The aged rats used were retired breeders 8 months of age.  This age of rat is 
typically characterized by elevated oxidative stress and endothelial dysfunction [75-77] and 
even much younger rats have been shown to exhibit impaired remodeling responses to 
chronically elevated blood flow [7]. Clinical studies have shown that collateral growth is 
impaired in the presence of risk factors for vascular disease, including hypertension [78-83].  
Based upon these clinical studies, and evidence that NO and eNOS were important for flow-
mediated remodeling in large conduit arteries [7, 42], and that shear level and presumably 
NO levels influenced specific remodeling events, we hypothesized that chronic oxidative 
stress impaired collateral growth through reduced NO bioavailability. 
SHR-Impairment of flow-related remodeling reversed by anti-oxidant therapy, requires 
intact NOS system 
 Nature of impaired flow-mediated remodeling. Our studies in the SHR mesentery 
demonstrated that, despite a comparable increase in blood flow and wall shear rate in the 
experimental collateral arteries relative to WKY, luminal expansion was significantly 
suppressed [74].  Cross-sectional wall areas and nuclear numbers for control and collateral 
arteries in SHR and their normotensive controls are reported in Table 2. Other than the 
reduced luminal expansion in SHR, the most notable difference was a suppressed intimal 
response.  Compared to same animal control arteries, the number of collateral intimal cell 
nuclei was increased 80% ± 23% in WKY but only 22% ± 7% in SHR [74].  Another major 
difference between SHR and WKY experimental collateral vessels was the lack of eNOS 
upregulation in the SHR (Fig. ==). These two endothelial abnormalities may have contributed 
to the impaired response observed in the SHR collaterals. 
Reversal by anti-oxidant therapy.  In seeking to identify potential mechanisms that might 
mediate the impairment of flow-mediated outward remodeling in SHR mesenteric arteries, 
we became aware that angiotensin converting enzyme inhibitors (ACEI) had been shown to 
promote collateral growth in both hypertensive humans [84] and animals [65].   In the SHR 
hindlimb, chronic administration of the ACEI ramipril increases tissue perfusion without 
altering skeletal muscle capillary or arteriole density [65], suggesting that its effect was 
mediated by collateral growth. Neither the clinical nor preclinical study identified the specific 
mechanisms responsible for the perfusion impairment or its reversal by ACEI.  Because 
ACEI are known to improve endothelial function, we performed pilot studies with the ACEI 
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==   Representative Western gel for 
protein extracts from four control and 
collateral arteries of both SHR and WKY 2 
days after model creation.   The level of 
eNOS protein was greater in collateral 
relative to same animal control arteries in 
WKY but not SHR, with the average 
collateral/control ratio being 2.28 ± 0.58 in 
WKY and 1.17 ± 0.06 in SHR.  Figure from 
Tuttle et al. [74].  
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=>   Percent increase in mesenteric collateral artery diameter for untreated WKY and SHR,  and various 
treatments in SHR.  Data from Miller et al. [73]. 
captopril, and observed a remarkable enhancement 
of collateral growth in the SHR [73].  Additional 
experiments were then performed to investigate the 
hypothesis that SHR collateral growth impairment 
is mediated by excess superoxide produced by 
NAD(P)H oxidase in response to stimulation of the 
angiogensin II type 1 receptor (AT1R) by 
angiotensin II (AngII) [73].  As illustrated in Fig. 
=>, our results demonstrated that SHR collateral 
growth was enhanced by captopril, the superoxide 
dismutase mimetic tempol, and the anti-oxidant 
and NAD(P)H oxidase inhibitor apocynin, but not 
by the AT1R antagonist losartan or the ACEI 
enalapril.  The effects of apocynin and tempol 
were observed to be dose dependent and the 
beneficial effects were independent of pressure 
changes [73].  Because captopril has anti-oxidant 
effects due to its sulfhydryl group [85] independent 
of its effects on AngII and activation of the AT1R, 
the data are most consistent with a beneficial effect 
of anti-oxidants.  The combination of low dose L-NAME with captopril greatly attenuated the 
response; providing additional supporting evidence for an important role for NO. 
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We performed additional studies [77,86] to investigate the effect of aging on flow-mediated 
remodeling and collateral luminal expansion in Wistar and WKY retired breeder (RB) rats, 
8 months of age. 
Nature of impaired flow-mediated remodeling and luminal expansion. As illustrated in Figure 
=0, the maximally dilated in vivo diameter of collateral arteries one week after arterial 
occlusion was significantly increased in young (33±7%) but not Wistar RB rats (1±5%).  No 
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=0  Percent diameter change in control and 
collateral arteries of young and retired breeder 
(RB) Wistar rats at 7 days after model creation 
From Tuttle et al. [86].  
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 =?   Number of intimal (endothelial) cell 
nuclei in cross-sections of control and collateral 
arteries from young and retired breeder (RB) Wistar 
rats at 7 days after flow elevation by arterial 
ligation.From Tuttle et al.[86]. 
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 =A  When protein expression patterns of 
control to collateral arteries were compared, 15 
arterial proteins differed in abundance (4 higher and 
11 lower) in the young animals, whereas 24 (5 
higher and 19 lower) proteins had differing 
abundances in the mature animals. There was no 
overlap in the proteins displaying altered expression 
in response to elevated flow (collaterals) between 
young and mature rats; none of the 15 proteins 
displaying altered expression in young rats 
exhibited altered expression in mature animals. 
From Tuttle et al. [86].  
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 =@  Medial cross-sectional area (x1000 
µm2) of control and collateral arteries from young 
and retired breeder (RB) Wistar rats at 7 days after 
flow elevation by arterial ligation.  From Tuttle et 
al. [86].

significant changes occurred in the diameters of control arteries.  Morphometric analyses of 
arterial cross-sections revealed that the number of endothelial nuclei were significantly 
increased in both young and retired breeder rats (Fig. =?).  Cross-sectional medial area was 
also increased in both age groups (Fig. =@).   
Molecular basis of impairment.  Proteomic analysis was performed to obtain insight into 
potential molecular mechanisms that might mediate the flow-mediated remodeling 
impairment observed in Wistar RB rats [86].  Control and collateral mesenteric arteries were 
harvested from each animal.  Proteomic analyses were performed using two-dimensional 
electrophoresis and peptide mass fingerprinting. Approximately 1200 protein spots were 
detected and matched in sample gel patterns.  Protein spots having altered expression 
between same animal collaterals and controls were identified.  While a similar number had 
increased and decreased expression between young and retired breeder rats, a fundamentally 
different expression pattern was observed as illustrated in Figure =A.  None of the proteins 
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=B   Percent diameter change 7 days after 
model creation in control and collateral arteries of 
retired breeder Wistar rats receiving no treatment 
or tempol with and without L-NAME. From 
Miller et al. [77]. 
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 =C   Percent diameter increase in control 
and collateral arteries of Wistar and WKY RB rats 
receiving no treatment, apocynin before (Pre-trt), 
or 1 week after (Post-trt) model creation. Data 
from Miller et al. [77].
with altered collateral expression were similar between young and RB. Proteins with 
increased collateral expression in young Wistars included vimentin, and heat shock proteins 
27 and 70.   The global difference in collateral protein expression between retired breeder and 
healthy young rats is consistent with the concept that redox status regulates gene expression 
in the vasculature [87-88] and impacts pathological as well as compensatory remodeling. 
Anti-oxidant therapy reverses age-related collateral growth impairment and requires intact 
NOS system.  Subsequent studies were performed to determine if anti-oxidant therapy could 
reverse the age-related impairment of collateral growth as observed in SHR [77]. As shown 
in Figure =B, there was no increase in collateral diameter measured under maximally dilated 
conditions 1 week after model creation in Wistar RB rats.  Pre-treatment with tempol restored 
the capacity for collateral growth as evidenced by the ~20% diameter increase.  This effect of 
tempol was prevented when administered in combination with low-dose L-NAME.  Figure =C
demonstrates that the anti-oxidant apocynin has effects similar to tempol in Wistar and WKY 
RB when administered both before and after occlusion.   
While the effects of apocynin and tempol when administered prior to model creation provide 
important evidence that the mechanisms mediating age-related collateral growth impairment 
are dependent upon increased oxidative stress, the similar effects observed with post-
treatment have clinical relevance as they suggest that aggressive anti-oxidant therapy may 
provide benefit to human with existing occlusive disease.    
The effects of anti-oxidant therapies on collateral growth in both SHR and retired breeders 
are consistent with the hypothesis that elevated oxidative stress impairs flow-mediated 
collateral growth.  The observation that low dose L-NAME prevents the beneficial effects of 
the anti-oxidants also suggests that the mechanism of impairment is related to bioavailable 
NO or flow-mediated NO production.  Vita et al. have recently shown a correlation between 
the capacity for acute flow-mediated dilation and flow-mediated remodeling in the ulnar 
artery in humans [10]. Based upon a strong negative correlation between P-selectin 
immunoreactivity and flow-mediated outward remodeling, they speculated that the existence 
of a pro-inflammatory state prior to elevated blood flow prevents outward remodeling.  Since 
a pro-inflammatory state and impaired flow-mediated dilation are associated with oxidative 
stress, the reversal of oxidative stress and restoration of endothelial function may restore and 
enhance the capacity for flow-mediated remodeling and collateral growth.  However, existing 
studies also suggest that a certain level of ROS are critical for flow-mediated remodeling in 
mesenteric arteries [89] and for compensation for vascular compensation to repetitive 
coronary artery occlusion [90]. Thus, additional experimentation is warranted to investigate 
the specific ROS involved in both the promotion and impairment of flow-mediated 
remodeling including collateral growth.    
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 >D Schematic representation of the acute 
model.  Our experimental model was modified to utilize 
a standard chamber for intravital microvascular studies.  
Flow, NO and H2O2 were measured simultaneously at 
sites illustrated before and after temporary occlusion of 
adjacent arteries to elevate flow.  The application of 
microvascular clamps to the adjacent arteries allowed 
flow to be elevated in a linear and stepwise manner as 
shown in Fig. ><. 
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 ><  Relationship between flow and 
clamp condition for WKY, SHR, and WKY-
RB.   NO and H2O2 were measured at control 
(baseline) and after placement of 1 and 2 
microvascular clamps on adjacent arteries.  In 
this review, only the combined clamp data is 
presented.  From Zhou et al. [76, 102].  
Impact of oxidative stress on bioavailable NO in mesenteric arteries 
Our studies described above are consistent with the hypothesis that a normally functioning 
eNOS system is required for flow-mediated remodeling and collateral growth and that 
impairment of these processes occur when elevated superoxide reduces NO bioavailability.  
While numerous studies with NOS inhibition and ablation have suggested NO and eNOS to 
be important, if not required, for flow-mediated remodeling and compensation to arterial 
occlusion, contradictory studies also exist [61,91].   Interpretation of results are confounded 
by studies which have shown that NOS inhibition can impact arterial remodeling by inducing 
oxidative stress and inflammation [92-93] and that vascular compensation occurs in eNOS 
knockout mice to maintain dilatory responses to flow-related stimuli [94-95]. Our studies, as 
well as others which have shown increased eNOS expression in enlarging collaterals, cannot 
be used to establish a definitive role for NO as these studies have not distinguished between 
membrane bound and total cellular eNOS protein, determined eNOS activity or 
phosphorylation, or evaluated eNOS uncoupling and superoxide production.  To complicate 
the issue even more, an NO-resistant state that can be reversed by anti-oxidant therapy has 
recently been described in diseased blood vessels from humans and animals [96-97].  The 
presence of an NO resistance state is consistent with studies in SHR and aged rats that have 
shown abnormalities in cGMP signaling mechanisms which include reduced sGC expression 
[98-101]. Thus, it is certainly possible that the beneficial effects of anti-oxidant therapy used 
in our studies of impaired mesenteric collateral growth involve mechanisms other than 
bioavailable NO.   
To begin to address these issues, we have made direct, in vivo measurements of per-arterial 
NO and H2O2 in young WKY, SHR [102] and WKY-RB [76].  The results described below 
were significantly different than we had expected and have revolutionized our perspective of 
the mechanisms responsible for collateral growth impairment. 
Model and experimental approach8Our model was modified as shown in Figure >D to permit 
measurements during step changes in blood flow (Fig. ><).     
     Arteriogenesis                          Unthank et al. 109
Control Apocynin gp91ds-tat
B
as
al
 P
er
o
xi
d
e 
(u
M
)
0
5
10
15
20
25
30 WKY
SHR 
WKY-RB 
* ,+: P<0.05 vs. WKY, Control
*
*
(8)
(11)
(11)
(3) (3)
(4)
(4)
(4)
(4)
+
+
+
+

>>  Direct in vivo measurement of periarterial H2O2 with WPI ISO-HPO-100 electrodes.  Under 
control conditions, H2O2 is elevated 2-3X WKY level in SHR and retired breeder WKY (RB-WKY). 
Apocynin pre-treatment and topical gp91ds-tat decrease the H2O2 to the concentration observed in 
untreated WKY.  Sample size is indicated by the number in parentheses in the column bar.  From Zhou et 
al. [76, 102]. 
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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>=   Direct in vivo measurement of periarterial NO with electrodes.  Under control conditions, NO 
is elevated 2-3X the WKY level in SHR and retired breeder WKY (RB-WKY).   Apocynin pre-treatment 
and topical PEG-catalase and gp91ds-tat decrease the NO to the concentration observed in untreated WKY.  
Sample size is indicated by the number in parentheses in the column bar.  From Zhou et al. [76, 102].
Peri-arterial NO is elevated in SHR and retired breeder-WKY and suppressed by NAD(P)H 
oxidase inhibitors. To our surprise, peri-arterial [NO] under baseline in vivo conditions in 
SHR and WKY-RB was not reduced but substantially increased (Fig. >=). Furthermore, pre-
treatment with the anti-oxidant apocynin, as performed in earlier studies and which reversed 
collateral growth impairment, reduced rather than increased baseline [NO] in both SHR and 
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 >0   Effect of topical H2O2  on periarterial 
[NO] under normal flow conditions in young WKY 
and SHR.  NO is increased in a concentration 
dependent manner by H2O2  in young WKY but not 
SHR.  From Zhou et al.[102].
WKY-RB. As we considered explanations, we found several reports of increased eNOS 
activity and NO production in SHR [103-106] and eNOS expression in aged [107-108] rats.  
In vitro studies have also indicated that increased NAD(P)H oxidase  activity elevates NO 
production from endothelial cells via H2O2-dependent activation of Akt and ERK1/2 [109-
110].  Additional experiments with the cell permeable form of catalase (polyethylene 
glycated, PEG-catalase) and the specific NAD(P)H oxidase inhibitor, gp91ds-tat, produced  
results similar to those of apocynin. Together, these results suggest that the increased 
bioavailable NO in SHR and WKY-RB under in vivo conditions is due to the stimulation of 
eNOS by hydrogen peroxide derived from NAD(P)H oxidase. 
Peri-arterial H2O2 elevated in SHR and retired breeder-WKY and suppressed by NAD(P)H 
oxidase inhibitors and PEG-catalase.  Measurement of peri-arterial H2O2 demonstrated a 
significant increase in SHR and WKY-RB relative to young WKY (Fig. >>). Pretreatment 
with apocynin and acute application of gp91ds-tat significantly decreased [H2O2] to levels 
measured in young WKY.  The elevation of vascular H2O2 in SHR and aged animals is 
consistent with previous studies showing increased ROS production and NAD(P)H oxidase 
expression/activity [75,111-114]. These studies are also consistent with the increased 
peroxide levels observed in the plasma of hypertensive humans [115-116] and the direct 
production of  H2O2 from NAD(P)H oxidase [117]. 
Topical H2O2 increases peri-arterial NO in 
WKY but not SHR.  To further evaluate 
the ability of H2O2 to increase NO 
production in vivo, topical H2O2 was 
added to young WKY and SHR (Fig. >0).  
Addition of exogenous H2O2 to increase 
the suffusion solution [H2O2] to the level 
observed in SHR arteries at rest (20µM), 
increased [NO] in WKY arteries to the 
level observed in SHR.  Further elevation 
of the bath [H2O2] resulted in an additional 
increase in WKY NO.  In SHR, additional 
[H2O2] did not elevate NO.  These data 
indicate that H2O2 is capable of elevating 
NO in vivo and suggest that this 
mechanism is maximally stimulated in the 
young SHR. 
Flow-mediated NO production abolished 
in SHR and retired breeder-WKY and 
restored by NAD(P)H oxidase inhibitors 
and PEG-catalase.  Under control 
conditions without any drug treatment, peri-arterial [NO] increased with flow only in young 
WKY.  This is shown in Figure >? for the highest level of flow elevation.  Pre-treatment with 
apocynin, and acute topical application of PEG-Catalase and gp91ds-tat all restored the 
capacity for flow-mediated NO production in SHR and WKY-RB. 
Abnormal flow-mediated H2O2 production observed in SHR and retired breeder-WKY and 
reversed by NAD(P)H oxidase inhibitors.   Peri-arteriolar H2O2 was observed to increase with 
flow in SHR and WKY-RB, but not WKY.  The percent increases under the highest flow 
conditions are shown in Figure >@.  Apocynin pre-treatment and acute application of gp91ds-
tat prevented the flow-related elevation of H2O2.  The increase in H2O2 with flow the SHR 
and WKY-RB is consistent with observations in diseased human arterioles [118-119].   
The combined results with NO and H2O2  measurements in both young SHR and older adult 
WKY show that in vivo basal NO in mesenteric resistance arteries is not suppressed, but 
elevated, and the capacity for flow-mediated NO production is abolished.  A critical role for 
peroxide is indicated by a) its elevation in SHR and RB-WKY, b) the reduction in basal NO 
and restoration of flow-mediated NO production by PEG-catalase, and c) the increase in NO 
with topical H2O2 in young WKY.  In SHR and RB–WKY both apocynin and gp91ds-tat 
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>?   Effect of increased flow (2-clamp condition in Fig. >D) on changes in peri-arterial [NO]. Under 
control conditions, NO was increased only in the young WKY.  Apocynin pre-treatment and topical PEG-
catalase and gp91ds-tat restored flow-mediated NO production in SHR and WKY retired breeder (WKY-
RB).  Sample size is indicated by the number in parentheses in the column bar. From Zhou et al. [76, 102].
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 >@   Effect of increased flow (2-clamp condition in Fig. <) on changes in peri-arterial [H2O2].  
Under control conditions, H2O2 was increased with flow in SHR and WKY retired breeder  (WKY-RB) but 
not young WKY.  With apocynin pre-treatment and topical gp91ds-tat, the response in SHR and WKY-RB 
was similar to young WKY. Sample size is indicated by the number in parentheses in the column bar.  
From Zhou et al. [76, 102].
correct abnormalities in basal concentrations and flow-mediated production of NO and H2O2.  
These results provide evidence that in resistance vessels the major enzymatic source of H2O2 
is NAD(P)H oxidase and also suggest that NAD(P)H oxidase-derived peroxide can exert a 
greater influence on NO levels than superoxide under in vivo conditions. The data are 
consistent with the hypothesis that a sub-phenotype of endothelial dysfunction exists which is 
characterized by high basal NO due to eNOS activation by NAD(P)H oxidase-derived H2O2.
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This hypothesis is consistent with recent reports of elevated H2O2  and of NO insensitivity in 
humans and animals with arterial disease [96-101,115]. 
Summary and Conclusion 
Hemodynamic forces, including the frictional wall forces associated with blood flow, are 
fundamentally important in regulating luminal diameter and wall structure in health and 
disease. We have utilized the mesenteric model to investigate cellular and molecular 
processes and mechanisms involved in successful flow-mediated remodeling of resistance 
vessels as well as the impaired remodeling that occurs in disease models characterized by 
oxidative stress. We have shown that specific remodeling events occur temporally rather than 
progressively during luminal expansion and that the specific level of flow or shear stimulus 
has a major impact on the rate and magnitude of remodeling as well as the associated cellular 
and molecular events.  As shear stress influences both NO and ROS production within the 
vascular wall, and these reactive species influence all the major processes involved in 
vascular remodeling, it is likely that changes in their concentrations are fundamentally 
important in the specific remodeling events observed during luminal expansion.  In the 
context of impaired flow-mediated luminal expansion, specific events like the intimal and 
medial responses proceed even without luminal expansion and the exact abnormality varies 
between models with different risk factors. Our data with direct in vivo measurement of NO 
and H2O2 indicate that the impairment of flow-mediated luminal expansion and remodeling in 
mesenteric arteries is not due to a reduction in bioavailable NO by superoxide scavenging as 
commonly thought.  Rather, elevated H2O2 appears to increase [NO] through eNOS 
activation and may also induce an NO-insensitive state.  Regardless, the ability of antioxidant 
therapies to reverse the impairment of flow-mediated mesenteric artery remodeling in 
hypertensive and retired breeder rats suggest that correction of a redox imbalance present 
with vascular risk factors represents a promising therapeutic approach to enhance the body’s 
natural compensatory mechanisms. Recent clinical observations that endothelial dysfunction 
and a pro-inflammatory state are associated with impaired flow-mediated luminal expansion 
support this possibility. The development of an optimal anti-oxidant therapy will require the 
identification of the specific ROS and the enzymes that produce them in various disease 
states. The impact of potential therapies on peri-arterial [NO] and NO sensitivity also 
represent important areas for future studies.  Because of its advantages, including direct in 
vivo measurement of ROS and NO, we believe the mesentery model for altering flow and the 
associated wall shear forces will have an important role in advancing our knowledge in these 
areas. 
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$: Epigenetics refers to chromatin-based pathways important in the regulation of gene expression due to 
mechanisms other than changes in DNA sequence.  It includes distinct mechanisms, i.e. DNA methylation, 
histone posttranslational modifications as well as RNA–based mechanisms. Epigenetic processes have profound 
effects not only in the fine tuning of gene expression, but also concerning fundamental processes such as cell 
proliferation and differentiation. This chapter aims to provide insights into epigenetic mechanisms in terms of an 
overview; it also focuses on processes affecting in particular endothelial as well as vascular smooth muscle 
specific gene expression. Mechanisms of epigenetic processes are highlighted using in particular endothelial 
nitric oxide synthase (eNOS) gene expression as an example. Although currently no data are available directly
demonstrating the influence of epigenetic modifications on the process of arteriogenesis, we attempt to illustrate 
the effects such modifications are likely to have on signal transduction cascades in arteriogenesis. Finally, we 
present data on bone marrow derived cells such as lymphocytes and monocytes and question the need for stem 
cells. In summary, this chapter aims to supply insight into epigenetics and epigenetic mechanisms, aiming to 
encourage scientists to accept the challenge to investigate the influence of epigenetic modifications on 
arteriogenesis and collaterogenesis. 
         
Introduction  
In the book On the generation of animals, Aristite postulated for the first time the view that 
during the embryonic development of an organism, structures are formed that are not 
preformed in semen or egg. The theory of epigenesis was born. The etymologic closely 
related biological term epigenetics was coined in 1942 by C. Waddington and today defines 
the “study of heritable changes in genome function that occur without a change in DNA 
sequence” [1]. 
Epigenetics is based on three pillars: DNA methylation [2], histone density and 
posttranslational modifications, and RNA-based mechanisms (Fig. <.) (for an overview see 
[3]. Epigenetic marks regulate the “open” or “closed” state for regions of the genome and 
thereby control the “on” and “off” status of a gene. Small interfering (si) RNAs as well as 
very big non-coding (nc) RNAs are the two epigenetic RNAs currently known. Whereas si 
RNAs are involved in establishing the “closed” configuration, the nc RNAs are known to be 
involved in both functions, establishing the “closed” as well as the “open” configuration. 
Histones forming the nucleosome can be modified at a number of sites e.g. by acetylation or 
methylation. Histone modifications can be read like a code and can determine whether a gene 
is switched “on” or “off” as well. The third component of epigenetic regulation is DNA 
methylation. Methylation of cytosine results in formation of “closed” chromatin and therefore 
in the switching “off” of genes. Epigenetic modifications can occur already during embryonic 
development, but also in adulthood, and are regulated by internal and external stimuli [4, 5]. 
The environmental factors influencing epigenetic marks are still poorly defined. However, it 
is clearly evident that even factors such as nutrition have an impact.  
Generally, it appears that most genes are regulated epigenetically, and that the process 
presents, beside the activation of a transcription activator or -repressor, a second or rather 
upstream check point of gene expression. Although epigenetic marks are classed as heritable 
changes in the genome, not all epigenetic modifications are destined to be passed to the next 
generation. Epigenetic regulation can be established cell-autonomously through intercellular 
signaling elicited by environmental influences. All cells of a body are subjected to epigenetic 
regulation and all epigenetic processes are reversible. They are required for fine-tuning of 
gene expression and for fundamental cellular processes such as proliferation and 
differentiation. Thus understanding epigenetic regulation is a key in the development of 
efficient therapeutics. 
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Although currently almost no data are available relating to epigenetics and arteriogenesis or 
collaterogenesis, it is apparent that epigenetic regulation plays a major role in both processes, 
and that mechanical forces such as shear stress are a determinant of epigenetic actions.  


<  The figure illustrates the three basic mechanisms of epigenetic gene regulation. 1. DNA methylation, 
2. histone modifications, and 3. RNA-based mechanisms (from [6], with courtesy of Journal of Applied 
Physiology).
A short overview of epigenetic mechanisms  
The three pillars of epigenetic modifications (for a summary see Table 1) have the function to 
modulate the structure and accessibility of DNA, thereby controlling transcriptional activity 
(for an overview, see [6]: They all are involved in the formation of euchromatin and 
heterochromatin. Euchromatin (decondensed chromatin) is actively transcribed and affiliated 
with activating epigenetic marks, whereas heterochromatin (condensed chromatin) has only 
limited transcription and is associated with repressive epigenetic marks [7].  
DNA methylation 
In embryonic development, the best understood epigenetic mark is DNA methylation [8]. It 
involves the covalent modification of the 5-position of cytosine to define the "fifth base of 
DNA," 5-methyl-cytosine [2], and was already described in 1925 by Johnson and Coghill, 
before the elucidation of the DNA double helix [9]. The unique pyrimidine continues to base 
pair with guanine. In mammals, DNA methylation is almost exclusively restricted to CpG 
dinucleotides, commonly referred to as CpG islands [10, 11]. DNA methylation is catalyzed 
by 3 different DNA methyltransferases (DNMTs): DNMT1, the “maintenance” 
methyltransferase, which transmits DNA methylation patterns during mitotic cell division, 
and DMNT3a and DMNT3b, which work as de novo methyltransferases and establish DNA 
methylation patterns during embryonic development  [10]. 
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Histone modifications 
In the nucleus, DNA is packed into chromatin as repeating units of nucleosomes, which form 
a “beads-on-a string” structure that can compact into higher order structures to affect gene 
expression. Nucleosomes are composed of 146bp DNA wrapped in histone octamers 
(composed of two H2a, H2b, H3, and H4) and are connected by a linker DNA, which can 
associate with histone H1 to form heterochromatin [10]. Histone proteins contain both a 
globular and an amino-terminal domain, with the latter being posttranslationally modified. Up 
to now, more than 60 modifications have been described, including the posttranslational 
modification of lysine (acetylation, methylation, ubiquitination, sumolyation), arginine 
(methylation) and serine and threonine (phosphorylation) [12, 13]. Many of these 
modifications are known to play functional roles in transcription.  
The functional roles of lysine acetylation and methylation on gene expression are the best 
understood. Histone acetylation enhances transcription by neutralizing the basic charges of 
lysine residues thereby preventing chromatin compactation [14]. The impact of histone lysine 
methylation on gene expression, however, is dependent on the specific lysine residue. 
Genome-wide profiles of histone methylation show that H3K4 and H3K6 methylation are 
associated with transcriptionally permissive chromatin, whereas H3K9 and H3K27 
methylation are markers of transcriptionally silent chromatin [15]. Furthermore, single lysine 
residues are variable methylated to mono-, di-, or trimethylated states. The different histone 
methylation states are functionally relevant. Active promoters are enriched in trimethylated 
H3K4, while enhancer elements are enriched in monomethylated H3K4 [16]. Similar to 
histone acetylation and deacetylation, which are mediated by histone acetyltransferases 
(HATs) and histone deacetylases (HDACs), histone methylation status at a particular lysine is 
dynamically regulated by histone methyltransferases and histone demethylases [17].  
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Mechanism        Transcriptional Effect 
DNA methylation (CpG dinucleotides)        
Histone posttranslational modifications 
 Histone H3 
  Acetylation        	
  Methylation       	/
  Phosphorylation       	/
 Histone H4 
  Acetylation         	
  Methylation         
 Histone H2A 
  Ubiquitination         
 Histone H2B 
  Ubiquitination         	
RNA-based mechanisms         
si RNA             
 ncRNA         	/
The table summarizes the major known epigenetic control mechanisms on DNA, Histone and RNA level [6, 18].  
   Arteriogenesis                   Ziegelhoeffer & Deindl124
RNA-based mechanisms: 
RNA-based mechanisms of epigenetic regulation involve the coordinated activities of both 
siRNAs and noncoding (nc) RNAs, together with other epigenetic activities, such as DNA 
methylation and histone posttranslational modifications. A large number of intervening non-
coding RNAs (lincRNAs) have been described in the genomes of human and mice, and about  
3.300 lincRNAs have been identified with computationally predicted roles in various cellular 
processes, including cell-cycle regulation [19, 20]. 
DNA methylation and repressive histone modifications have been shown to be elicited at 
target gene promoters following treatment of cells with exogenous administration of siRNAs, 
and a similar phenomenon may be mediated by endogenous miRNAs [21]. 
Epigenetic Pathways in Vascular Biology 
Non-Mendelian diseases 
Common cardiovascular diseases demonstrate non-Mendelian patterns of inheritance. 
Nonetheless, much can be learned from such diseases, for example from Hutchon-Gilford 
progeria syndrome (HGPS), a childhood disease of premature aging. Affected children 
develop severe atherosclerosis and die from myocardial infarction and stroke at about 13 
years of age [22]. HGPS results from a specific mutation (a C-to-T substitution) in the LMNA 
gene coding for laminin A [23]. The genetic mutation activates a cryptic splice donor site 
resulting in a new mRNA species that is translated to progerin. Although it is unclear how 
progerin causes HGPS, evidence suggests that changes in epigenetic pathways are involved. 
Similar to normally aged cells, the normal organization and structure of chromatin is 
disrupted in HGPS nuclei [23-26]. In particular, these cells demonstrate dramatically reduced 
heterochromatin (regions of limited transcription) that is preceded by the progressive loss of 
repressive epigenetic marks including trimethylated H3K9 and H3K27 [27]. In terms of 
collateral artery growth, it is interesting to note that progerin activates the effectors of Notch 
signaling pathways (see chapter 3).  
Involvement of shear stress 
Interestingly, laminar shear stress can elicit both global and gene-specific histone 
modification changes in cultured human endothelial cells (ECs) [28]. Shear stress can affect 
changes in global histone modification in mouse ES cells and promote their differentiation 
into an EC lineage [29, 30]. Laminar shear stress can also induce histone modifications at 
specific sites in the genome as demonstrated by the dependency on p33/HAT mediated H3 
and H4 acetylation in laminar flow induced eNOS-expression [31]. Whether epigenetic 
pathways contribute to different regions in the vasculature in a different manner and what 
their functional role may be in arteriogenesis is worthwhile considering. 
Endothelial cell specific gene expression 
eNOS 
The contribution of epigenetic pathways in endothelial response to external stimuli such as 
physical forces (e.g. shear stress), hypoxia, cytokines [32-34], and entry into cell cycle [18] 
have recently been described. Using eNOS as an example, it is evident that epigenetics 
provides a new vantage point for understanding transcriptional control paradigms in vascular 
endothelial cells (for an overview see [6]). Although eNOS can be expressed by other cell 
types, it is mainly transcribed by vascular endothelial cells. eNOS deficient mice are 
characterized by a variety of malfunctions, among them impaired wound healing, 
angiogenesis and reduced vascular leakage during inflammation, as well as impaired 
arteriogenesis ([35-37] and see chapter 6). Due to the pivotal physiological role of eNOS in 
the vascular endothelium, its regulation has been extensively studied. 
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eNOS is probably the best characterized example of an EC-specific gene that is regulated by 
chromatin accessibility. eNOS evidences a TATA-less promoter with two 5´cis regulatory 
elements, known as positive regulatory element I and II (pos. -104/-95 and -14/-155  [38, 39]. 
Furthermore, eNOS has a 269bp enhancer that is located -4,9kb from the transcriptional start 
site [40]. Similar to other EC-restricted genes, the regulatory DNA elements of eNOS can 
bind ubiquitous transcription factors, such as Sp-1 and Ets [18, 40]. Although transient 
transfection experiments of eNOS promoter-reporter constructs into various cell types showed 
robust promoter activity [41], eNOS promoter-reporter transgenic mice show endothelial 
restricted expression [42]. These data suggest the chromatin context of eNOS is involved in 
regulating EC-specific expression. In fact, the chromatin structure at the eNOS promoter is 
transcriptionally permissive in ECs and repressive in non-ECs. To date, the eNOS promoter in 
ECs was found to be DNA hypomethylated and enriched with activating histone post-
transcriptional modifications, including acetylated H3K9, acetylated H4K12 , and di- and 
trimethylated H3K4 [43, 44]. In contrast, analyses of the promoter in non-expressing cells, 
such as vascular smooth muscle cells (vSMCs), showed DNA hypermethylation and a lack of 
histone posttranslational modifications. Consistent with the differences in chromatin structure 
of the eNOS promoter, chromatin immunoprecipitation analyses showed selected recruitment 
of Sp1, Sp3, Ets transcription factors and RNA polymerase II to the eNOS proximal promoter 
in ECs, while MeCP2 (methyl CpG binding protein 2) and HDAC1 were specifically 
localized to the promoter in in vSMCs [41, 44, 45]. Pharmacological inhibition studies 
demonstrated the functional importance of the eNOS promoter. While treatment of vSMCs 
with 5-azazytidine, a DNMT inhibitor, as well as trichostatin A, a HDAC inhibitor, resulted in 
upregulation of eNOS mRNA expression, treatment of ECs with methylthioadenosine, a 
H3K4 methylation inhibitor, provoked downregulation of eNOS expression [6]. 
eNOS is furthermore regulated by RNA-based mechanisms. A 27 nucleotid RNA duplex 
produced at the variable number tandem repeat region (VNTR) of inton 4 in eNOS was 
demonstrated to be expressed and localized exclusively in the nucleus of ECs [46, 47]. 
Experimental exogenous administration of the small 27 nt RNA to ECs induced H3K9 and 
H4K12 hypoacetylation at the eNOS promoter and reduced transcription [46, 48]. The 
repressive function of the 27 nt RNA was supported by the ability of salvage eNOS 
expression in the small RNA transfected cells by HDACIII depletion and treatments with 
trichostatin A and 5-azacytidine [48]. It is worthwhile to note that the copy number and 
polymorphism of the eNOS VNTR have been described to be associated with risk for 
ischemic heart disease [43]. 
In summary, chromatin-based mechanisms of gene regulation ensure that eNOS expression is 
mainly restricted to ECs. Furthermore, it is interesting to note that chromatin-based gene 
regulation is also observed in other EC-restricted genes, including vWF [49], Notch-4 [50], E-
selectin [51-53] and EPHB4 [54]. 
iNOS 
Whereas eNOS is mainly expressed by ECs, inducible nitric oxide synthase (iNOS) is 
silenced in the same cell type. In a recent study, Chan et al. [32] showed that the human iNOS 
promoter is epigenetically repressed by DNA methylation and histone H3 lysine 9 
methylation. Whereas in human cell types notoriously resistant to iNOS induction (e.g., 
primary endothelial cells and vascular smooth muscle cells), the NOS2A proximal promoter 
was densely methylated at CpG dinucleotides human primary cell types and transformed cell 
lines capable of iNOS induction (e.g. the human colon carcinoma cell line DLD-1) had a 
lower density of methylated CpGs at the NOS2A proximal promoter. The prolonged 
inhibition of DNA methyltransferase activity in human DLD-1 cells resulted in DNA 
demethylation of the iNOS promoter and a 3-fold increase in cytokine-induced iNOS mRNA 
expression. ECs, however, were resistant to DNA demethylation, and iNOS remained 
silenced even after repeated 5-azacytidine treatments. These findings suggested that additional 
repressive epigenetic mechanisms are contributing to DNA methylation-dependent NOS2A 
silencing in ECs. Studies on Neurospora crassa and Arabidopsis thaliana indicated that 
maintenance of DNA methylation is dependent upon histone H3 lysine 9 methylation [55, 
56]. And indeed histone H3 lysine 9 methylation was identified as an additional epigenetic 
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modification responsible for maintaining the silenced state at the NOS2A promoter in human 
ECs [32]. 
Furthermore, it was found that the iNOS promoter DNA methylation status varied strongly 
between human and mouse, i.e. the murine iNOS proximal promoter was hypomethylated 
relative to human sequences indicating that differential DNA methylation of the human and 
mouse iNOS promoters contributes to the marked difference in cytokine-induced gene 
expression [32].  
Smooth muscle cell specific gene expression 
Up to now, no endothelial-specific master regulator has been identified [57]. However, 
recently a PRDM6, a PR/SET domain containing protein was identified in flk1(+) cells at 
selected time points during differentiation [58]. The zinc finger protein belongs to the PRDM 
(PRDI-BF1 and RIZ homology domain) family of transcriptional repressors [59] named 
PRISM (PR domain in smooth muscle), containing a modified SET domain (named for the 
Drosophila melanogaster proteins Su(var)3-9, Enhancer-of-zeste, and Trithorax (reviewed in 
reference [60]). Like other SET [61] and PR [62] proteins, PRISM are known to interact with 
class I HDACs [63]. PRDM6, is enriched in flk1(+) hematovascular precursor cells [58] and 
was also detected in embryonic and adult-derived endothelial cell lines. PRDM6 is co-
localized with histone H4 and methylates H4–K20 (but not H3) in vitro and in vivo, which is 
consistent with the known participation of PR domains in histone methyltransferase activity. 
Overexpression of PRDM6 in mouse embryonic endothelial cells inhibited cell proliferation 
and induced apoptosis in ECs, but not in SMCs [58]. Based on the finding that PRDM6 is 
preferentially expressed in flk1(+) vascular precursor cells and its differential effects on 
endothelial and smooth muscle cells by modulating local chromatin-remodeling activity 
within hematovascular subpopulations during development, it was speculated that PRDM6 
may coordinate cell fate decisions in vascular progenitor cells that favor smooth muscle over 
endothelial differentiation, or may selectively ablate cells progressing down the endothelial 
lineage during early stages of vascular remodeling [58].  
Interestingly, a splice variant of PRDM6 was recently identified in a search for mRNAs 
highly expressed in aortic smooth muscle [63]. The protein was characterized as an SMC-
restricted epigenetic regulator, and therefore named PRISM/PRDM6. In contrast to PRMD6, 
which methylates histone H4 at residue 20, PRISM/PRDM6 associates with G9a and 
methylates histone H3 [63]. Overexpression of PRISM in cultured primary SMCs induced 
expression of genes associated with the proliferative smooth muscle phenotype while
repressing regulators of differentiation, including myocardin and GATA-6. Conversely, small 
interfering RNA-mediated knockdown of PRISM slowed cell growth and induced myocardin, 
GATA-6, and markers of SMC differentiation [63]. Myocardin is known to recruit histone 
acetyltransferase activity to the promoters of smooth muscle contractile genes [64], thereby 
resulting in gene activation. In addition to myocardin, GATA-6, a member of the GATA 
family of zinc finger transcription factors [65], promotes the contractile or differentiated 
smooth muscle phenotype through the induction of the cyclin-dependent kinase inhibitor 
p21(Cip1) [66]. 
However, the best-characterized regulator of smooth muscle gene expression is serum 
response factor (SRF), which binds a DNA sequence known as a CArG box and recruits
members of the myocardin family of coactivators to activate smooth muscle contractile 
protein genes [67, 68]. The MADS-box transcription factor SRF plays a central role in 
arteriogenesis (see chapter 5 and below). 
Signal transduction cascades in arteriogenesis 
Growth factor signaling provokes SMCs to reenter the cell cycle with a consequent activation
of genes involved in proliferation and a concomitant down-regulation of contractile transcripts 
[69]. Reportedly, arteriogenesis relies on the activation of the endothelium by increased shear 
stress. It is assumed that one or several shear stress induced endothelial mediators, in 
conjunction with recruitment of macrophages, promote vascular cell proliferation as a 
prerequisite for collateral growth and remodelling. Endothelium derived platelet derived 
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growth factor (PDGF) seems to be one of these mediators as its expression is differentially 
controlled by shear stress [70]. A recent publication demonstrates that endothelial cells 
derived from old animals do not express PDGF anymore, suggesting altered epigenetic 
control [71]. Co-administration of PDGF-BB and fibroblast growth factor-2 (FGF-2), another 
arteriogenic factor, has recently been described not only to promote arteriogenesis, but to 
induce vascular networks that remain stable for more than a year [72]. Most importantly, 
FGF-2 is also regulated epigenetically [73]. Furthermore, collateral artery growth is 
associated with an activation of the Rho-GTPase pathway (regulating actin dynamics) in 
smooth muscle cells, leading to altered activity of SRF that binds as a homodimer to CArG 
box DNA and activates transcription of genes involved in both muscle differentiation (α-
SMA, SM-MHC, SM22α) and proliferation (early growth response-1, Egr-1) [71, 74, 75]. All 
of these smooth muscle genes have been found to be differentially expressed during 
arteriogenesis (own unpublished data), reflecting a switch from the contractile to the synthetic 
(proliferating) phenotype of vSMCs. Recently, it has been shown that vSMC-restricted 
binding of SRF to murine vSMC CArG box chromatin is associated with patterns of 
posttranslational histone modifications within this chromatin that are specific for the vSMC 
lineage in vitro and in vivo, including methylation and acetylation to histone H3 and H4 
residues [76]. Myocardin (MYOCD), a SRF transcriptional cofactor, is essential for cardiac 
and smooth muscle development and differentiation. Myocardin increased SRF association 
with methylated histones and CArG box chromatin during activation of SMC gene 
transcription, whereas the myogenic repressor Kruppel like factor 4 (KLF4) recruited histone 
H4 deacetylase activity to vSMC genes and blocked SRF association with methylated 
histones and CArG box chromatin during repression of SMC gene expression. PDGF-BB 
treatment resulting in proliferation of vSMCs increased expression of KLF4 and decreased 
expression of myocardin being associated with decreases in SRF binding and H4Ac at CArG 
boxes [76].  
Together these data indicate that epigenetic mechanisms are likely to control the expression 
and function of key mediators in arteriogenesis (see also chapter 5) and may account for 
reduced arteriogenesis observed in senescent animals (own unpublished data).  
Bone marrow derived cells 
A variety of studies are available describing epigenetic modification in bone marrow derived 
cells such as monocytes and macrophages or T-cells. In 2005, Fraga et al published a 
landmark report describing global and locus-specific differences in DNA methylation and 
histone H3 and H4 acetylation in peripheral blood lymphocytes in a large cohort of young and 
elderly MZ twins [77]. Of 40 twin pairs, 35% demonstrated significant differences in the three 
epigenetic marks. Remarkably, these epigenetically discordant twins were more likely to be 
older, spent less of their lifetime together, and reported the greatest differences in natural 
health/medical history.  
Aging is known to be associated with global hypomethylation and dense hypermethylation of 
certain CpG islands presenting a major risk factor for atherosclerosis [78]. A global DNA 
hypomethylation has been observed in vascular lesions and leukocytes of atherosclerosis 
patients and proliferating SMCs in animal models [79-81]. 
An interesting study was recently published by Lund et al [82]. Investigating Apolipoprotein 
E deficient mice -  genetically prone to atherosclerosis - they found that DNA methylation 
polymorphism were significantly more frequent in circulating inflammatory cells, and/or 
immune cells (as well as aorta) [83, 84], in comparison to control tissue (liver, pericardial fat, 
skeletal muscle), even before the appearance of histologically detectable vascular lesions. In 
particular, they found a significant global hypomethylation of genomic DNA in PBMCs 
(peripheral blood mononuclear cells) as well as in aorta. Furthermore, they showed for the 
first time that atherogenic lipoproteins promote global DNA hypermethylation in a human 
monocyte cell line, i.e. THP-1 cells. In this current volume, Vincent van Weel (Chapter 9) 
reports on the role of bone marrow derived cells in arteriogenesis. He previously published a 
study showing that perfusion recovery was strongly decreased in APOE3*Leiden mice after 
femoral artery occlusion, as well as that hypercholesterolemia is associated with reduced 
arteriogenesis [85]. 
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Is there a need for stem cells? 
Epigenetic research is of fundamental relevance for stem cell technology. Stem cells are able 
to differentiate into all cells of a body. Stem cells, as well as each cell of the body, contain the 
same DNA sequence and genes. Epigenetic modifications, however, control gene usage. Stem 
cells are able to give rise to every cell type and studies indicate that their DNA is more open 
to instructions and “manipulations”, i.e. their epigenetic instructions are missing and not yet 
enforced [3]. Reprogramming differentiated cells in terms of epigenetic remodifications may 
present one of the utmost future challenges. 
Conclusion 
Epigenetics is a relatively new field in research. Epigenetic modifications present a check 
point of gene expression affecting each cell of a body. They are upstream of transcription 
activators or –repressors and therefore have to be recognized at a more global level. Although 
currently no data of direct investigations on epigenetic modifications in arteriogenesis or 
collaterogenesis are available, it is clearly evident that they must play a major role in both 
processes. 
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$ Thymosin ß4 is a small water soluble peptide of 5 kDa, which was isolated by Goldstein and White in 
1966 from the thymic gland [1]. Since then, its clear role in distinct processes such as wound healing [2], hair 
growth via stem cell migration [3,4], cardioprotection [5] and angiogenesis [6] is contrasted by a high level of 
uncertainty with respect to the exact mechanisms providing these pleiotropic effects (Table 1). However, several 
approaches render thymosin ß4 as a possible candidate for future clinical therapy, including cardioprotection and 
neovascularisation. Therefore, we focus on the modes of action involved in thymosin ß4 signaling in the 
cardiovascular system, in particular its significance for angiogenesis and arteriogenesis. 

Family and background: 
In the 1960s the laboratory of Abraham White at the Albert Einstein College of Medicine in 
New York firstly isolated and partially purified a group of hormon-like peptides from the 
thymic gland and coined the term thymosins for them [1]. Although initially thought to be a 
single polypetide of approximately 14 kDa thymosins later turned out to be a mixture of 
several peptides weighing 1 to 15 kDa. Due to 5 steps of preparation, this mixture was named 
thymosin fraction 5 [7,8]. This family of thymosins consisting of a number of small peptides 
received their nomenclature from their isoelectric points: - thymosins below a pH of 5.0, ß- 
thymosins between a pH of 5.0 – 7.0 and 
-thymosins with a pH of 7.0 and higher [9].  
Two members of this thymosin fraction 5 family, thymosin 1 and ß4, are in advanced stages 
of clinical trials. Here we want to focus exclusively on the functions and interactions of 
thymosin ß4. 
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Thymosin ß4 and actin 
In 1990 Dan Saver and his colleagues were able to show that thymosin ß4 plays an important 
role in the sequestration of actin [10,11]. Actin is the major molecule of cellular locomotion, 
cell shape, cell division and intracellular transport. These dynamic changes of the 
cytoskeleton require rapid assembly of monomeric g-actin to filamentous f-actin and in return 
quick disassembly. Looking at purified actin under ionic conditions in a test tube, more than 
90% would polymerise forming f-actin while resting cells show equal amounts of f- and g-
actin [12]. How does the cell manage to keep this constant pool of single actin molecules? 
Specific actin-monomer binding proteins are indispensible. The most abundant protein 
complexing with g-actin and preventing its polymerisation is thymosin ß4, which can be 
found in almost any eukaryotic cell, binding monomeric g-actin in a stoichometric 1:1 
complex preventing it from ionic induced assembly. Stimulation of cells induces actin 
polymerisation via filament-barbed-ends. In this case free monomeric actin is provided either 
by dissolving of the thymosin- actin complex or by aggregation of g-actin with profilin. 
Profilin bound actin may polymerise forming changes in cellular shape. To complete the cycle 
of actin organization, f-actin is depolymerised through cofilin and gesolin family proteins 
resulting in monomeric g-actin (Fig. <) [13,14]. Tight regulation of these binding proteins is 
mediated by changes in intracellular calcium-ion concentration, phosphorlylation of 
branching sites and various pathways  [15]. 


< Thymosin ß4 sequesters monomeric g-actin, while profilin assists in f-actin polymerisation. Cofilin is 
involved in the process of depolymerisation from f-actin to g-actin. 

Thymosin ß4 and angiogenesis 
The first hint of thymosin ß4 mediating angiogenesis was observed in Matrigel assays by 
Kleinman and Goldstein in 1995 [16]. Endothelial cells transfected with thymosin ß4 started 
to spread and attach significantly higher on Matrigel than control cells and rapidly arranged 
into capillary-like tube networks. In vitro thymosin ß4 acts as a chemoattractant for 
endothelial cells. In vivo, using the subcutaneous implantation of Matrigel thymosin ß4 forced  
endothelial cell migration [17]. Vascular sprouting of coronary artery rings accelerated after 
exogenous application of only 100 ng thymosin ß4 resulting in a doubling of the vessel area 
[18]. Interestingly, uptake of thymosin ß4 via internalization or binding to an unknown cell 
surface receptor was suggested, implying both an autocrine and paracrine role of thymosin ß4 
  Arteriogenesis                                                      Trenkwalder et al.  135
in vessel formation. Due to the fact that controlled angiogenesis is essential for effective 
wound healing, thymosin ß4 increased wound healing rates, collagen deposition and 
keratinocyte migration [2].  
Role of a cleavage product of thymosin ß4: AcSDKP 
Besides the pleiotropic roles of full-length thymosin  ß4, cleavage of its N-terminus between 
the amino acids Pro 4 and Asp 5 by an endopeptidase [19] generates a bioactive fragment 
namely Ac-SDKP. Ac-SDKP is ubiquitously present in various tissues and occurs in the 
plasma at nanomolar concentrations [20]. The angiotensin- converting- enzyme (ACE) is 
responsible for Ac-SDKP degradation and ACE-inhibitor therapy results in increased plasma 
levels of Ac-SDKP [21]. This might contribute to the effects seen after ACE-Inhibitor-
administration in patients. Ac-SDKP has been shown to provide angiogenesis in vitro and in 
vivo [22] and suffices to enhance neovascularisation in hindlimb ischemia through MCP-1 
signaling [23]. MCP-1 induces upregulation of hypoxia-inducible-factor-1-alpha (HIF-1) 
and consequently vascular endothelial growth factor-A (VEGF-A) expression [24]. 
Additionally, MCP-1 attracts monocytes to the area of conductance vessel maturation as an 
important part of arteriogenesis [25]. Concurrent with these findings systemic administration 
of Ac-SDKP accelerated revascularization following myocardial infarction [26] and 
knockdown of thymosin ß4 in the developing heart was accompanied by a significant 
reduction in Ac-SDKP level [27]. Attempts to restore full function in the embryonic cardiac 
setting lacking thymosin ß4 by injecting Ac-SDKP into pregnant female mice failed, 
demonstrating the importance of the full-length protein at least during embryonic 
vasculogenesis. However, in adult epicardial explants Ac-SDKP induced differentiation of 
Flk-1+ progenitor cells to endothelial cells but not smooth muscle cells, unlike Tß4 
administration. Furthermore, Ac-SDKP was not sufficient to induce a significant outgrowth 
[28]. Interestingly, Ac-SDKP provides anti-fibrotic qualities eventually contributing to its 
cardioprotective effect as after myocardial infarction Ac-SDKP lowers the remodeling from 
necrosis to fibrosis resulting in decreased scar formation [29].   
Cardioprotective effect of Thymosin ß4 during myocardial ischemia – reperfusion   
Since repair mechanisms are predominant in wound healing after coronary occlusion, several 
laboratories followed the hypothesis that thymosin ß4 would contribute to the limitation of 
tissue damage and adverse remodeling after myocardial ischemia. Ildiko Bock- Marquette and 
Deepak Srivastava first unmasked the potential of thymosin ß4 to increase post-ischemic 
cardiomyocyte survival in a murine model of myocardial infarction [30]. Surprisingly, this 
pro-survival capacity still held up when thymosin ß4 was applied after the initiation of 
ischemia, a scenario most likely occuring under clinical circumstances.  
Supporting this notion, we used a preclinical model of ischemia and reperfusion in pigs for 
the assessment of acute cardioprotection. We observed an enhanced myocyte survival at 24h 
after reopening the occluded LAD upon regional thymosin ß4 application into the ischemic 
area [5], involving a decrease in apoptosis and postischemic inflammation. 
Intracellular modes of action of Thymosin ß4  
Regarding the mode of action of thymosin ß4 signaling, several possibilities exist. Despite 
intense research, no receptor structure has been revealed yet (Fig. =), rendering other 
possibilities likely. Bock-Marquette demonstrated intracellular thymosin ß4 uptake using 
phage particles as a carrier. Phage particle expressing thymosin ß4 on their surface were 
added to mouse embryonic heart explants and then detected using an antiphage antibody. The 
antiphage antibody covered the cell surface, parts of the cytosol and was even detectable in 
the nucleus whereas control phages without thymosin ß4 expression were not traceable 
throughout the cells [31]. Similarly, Huff et al. demonstrated a nuclear uptake of exogenously 
applied thymosin ß4, postulating an active uptake mechanism [32]. Exogenous administration 
of thymosin ß4 onto a system of embryonic heart explants promoted cardiomyocyte and 
endothelial cell migration away from the explant. Cardiac myocytes which usually do not 
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migrate were also stimulated in migration identified as spontaneously beating, cardiac muscle 
-actin positive cells. Besides neonatal cardiomyocytes treated with thymosin ß4 showed an 
increase in survival, they were able to contract regularly and for a longer period of time than 
controls [31]. 

8 =  Suggested mechanisms of thymosin ß4 signalling: Thymosin ß4 is proposed to enter the cell via 
internalisation or providing its effects via a cell surface receptor. Conversely it is likely to be secreted. 
Intracellulary it regulates actin sequestration and can be found as part of a ternary complex with PINCH and ILK 
activating the AKT. Thymosin ß4 can also enter the nucleus, maybe using an active transport mechanism and 
mediate gene transription. 

The exact mechanism of action how thymosin ß4 is able to promote migration and survival is 
unclear but at least some interactions are well described. It has been reported recently that 
thymosin ß4 interacts with PINCH (Particularly Interesting New Cys-His Protein ) a LIM 
domain protein. PINCH interacts through its first LIM domain with the Integrin–Linked- 
Kinase (ILK) building a complex which indirectly takes part in the regulation of the actin 
cytoskeleton assisting in connecting to the extracellular matrix. This expanded complex is 
also known as the focal adhesion complex, being centrally involved in cell motility [33], cell 
modulation and cell survival and optimal activation of the Proteinkinase-B (AKT) [34]. 
Phosphorylation of the serin-threoin-kinase AKT is a central step of signaling pathways 
involved in cell survival and growth [35,36]. Thymosin ß4 binds PINCH and ILK 
independently showing a stronger interaction with PINCH, being integrated into this ternary 
complex of all three proteins (Fig. =). In comparison to the ILK interacting with the first LIM 
domain of PINCH, thymosin ß4 connects to the complex at the fourth and fifth out of five 
LIM domains of PINCH. In addition to thymosin ß4 operating with ILK and PINCH, 
treatment of C2C12 cells with thymosin ß4 showed increased levels of ILK and its substrate 
P-AKT [27]. Activation of the AKT requires phosphorylation of two amino acids, Thr 308 
and the Ser 473. Thr 308 is phosphorylated by the enzyme PDK1 whereas the kinase for Ser 
473 phosphorylation has not been identified yet [37] but a possible candidate could be the 
ILK. Consistent with this hypothesis the therapy of infarcted mice hearts with thymosin ß4 
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accelerated levels of ILK and Ser 473 phosphorylation of the AKT [30]. These results 
demonstrate a possible pathway resulting in activation of the AKT/ protein kinase B 
consistent with the recent finding of thymosin ß4-induced protein kinase C activation [38], a 
different pathway of AKT activation.  

Thymosin ß4 is essential for coronary vessel formation
Thymosin ß4 is known to be upregulated in early embryogenesis of mice, in particular in 
regions of blood vessel formation and in endocardial cushions [39]. The conventional 
formation of coronary blood vessels requires growth and maturation of microcirculatory as 
well as macrocirculatory vessel.  Smart et al. identified thymosin ß4 as essential for all three 
steps in the developing heart. During coronary vessel formation in embryonic mice epicardial 
progenitor cells differentiate and migrate into the inner layers of the developing heart giving 
rise to a vascular network sufficient to feed the growing myocard [40,41,42]. Transgenic mice 
carrying an alpha-MHC-restricted knock-down of thymosin ß4 are still able to induce 
transformation of these epicardial derived cells but lack migration into the inner layers. 
Subsequent to missing migration, thymosin ß4 knockdown hearts display clusters of 
immobilized endothelial and smooth muscle cells in the epicardial layer. Interestingly, besides 
coronary vessel formation the development of large thoracic vessels, e.g. branching of the 
aorta and subclavian arteries was impaired due to a lack of smooth muscle cell migration [27]. 
Recent data also identified thymosin ß4 as a stimulator of actin-dependant pseudopodia 
formations which are of utmost importance for cell migration as they determine the direction 
of movement [43].These findings suggest a paracrine role of thymosin ß4 signaling between 
the myocard and the epicard as a key step in embryonic cardiac vessel formation [44].  
eEPCs, thymosin ß4 and arteriogenesis
The contribution of endothelial progenitor cells (EPC) to new blood vessel formation is a 
central subject for current investigations. Recent evidence supports the concept of progenitor 
cells contributing to neovascularization via secretion of paracrine factors. Earlier work of our 
lab demonstrated the beneficial role of eEPCs [45] in two animal models of acute and chronic 
ischemia. The local retroinfusion of eEPCs into the ischemic hindlimb of rabbits as well as 
the systemic injection following myocardial infarction in mice showed an increase in 
neovascularisation and promotion of tissue recovery [46]. Embryonic EPCs increased limb 
perfusion via capillary sprouting and conductance vessel formation in rabbits and limited 
cardiac dysfunction in mice. Additionally, eEPCs reduced ischemia reperfusion injury in pigs 
involving the PI3/AKT pathway [47].  
To further analyze the contribution of eEPCs to cardiomyocyte survival and vessel formation, 
we performed a transcriptome analysis of eEPCs, revealing a broad range of angiogenetic 
factors, among others thymosin ß4. Indeed, the cardioprotection provided by embryonic EPCs 
was lost when thymosin ß4 was knocked down using a thymosin ß4 specific shRNA [5]. In 
vitro cardiomyocytes exposed to hypoxia and reoxygenation improved in survival after eEPC 
treatment unless thymosin ß4 was knocked down using shRNA. Similar endothelial cell 
apoptosis was reduced in a setting of eEPC treatment apart from shRNA transfection. 
Consistently, a lack of Tß4 in eEPCs abrogated their cardioprotective potential, whereas Tß4 
alone sufficed to limit infarct size and postischemic inflammation [48].  
As mentioned earlier the model of chronic hindlimb ischemia in rabbits showed beneficial 
effects on angiogenesis and arteriogenesis after treatment with eEPCs. The knock down of 
Tß4 in eEPCs blunted the neovasculatory response usually obtained after application of 
wildtype eEPCs into the chronic ischemic limb vasculature. Of note, conductance vessels 
(Fig. >, Fig. 0) were affected to a similar extent as microcirculatory vessels (Fig. >,), 
diminishing the resulting blood flow (Fig. >). Thus, although eEPCs secrete a variety of 
proteins involved in the process of neovascularisation, thymosin ß4 expression appears 
indispensable for their neovasculatory response in vivo [49].  
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> Postischemic neovascularisation in the hindlimb of rabbits. A & C, Collateral growth and perfusion 
were increased after regional retroinfusion of eEPCs , unless Tß4 was down regulated. B, Quantification of 
capillaries per muscle fiber of the ischemic calf muscles demonstrating accleration of capillaries after eEPC 
application, whereas sh-RNA cotransfection blunted these effects. (n=3; * P< 0,05 vs. control) 

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0 Angiographies after 35 days in a model of chronic hindlimb ischemia in rabbits. The treatment with 
eEPCs showed an increase in collateral formation in comparison to the control group, whereas co-application of 
thymosin ß4 shRNA abolished this effect [49]. 
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Our findings reveal a surprising effect: thymosin ß4, a small protein might be the key factor in 
eEPC mediated stimulation of arteriogenesis. It will be interesting to see, if this protein is 
capable of stimulating arteriogenesis and showing anti-inflammatory properties (see below) at 
the same time, a combination which is of utmost importance for a future therapeutic use. 
Thymosin ß4 in inflammation:
Atherosclerosis is a disease caused by chronic endothelial activation and 
monocyte/macrophage recruitment during the process of plaque formation [50,49]. On the 
other hand, recruitment of monocytes is a central function of arteriogenesis [50], which at 
times was experimentally enhanced by pro-inflammatory stimuli. Given the pro-arteriogenic 
effect of thymosin ß4, its role in defined models of inflammation was investigated by several 
groups.  
In particular, Sosne et al analyzed a model of corneal wound healing. The local application of 
thymosin ß4 intensified the re-epithelialisation following corneal injury and modulated 
several cytokines for example interleukin (IL)-1ß and IL-18 [51]. Following alkali injury 
thymosin ß4 stimulated corneal wound healing and again showed anti-inflammatory 
properties by downregulating chemokines like macrophage inflammatory protein (MIP)-1, 
MIP-1ß, MIP-2 and again the cytokine IL-1ß [52]. Using TNF-, a well-know pro-
inflammatory cytokine thymosin ß4 co-application was efficient to downregulate NF-b 
activation in human corneal epithelial cells. The effect on NF-b down regulation comprised 
NF-b phosphorylation, activity and nuclear translocation [53]. Thymosin ß4 also decreased 
the number of inflammatory cells in corneal wound healing [52] and showed a modulation of 
the MMP/TIMP balance in mice after corneal alkali injury [54] and reduced the levels 
inflammatory chemokines and cytokines in studies of septic shock [55]. 
Discussion:
Thymosin ß4 contributes to a wide range of cellular processes, and a number of gene 
expression changes [56,57] have been reported. Infection of lung tumor cells either with an 
adenovirus expressing thymosin ß4 or the single peptide showed an increase in VEGF 
expression [58]. Additionally, thymosin ß4 knockdown hearts appeared to have lower 
expression levels of VEGF [27] but still it is not clear if there is a direct interaction of 
thymosin ß4 and VEGF. 
Regarding the role of thymosin ß4 in the cytoplasm, a signaling cascade of thymosin ß4 
interacting with PINCH and ILK leading to AKT activation has been shown to be relevant. 
But do these complex interactions require the g-actin sequestering function of thymosin ß4? 
Neither stimulation of f-actin formation nor the inhibition of actin polymerisation influenced 
the levels of ILK after thymosin ß4 administration in C2C12 cells. In addition blocking PI3-
kinase, an upstream enzyme of the ILK abolished thymosin ß4 induced effects [30] showing 
the importance of this signaling pathway for thymosin ß4 action.   
To date, options for therapeutic neovascularisation are still confined but expandable. 
Considering its multifarious effects on the cardiovascular system, thymosin ß4 is likely to be 
an auspicious therapeutic target. For instance, it is essential for embryonic coronary vessel 
formation [27], angiogenesis [18] and eEPC mediated arteriogenesis. Another advantageous 
property of thymosin ß4 is its anti-inflammatory potential [53]. 
Taken together thymosin ß4 is involved in any process of cellular shape and migration 
through its function in actin polymerization. It is of great interest to define the mechanism of 
action and the molecular pathways involved in thymosin ß4 signaling in health and disease. 
Despite a lack of mechanistically certainty, the current evidence suggests that thymosin ß4 is 
likely to show great promise in future therapeutic strategies in injured tissues. 
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$ In recent years cell therapeutic approaches for induction of arteriogenesis, including injection of 
autologous bone marrow, have gained popularity for experimental treatment of patients with coronary or 
peripheral arterial ischemic disease. However, beneficial results of these cell therapies in patients remain 
inconsistent to date. Evidence points towards a supportive paracrine role of bone marrow derived cells by 
secretion of various pro-arteriogenic cytokines and growth factors. Moreover, inflammatory cells, originating 
from the bone marrow, are recently pointed out as the key regulators of arteriogenesis. This chapter focuses on 
the role of leukocytes in arteriogenesis. In particular, the role of monocytes, natural killer cells and T-cells, 
including various subpopulations of T-cells, are addressed. Activation (or inhibition) of selective leukocyte 
subpopulations may ameliorate pro-arteriogenic cell therapy in the future. 
Introduction 
In the past ten years, therapeutic arteriogenesis using bone marrow derived cells has become a 
promising treatment for patients with either coronary or peripheral ischemic disease [1-6]. 
Although initial reports of autologous bone marrow transplantation for patients with limb 
ischemia were very promising [7], beneficial results of cell therapy in patients with peripheral 
arterial disease (PAD) are not very consistent to date [8].  
Although the concept of the development of adult collateral arteries from a pre-existing 
arteriole network is indisputable for therapeutic intervention, the exact cellular mechanism 
underlying arteriogenesis remains unclear. There are different hypotheses on the role of bone 
marrow derived cells in arteriogenesis. Nowadays, evidence points towards a more supportive 
paracrine role of bone marrow derived cells by secretion of various factors instead of the 
initially proposed role in promoting arteriogenesis by incorporating into the vessel walls [9]. 
Also the role of different inflammatory cells, originating from the bone marrow, has 
extensively been studied in order to evolve a more efficient cell therapeutic approach than 
infusion of the total bone marrow derived cell fraction. Previously, numerous animal studies 
have established that ischemia induced angiogenesis and shear stress induced arteriogenesis 
can be enhanced with different types of leukocytes, cytokines and growth factors. The 
molecular and cellular mechanisms that play a role in collateral artery formation start to 
become unravelled more recently. Increased shear stress induces arteriogenesis by stimulating 
the attraction, adhesion and invasion of circulating inflammatory cells [10] such as 
monocytes, T-lymphocytes and NK-cells. Growth factors that are already present in the 
ischemic tissue, as well as those that are produced by the invading cells play an important role 
too. Recently, also subpopulations of T-lymphocytes, such as CD4+ T cells, CD8+ T cells 
and CD4+CD25+FoxP3+ T cells and their role in arteriogenesis have been studied in more 
detail. This chapter will focus on the role of leukocytes in collateral artery formation. 
Monocytes in arteriogenesis 
Monocytes play a crucial role in mediating neovascularization in response to increased shear 
stress and ischemia. Already in the 1970s monocytes were found to invade the vessel wall of 
developing coronary collateral arteries [11,12]. Later on, functional proof for the participation 
of monocytes in arteriogenesis has been reported by the results that after increasing blood 
monocyte concentration in a hind limb ischemia mouse model, arteriogenesis is enhanced 
[11-13]. In contrast, after depletion of monocytes, collateral artery formation is much 
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attenuated [12]. Increased shear stress, due to the arterial occlusion, activates the vascular 
endothelium. The activated endothelial cells upregulate the monocyte chemoattractant MCP-1 
and adhesion molecules (eg. ICAM-1 and VCAM-1) to which the receptor of monocytes 
binds [14,15]. This leads to monocyte adhesion and infiltration with the subsequent 
production of growth factors and proteases. In the next paragraph we will discuss these 
aspects of monocytes in arteriogenesis into more detail.  
The local production of cytokines and chemokines within the first 3 days after ischemia 
mediates the recruitment of monocytes to the ischemic area [16-19]. To stimulate 
arteriogenesis, monocytes must home and retain around the arterial occlusion. There is 
evidence that MCP-1, but also VEGF and SDF-1 contribute to the recruitment and retention 
of monocytes [19-23]. For example, local infusion of MCP-1 [24] or MCP-1 gene transfer 
[25] in a hind limb ischemia rabbit model increase the local number of monocytes in the 
ischemic area and enhance revascularization. Voskuil et al. [26] reported impaired monocyte 
recruitment after hind limb ischemia in MCP-1-/- mice. This effect was reversed with 
treatment of the MCP-1 protein.  Furthermore, Heil et al. [27] showed that disruption of the 
MCP-1 receptor (CCR2) in CCR2-/- mice leads to an impaired blood flow restoration after 
femoral artery ligation. This impairment was based on a reduced migration capacity of these 
monocytes.  
The interaction of the monocyte with the activated endothelium is a complex multistep 
process. Auffray et al. [28] reported recently the importance of the role of monocytes in the 
initial recruitment of blood monocytes. They observed a subset of monocytes that could crawl 
on endothelial cells. These resident monocytes patrol healthy blood vessels and allow rapid 
tissue invasion by monocytes in case of ischemic injury or tissue damage [28]. Two integrins 
are responsible for the interaction of monocytes with endothelial cells: Mac-1 and LFA. These 
intergrins interact with adhesion molecules on the endothelial surface, like selectins, 
intercellular adhesion molecules (ICAM-1 and ICAM-2) and vascular adhesion molecules 
(VCAM-1) [14]. It was demonstrated that factors like MCP-1 and VEGF, released by the 
activated endothelial cells, can increase the expression of integrins on monocytes and enhance 
monocyte adhesion [29-31]. After monocyte adhesion, integrins also mediate transmigration 
of monocytes into the perivascular tissue. Hoefer et al. showed that in vivo treatment with 
antibodies against ICAM-1 blocked collateral artery growth [32].  
For invading into deeper vessel wall layers, monocytes can use their capacity to produce 
proteases such as matrix-metalloproteinases and u-PA. Their proteolytic activity can create 
gaps by which monocytes can migrate further into the vessel wall [33-35]. After 
transmigration into the perivascular tissue, monocytes differentiate into macrophages and 
secrete growth factors and cytokines that attract other inflammatory cells and stimulate 
smooth muscle cell proliferation and endothelial cell mitosis, both necessary for collateral 
growth [36]. One of the pro-inflammatory factors secreted by monocytes and macrophages is 
TNF-. In a rabbit hind limb ischemia model, it is demonstrated that arteriogenesis is 
attenuated after treatment with TNF- inhibitors, most likely due to the inhibition of 
leukocyte infiltration around collateral arteries and lower vascular smooth muscle cell 
proliferation [37]. Also fibroblast growth factors (FGF), provided by monocytes in a 
paracrine way, do have a stimulating effect on arteriogenesis [13].  
The potential of transplantation of monocytes to stimulate collateral artery formation in the 
clinical situation has now been studied by using the hind limb ischemia animal model. Herold 
et al. [15] showed that although autologous monocytes only demonstrated a marginal increase 
in arteriogenesis, their transduction with GM-CSF before transfusion into the hind limb 
ischemia model resulted in a robust stimulation of arteriogenesis. Also Urbich et al. [38] 
provided evidence that transplantation of engineered monocytes represents a highly effective 
therapeutic approach to stimulate collateral artery formation. In contrast, monocytes injected 
directly after isolation, without any stimulation, did not show any stimulating effect on 
arteriogenesis. Isolation of monocytes can easily be done in humans by leukapheresis and 
these cells have been safely administered for patients with malignancies. The strategy of 
transplantation of pro-arteriogenic monocytes seems feasible, but further research towards the 
side effects (e.g. pro-atherogenic effects) is warranted.  
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T cells in arteriogenesis 
More recently, it was found that other leukocytes than monocytes also contribute to collateral 
artery formation. T lymphocytes also play a role in many vascular diseases ranging from a 
pro-atherogenic role in atherosclerosis towards a beneficial role in arteriogenesis. Couffinhal 
[39] showed that nude mice, which are deficient for all types of mature T lymphocytes, did 
have a hampered capacity to form collateral arteries after induction of hind limb ischemia. 
The role of T lymphocytes in arteriogenesis has recently been studied more extensively, with 
focus on arteriogenic function of specific subpopulations of T lymphocytes. Although the 
exact role is not completely understood yet, we will discuss the contribution of CD4+ T cells 
(Helper T cells), CD8+ T cells (Cytotoxic T cells), CD3+CD31+CXCR4+ T cells (angiogenic 
T cells) and CD4+CD25+FoxP3+ T cells (regulatory T cells). See Figure < for a schematic 
representation. 
The importance of CD4+ T cells in collateral artery formation has been demonstrated 
recently. CD4-/- mice, which do have a normal development of CD8+ T cells and myeloid 
cells showed a markedly reduction in ischemia-induced collateral artery formation. Compared 
to controls, there was a 25% decrease in blood flow restoration after femoral artery ligation 
during 28 days in these CD4-/- mice [40]. In a rescue experiment, CD4-/- mice received 
spleen-derived purified CD4+ T cells and restored blood flow recovery after ischemia to the 
levels of wild type mice [40]. Additionally, CD4 depleted mice, show significantly impaired 
blood flow restoration after femoral artery ligation [41]. Furthermore, MHC class II deficient 
mice, which are characterized by the selective lack of the maturation of CD4+ T cells, display 
impaired arteriogenesis too [41].  
The most likely mechanisms contributing to the arteriogenic-enhancing effects of CD4+ T 
cells appears to be that CD4+ T cells play an important role in the classic immune response in 
the ischemic area. In wildtype C57BL/6 mice, CD4+ T cells accumulate around collateral 
arteries within 3 to 7 days after ligation of the femoral artery [41]. It is believed that 
perivascular presence of T cells is necessary to destroy cells to create space for collateral 
growth [42]. Also exogenous CD4+ T cells home to the inflammatory cell infiltration in the 
ischemic hind limb within 24 hours after transfusion. In contrast, CD4 negative cells do not 
have selective homing to the ischemic hind limb [40]. CD4+ T cells secrete various cytokines 
for example to induce monocytes/macrophage accumulation in the ischemic muscle [43]. 
These monocytes and macrophages secrete large arrays of cytokines and growth factors which 
further facilitate arteriogenesis [43]. Recently, van Beem et al. [44] described the role of 
CD4+ T cells in the stimulation of CD14+ monocytes to differentiate into a pro-angiogenic 
cell type, namely endothelial progenitor cell colonies (CFU-ECs). Paracrine factors produced 
by activated CD4+ T cells present in the ischemic tissue facilitate CFU-EC formation. The 
exact cocktail of soluble factors stimulating CD14+ monocytes and the role of these CD4+ T 
cell - stimulated monocytes need to be further investigated.  
The role of CD8+ T cells in arteriogenesis is demonstrated by an impaired blood flow 
restoration in CD8-/- mice after hind limb ischemia. An attenuated blood flow persisted from 
day 3 till day 28 after femoral artery ligation compared to controls. After transfusion of 
exogenous CD8+ T cells into CD8-/- mice, the impaired blood flow recovery after ligation 
was rescued [45]. CD8+ T cells are one of the first cells involved in collateral artery 
formation [45]. When CD8+ T cells infiltrate into the ischemic muscle, they express IL-16, 
which is an important chemo-attractant for several immune cells such as monocytes, 
eosinophils and dendritic cells [46-48]. Similarly, IL-16 participate in the recruitment of 
CD4+ T cells since it has been shown that IL-16 is a natural ligand for CD4 [48].   
More recently, the role of a specific subset of CD4+ T cells, the regulatory T cells, has been 
studied.  CD4+CD25+FoxP3+ regulatory T cells constitute 10% of CD4+ T cells in the 
peripheral blood. This T cell population is specialized to suppress immune responses and 
contributes to the maintenance of immunological self-tolerance and immune homeostasis. In 
addition, these regulatory T cells do have an important function in the T cell homeostasis and 
suppress T cell responses against self-antigens or foreign antigens. Interestingly, it has been 
shown that regulatory T cells participate in the control of the development of atherosclerotic 
lesions. The role of regulatory T cells in ischemia-induced collateral artery formation has 
been recently studied by Zouggari et al. [49]. They modulated regulatory T cell levels by 
intervening in the B7/CD28 interaction, which is required for regulatory T cell generation and 
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homeostasis. In this regard, hind limb ischemia was induced in CD28-/- and B7-1/2-/- mice, 
which are deficient for regulatory T cells. In these mice, a 1.2 to 2.0 fold increase in 
neovascularization after hind limb ischemia induction was found. In line with this, collateral 
artery formation was also increased in anti-CD25-treated mice compared to controls [49]. 
Taken together, regulatory T cell reduction with B7- or CD28 deficiency or anti-CD25 
treatment, increases post-ischemic neovascularization. So, regulatory T cells play an 
important role in arteriogenesis, most probably by controlling the effector immune cell 
response [49]. Modulation of the regulatory component of post-ischemic inflammatory cell 
response, could provide a novel level of therapeutic intervention for pro-arteriogenic 
strategies for the treatment of PAD.   
Another subpopulation of T cells, CD3+CD31+CXCR4+ T cells, has been suggested as a 
potential target for ischemic cardiovascular diseases. This cell is also referred as angiogenic T 
cell in literature. Hur et al. [50] report that the central cluster of endothelial progenitor cells 
(EPCs), which play an important role in neovascularization [51,52], is composed of 
CD3+CD31+CXCR4+ T cells. These angiogenic T cells are required for colony formation 
and early EPC differentiation as was investigated by depletion and adding these T cells during 
EPC-culture.  
Furthermore, CD3+CD31+CXCR4+ T cells secrete various pro-angiogenic cytokines such as 
VEGF, IL-8, IL-17 and granulocyte colony-stimulating factor. Moreover, these cells also 
secrete MMP-9 which is known to play an important role in angiogenesis related extracellular 
matrix degradation. In vitro experiments as tube formation assays, as well as in vivo 
experiments further illustrate the pro-angiogenic capacity of CD3+CD31+CXCR4+ T cells. 
Infusion of CD3+CD31+CXCR4+ T cells in a hind limb ischemia mouse model improved 
blood flow recovery significantly. Clinical studies showed that the level of angiogenic T cells 
in peripheral blood MNCs is decreased when risk scores for cardiovascular disease are 
increased. This stresses the clinical relevance of this subpopulation T cells and further 
research towards this cell as target for cell therapy or as biomarker of cardiovascular disease 
is necessary [50].  
Natural killer cells in arteriogenesis 
Natural Killer (NK) cells were recently proven to contribute to arteriogenesis as well [41]. As 
explained previously, collateral growth is initiated by shear stress induced release of 
chemoattractants, such as MCP-1. Not only is MCP-1 a potent chemoattractant for monocytes 
[24,53] but also for NK cells [54]. 
The role of NK cells in processes of vascular remodeling, e.g. atherosclerosis [55] but also 
remodeling of spiral arteries in the placenta [56] was already described. Mice deficient for 
functional NK cells have reduced atherosclerotic lesions and mice deficient for uterine NK 
(uNK) fail to modulate spiral arteries feeding the placenta.  
The role for NK cells in arteriogenesis was established when these cells were found to 
accumulate around collateral arteries and by the observation of impaired arteriogenesis 
following femoral artery ligation in mice depleted or deficient for NK cells [41]. Unlike a 
well established role for NK-T cells in atherosclerosis [57], this could not be proven for type 
1 NK-T cells in arteriogenesis. Especially since J-alpha281-knockout mice, that selectively 
lack V-alpha14 NK-T cells, did not show impaired arteriogenesis after femoral artery ligation 
[41]. However, the role of type 2 NKT cells is unclear. 
NK cells are cytolytic effector cells of the innate immune system primarily involved in the 
defense against infectious pathogens, especially viruses. Their state of action is determined by 
dual signaling via inhibitory and activating surface receptors [58]. Many of these receptors, 
e.g. NKG2D, NKrp1c (NK1.1), CD94/NKG2, and the highly polymorphic Ly49 receptor 
family, code for in the Natural Killer gene complex (NKC) [58,59]. Ly49 and CD94/NKG2 
receptors are expressed in a stochastic and independent fashion, which results in NK cell 
subsets expressing distinct combinations of these receptors. NK cell function is, in part, based 
on the interaction of their inhibitory receptors with Major Histocompatibility Complex class I 
(MHC I) molecules, expressed on the target cell surface in a complex with 2-microglobulin 
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2m) [60]. Often, activating NK cell receptors recognize inducible molecules on the target 
cell, which can be induced upon cellular stress such as hypoxia or infection [61]. 
Upon activation NK cells produce a variety of cytokines, e.g. perforin, TNF-, TNF-, IL10 
and most dominantly IFN-
 and sometimes even vascular growth factors [62]. By their IFN-

production, NK cells are an early source important in T-helper 1(Th1) polarization [63] which 
is associated with profound vascular remodeling, unlike Th2 that leads to less profound 
vascular remodeling [64].  
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 < Involved leukocyte subsets in outward remodeling of collateral arteries. Cytotoxic CD8+ T cells 
invade the vessel wall early and secrete IL-16, which in turn attracts CD4+ T helper lymphocytes. These CD4+ 
T helper lymphocytes secrete a variety of pro-arteriogenic cytokines IL-12, IFN
 and the chemoattractant MCP-
1. The latter induces of perivascular monocyte recruitment. Monocytes adhere to activated endothelium, which 
expresses increased levels of ICAM-1 and VCAM-1 molecules. Next, monocytes invade in the vessel wall, 
excrete growth factors such as Fibroblast Growth Factor (FGF) and cytokines such as TNF. Furthermore, 
monocytes can differentiate towards macrophages. NK cells are also attracted by MCP-1, and probably via NK 
ligands that are produced upon endothelial cell stress. In the vessel wall NK cells are supposed to act as cytokine 
factories by secreting an array of pro-arteriogenic cytokines; IFN
, TNF and the cytolytic perforin. 
Furthermore, they might have relevant interactions with dendritic cells. Recent experiments did not demonstrate 
involvement of type I NK-T cells in arteriogenesis. Regulating T lymphocytes inhibit the pro-arteriogenic action 
of CD4+ T helper lymphocytes and of the angiogenic CD3+, CD31+, CXCR4+ T lymphocytes. The latter are 
attracted by hypoxia derived factors such as SDF-1 and have the ability to secrete VEGF, IL8 and MMP-9. The 
subtle balance of this inflammatory cascade should optimally lead to enlargement of the collateral diameter. 
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The Th1 response leads to rapid arteriogenesis in C57BL/6 mice, whereas BALB/c mice 
respond poorly due to a Th2 response. Introduction of C57BL/6 genes into BALB/c mice by 
the creation of a C57BL/6 x BALB/c F1 led to significant improved arteriogenesis when 
compared to the parent BALB/c strain [41]. This indicates that BALB/c mice are lacking a 
crucial factor for proper arteriogenesis.  
The genetic differences between C57BL/6 and BALB/c mice also include a relevant 
difference in the content of the above-mentioned Natural Killer gene complex (NKC), as 
BALB/c mice lack a 200 kb region. This region codes for members of the Ly49 receptor 
family of which the C57BL/6 NKC region possesses 12 Ly49 genes, whereas the BALB/c 
strain only has 7 Ly49 genes. Importantly, BALB/c mice lack the NK receptor Ly49H [65] 
which is crucially involved in murine cytomegalovirus (mCMV) resistance, and is therefore 
specifically targeted against the viral mCMV glycoprotein m157 [66]. There are strong 
indications that the key NK cell receptor for arteriogenesis lies within this gene locus, which 
is normally lacking in BALB/c.  
Current research now focuses on the identification of this key NK cell receptor in 
arteriogenesis. This will also give insight in possible therapeutic ligands to specifically 
stimulate NK cells for therapeutic arteriogenesis. Next, more insight in NK cell dynamics 
during arteriogenesis is required, including insight in local effector function. The local 
effector function could include perivascular cytolysis to create space for outward remodeling, 
but also cytokine production for modulating the local inflammatory response.  
Summary 
The role of leukocytes in arteriogenesis is evident, but highly complex. To design new 
arteriogenic treatment strategies using leukocytes, it is necessary to refine our knowledge on 
which subsets of leukocytes are involved in collateral formation and how. Ex-vivo activation 
(or inhibition) of specific inflammatory cell subpoplutions may prove beneficial for 
stimulation of arteriogenesis by cell therapy in the future. A major challenge for the 
development of these therapies remains that pro-arteriogenic leukocytes and growth factors 
may contribute to adverse effects such as plaque progression and neointima formation 
[67,68]. 
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 The use of targeted drug delivery is a promising approach to improve arteriogenesis using both old 
and novel compounds. Various vehicles to deliver and release drugs have been developed to avoid systemic side 
effects and to improve efficacy of drugs with a short in-vivo half life.  The smallest drug delivery vehicles are 
nanoparticles which can either encapsulate a drug or present a drug at extending polymer tips. However, 
nanoparticles need a targeting modality, as they would otherwise diffuse unselectively into the tissue. Their use 
has therefore mainly been limited to intramuscular injections. Larger vehicles, such as microbubbles (1-8 µm) 
can be administered intravenously, as they are small enough to transverse through the capillary system. 
Subsequently, the drugs are released locally via targeted ultrasound mediated microbubble destruction, which in 
addition increases endothelial permeability, thereby enhancing drug uptake. Microspheres on the other hand 
(>10 µm) cannot traverse through the capillary system and therefore have to be injected intra-arterially after 
which they become lodged in the capillaries where they are degraded and subsequently release their content. All 
these vehicles, or combinations of, have been used in arteriogenic research and have shown promising results in 
both in vitro and in vivo research. Microbubbles and microspheres are currently the most advanced approach in 
this field. However, further research is needed in order to make targeted drug delivery in the clinical setting a 
reality.  
Introduction 
Targeted drug delivery aims to selectively transport or release drugs to the target tissue, 
thereby improving efficacy and reducing systemic side effects. Various strategies have been 
developed over the years, including the use of targeting molecules for ligands expressed on 
the endothelium, ultrasound to destroy drug bearing microbubbles at sites of interest and the 
implantation of devices which gradually release drugs over time. Despite the limited number 
of studies on targeted drug delivery in collateral artery growth (arteriogenesis), results so far 
are promising and indicate its enormous potential in the coming decades. In addition to the 
delivery of novel factors, targeted drug delivery might enable the use of therapeutic targets 
that were previously regarded obsolete because of their systemic side effects or short half life.  
Examples of the latter are pro-arteriogenic chemokines and cytokines. If given systemically, 
effective local concentrations would inevitably be accompanied by systemic levels, possibly 
inducing side effects due to their manifold involvement in physiological and pathological 
processes. In addition, the biological effects of many cytokines are based on the creation of a 
chemotactic gradient, which cannot properly form when given systemically. Targeted drug 
delivery can be used to selectively increase local concentrations and might therefore open up 
new avenues of treatment. Drug delivery vehicles will possibly also allow using different 
forms of RNA (mRNA, siRNA, miRNA) as drugs, which are otherwise rapidly degraded 
when circulating freely in the blood.  
In this chapter we will discuss the current stand of knowledge and recent research on targeted 
drug delivery to enhance arteriogenesis, particularly focusing on the use of nanoparticles, 
microbubbles and drug eluting stents.  
Nanoparticles 
Nanoparticles are particles smaller than 1 µm and can be used to achieve sustained release of 
factors with a short half life in vivo such as cytokines or chemokines. Nanoparticles have been 
made in various sizes and from various materials. They can be tailored to encapsulate drugs, 
to incorporate it into the nanoparticle structure or to ‘present’ the drug at the tips of extending 
polymer chains. Although nanoparticles themselves can be designed to meet many needs, 
their possibilities are limited when used for cytokine or growth factor delivery, as proteins 
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often cannot endure certain steps of the fabrication process involving high temperatures, 
extreme pH values or pressures. Nanoparticles have been used in many areas of research to 
deliver active factors and to prolong their presence at sites of interest [1-5] or for imaging the 
presence and expression of specific molecules [6-8]. Here, we will focus on nanoparticle 
delivery in angiogenesis and arteriogenesis.  
Nanoparticles in arteriogenesis 
To achieve accumulation of nanoparticles at sites of interest, the nanoparticles need to be 
targeted against locally expressed molecules using specific ligands, as they would otherwise 
remain in the circulation until they are excreted or diffused into the tissue due to their small 
size. Xie et al developed a ligand for the v3-integrin which displayed highly specific binding 
properties in contrast to non-targeted control particles in vitro [3]. When added to cells, 
nanoparticles conjugated to this ligand accumulated in the cytoplasm within minutes 
suggesting receptor mediated endocytosis of these compounds. Moreover, these targeted 
nanoparticles were also tested in vivo by injecting them intravenously in tumor-bearing mice 
to determine the ability to selectively target angiogenic vessels. Lectin stainings proved 
incorporation of the particles into angiogenic vessels two hours after injection. However, 
nanoparticles also accumulated in other tissues such as liver, spleen and lung capillaries 
which could result in unwanted side effects, especially when the nanoparticles are loaded with 
drugs. 
Nanoparticles can also facilitate the sustained delivery of plasmid DNA to tissue following 
intramuscular injection, as shown in a murine ischemic hind limb [9]. When loaded with 
VEGF encoding plasmids, VEGF expression after 12 days was significantly higher when 
compared to control or naked VEGF plasmid treatment. Biological activity was confirmed by 
a significant increase in BrdU positive capillaries 4 weeks after induction of ischemia. 
The ability of nanoparticles to locally deliver statins was assessed using nanoparticles in 
which either FITC or pitavastatin was entrapped in the polymer matrix. In the mouse hind 
limb ischemia model, FITC-labeled nanoparticles were injected intramuscularly directly after 
ligation. Strong fluorescent signals were localized predominantly in capillaries and arterioles 
with minor signal in myocytes 7 days after ligation. Fourteen days after injection, 
nanoparticles mainly accumulated in capillaries and arterioles and were not observed in 
myocytes anymore. No nanoparticles were detected at any time point in the non ischemic 
contra lateral hind limb or other organs such as heart, liver, spleen or kidney. Injection with 
pitavastatin nanoparticles resulted in increased blood flow and increased density of CD31+
cells (angiogenesis) and SMA+ vessels (arteriogenesis) 14 days after ligation [10]. The same 
pitavastatin releasing nanoparticles have been further tested in a rabbit hind limb model. 
Preliminary results indicate that pitavastatin bearing nanoparticles increase angiographically 
visible collaterals and prevent exercise induced ischemia [11]. 
Despite these encouraging results, nanoparticles have certain important disadvantages. Their 
loading capacity is smaller than that of microbubbles or microparticles. Hence, the 
nanoparticle doses need to be increased accordingly to ensure efficient drug delivery. Most 
importantly, recent studies have raised safety concerns regarding nanoparticle use as they may 
impair cellular function [12], increase production of reactive oxygen species [13] and 
potentially have carcinogenic effects [14-16]. 
Microbubbles 
Microbubbles are fast and reliable carriers for targeted drug delivery. Their properties can be 
easily adapted to accommodate specific needs regarding release or targeting.  
Microbubble construction and types of microbubbles  
Microbubbles are small (1-8 µm) gas filled vesicles which can be made from proteins, lipids 
or biocompatible polymers (biopolymers). The latter two have mainly been used for drug 
delivery, as their properties can be easily modified to adjust e.g. degradation kinetics, 
microbubble size, or to incorporate targeting modalities on the outside of the microbubble. 
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Lipid and biopolymer microbubbles behave differently when ultrasound is applied (Fig. <).
Lipid based microbubbles oscillate during application of ultrasound with a very low to low 
acoustic power, resulting in ultrasound scattering ideal for imaging. When ultrasound with a 
higher acoustic power is applied, the microbubble undergoes forced expansion and 
compression leading to microbubble destruction and release of the gas core. Biopolymer 
based microbubbles are stiffer and are therefore hardly deformed when subjected to 
ultrasound. When the acoustic power exceeds a certain threshold, cracks appear through 
which the incorporated gas can escape. A further increase in the applied acoustic power leads 
to complete microbubble disintegration. The choice whether to use lipid or biopolymer based 
microbubbles therefore highly depends on the actual requirements and needs. As lipid based 
microbubbles are able to oscillate at low intensity, they are ideal for imaging and their lipid 
bi-layer enables them to fuse with target cells to release their content intracellularly. 
Biopolymer based particles are more robust and, contrary to lipid based microbubbles, their 
content is often released immediately when subjected to high acoustic powers. This decreases 
the risk of undesired drug release before high intensity ultrasound is applied to release all the 
encapsulated drugs in one single burst [17]. 

< Schematic representation of ultrasound mediated microbubble destruction. Lipid microbubbles only 
oscillate when low intensity ultrasound is applied and implode when higher intensity ultrasound is applied. 
Polymer based microbubbles do not oscillate under low intensity ultrasound but cracks do appear in the 
microbubble shell through which the content can escape. High intensity ultrasound leads to complete 
microbubble destruction when a certain threshold is reached. Adapted from Hernot and Klibanov, Advanced 
Drug Delivery Reviews, 2008 [17]. 
One of the biggest advantages of microbubbles is their ability to traverse through the capillary 
system of the lungs and to reach the whole body when injected intravenously. Using low 
intensity ultrasound the microbubbles can be followed before destruction and content release. 
During destruction of the microbubbles the endothelium is often perforated by the small ‘jets’ 
which are produced during microbubble destruction. In combination with the increased 
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endothelial leakage due to the ultrasound application, local drug uptake might be further 
enhanced [18,19]. 
Microbubble treatment in combination with ultrasound 
The use of ultrasound and ‘non loaded’ microbubbles by itself might induce an arteriogenic 
response as this might lead to increased activation of the endothelium and subsequent 
leukocyte extravasation resulting in increased arteriogenesis. As previously shown, ultrasound 
treatment of rat skeletal muscle after injection of microbubbles results in an increase in the 
number of arterioles and an increase in blood flow when compared to sham treated muscle 
[20]. After arterial occlusion, treatment with ultrasound and microbubbles increased blood 
flow significantly at various time points and resulted in a restoration of blood flow during 
reactive hyperemia to normal levels within 7 days. Furthermore, the number of arterioles as 
assessed by smooth muscle actin staining per muscle fiber was significantly upregulated 14 
and 28 days after intervention [21]. This effect might be due to the enhanced extravasation of 
VEGF producing inflammatory cells. Immunohistochemical analysis of muscles treated with 
ultrasound and microbubbles after arterial occlusion revealed a greater leukocyte (CD45+) cell 
count 3 and 7 days after intervention. These cells included F4/80+ (macrophages) and CD3+
(T-lymphocytes) cells which were both positive for VEGF staining [22]. 
Microbubble treatment in combination with ultra sound and systemic administration of 
arteriogenic factors 
As described above, the use of microbubbles results in an increased permeability of the 
endothelium and vascular leakage which might be used to enhance the diffusion and/or uptake 
of arteriogenic factors by the tissue. Mukherjee et al. showed that this was feasible in a rat 
model where VEGF was infused intravenously and ultrasound was subsequently applied to 
the chest [23]. The result was an increased uptake of recombinant VEGF by the endothelium 
(8-fold), which was further enhanced to a 13-fold increase when combined with a contrast 
agent. In addition, microbubbles in combination with ultrasound can also be used to enhance 
the local uptake of plasmids encoding arteriogenic factors [24]. The expression of transgenes 
was highly increased for four days after treatment before declining rapidly. Repetition of the 
procedure resulted in a second peak which displayed similar decay effects, thereby providing 
a reliable method to regulate transgene expression. Microbubbles in combination with 
ultrasound can also be used to improve cytokine and growth factor delivery [25]. G-CSF 
injection at six days after ligation of the femoral artery resulted in enhanced vascularization 
28 days after ligation, while combined treatment with microbubbles and ultrasound further 
improved vascularization. However, as enhanced uptake of G-CSF by the ultrasound treated 
tissue was not shown, it remains to be elucidated whether the observed increase is due to two 
different processes or a synergy of G-CSF administration and ultrasound treatment.  
Microbubble induced endothelial perforation can also be used to enhance the extravasation of 
nanoparticles. In an ex vivo study the effect of different injection sites and ultrasound 
variables on microbubble mediated extravasation of nanoparticles to muscle was assessed 
[26]. The extravasation points created by the microbubbles and the subsequent extravasation 
of nanoparticles through these openings were imaged. A significant difference in 
extravasation was not observed when different injection sites (venous vs. arterial) were used, 
however shortening the injection time from 40 s to 10 s did increase the amount of delivered 
nanoparticles significantly. Furthermore, it was observed that an ultrasound pulse interval of 
5-10 s used for microbubble destruction yielded the highest overall extravasation of 
nanoparticles. This strategy was also tested in a hind limb ischemia model where a 
combination of FGF2-bearing nanoparticles, microbubbles and ultrasound resulted in an 
increase in both the number and overall luminal expansion of arterioles [27]. The delivery of 
nanoparticles to the heart was assessed after intravenous administration of nanoparticles [28]. 
Microbubbles in combination with ultrasound treatment highly enhanced nanoparticle 
delivery to the heart, which increased with rising ultrasound peak pressures. However, higher 
peak pressures also increase the risk and amount of epicardial hemorrhage. It remains 
therefore imperative to continuously balance the benefits of nanoparticle delivery and the 
detrimental effects of ultrasound treatment.  
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Arteriogenic factors can also be incorporated in the microbubble itself and subsequently 
released when the microbubble is destroyed using ultrasound. Treatment of severe chronic 
hind limb ischemia in rats with microbubbles bearing VEGF resulted in a significant increase 
in vessel density and tissue perfusion 14 days after delivery of microbubbles when compared 
to non-treated rats [29]. Microscopic analyses after injection of GFP encoding plasmid 
bearing microbubbles showed efficient transfection of arterioles, capillaries and muscle fibers 
adjacent to capillaries. After 14 days, the GFP signal was mainly located in the endothelium 
of small to medium sized arterioles. In contrast to the aforementioned studies, the authors did 
not find a beneficial effect of treatment with ultrasound in combination with microbubbles 
bearing GFP plasmid only. This might be due to differences in the acoustic power applied, 
dosage/composition of microbubbles or conditions under which perfusion restoration was 
assessed (resting conditions vs. vasodilatation). 
Recently, Chappell and colleagues aimed to elucidate the mechanism underlying the pro-
arteriogenic effect of microbubble and ultrasound treatment alone [30]. Rats and mice were 
subjected to bilateral ligation of the femoral artery. Subsequently, microbubbles were injected 
intravenously and one of the hind limbs was treated with ultrasound. Both, rat and wild-type 
mice hind limbs displayed enhanced perfusion restoration compared to contralateral controls 
up to 28 days after surgery. Ultrasound application furthermore led to increased CD18 
mediated recruitment of CD11b+ mononuclear cells as no effects of ultrasound were observed 
in chimeric mice carrying CD18 -/- bone marrow. These findings are consistent with earlier 
experiments in ICAM-1 -/- and Mac-1 -/- mice [31] and suggest an enhancement of leukocyte 
adhesion and extravasation as the primary mechanism of microbubble-induced stimulation of 
arteriogenesis. 
Microbubble treatment in combination with ultra sound and systemic administration of cells 
In light of the results mentioned above, ultrasound in combination with microbubbles could 
also be used to enhance the efficacy of cell transplantation. Usually, intramuscular injection is 
superior to intravenous delivery with regards to cell number reaching and remaining at the site 
of interest. However, combination of intravenous cell injections with microbubbles and 
ultrasound can result in arteriogenic effects equal to intra muscular injection of cells [32]. In 
vitro experiments indicate that this enhanced cell homing might be due to increased activation 
of the endothelium as a result of treatment with ultrasound and microbubbles. This effect 
seems to be mediated by platelets, as their depletion from the culture medium completely 
abolished endothelial activation after ultrasound stimulation as measured by P-selectin and 
ICAM-1 expression. Treatment with ultrasound and microbubbles might also exert additive 
beneficial effects on intramuscular injection of cells, as this resulted in an increase in blood 
flow and capillary density when compared to intramuscular injection of cells alone [33]. The 
use of ultrasound in combination with microbubbles to augment intravenous cell delivery was 
also tested in a hamster cardiomyopathy model. Either treatment alone did not significantly 
improve outcome. However, combination of both treatments resulted in a significant 
improvement in tissue perfusion and cardiac function [34].
Instead of administrating purified cell fractions, another option could be the injection of “cell 
beads” consisting of a tissue or cellular core encapsulated by a porous membrane, which 
allows the diffusion of soluble factors but prevents immune reactions leading to the rejection 
of the transplanted tissue by the host. First studies using such an approach have shown 
promising results both in vitro and in vivo indicating that this ‘of the shelf’ product can be 
used to achieve sustained long term delivery of therapeutic factors without the risk of an 
immune response [35]. 
Imaging using microbubbles in combination with ultrasound 
Recent advances in targeted imaging may offer new ways to improve the efficacy of targeted 
delivery. In vitro adhesion of microbubbles targeted to ICAM-1 on the endothelium increases 
with increasing levels of inflammation indicating the possibility of targeting endothelial 
inflammation using targeted microbubbles [36]. In vivo, -integrin targeted and contrast filled 
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microbubbles have been used to image endothelial integrin expression in rat hind limbs after 
femoral artery ligation. Adductor muscle integrin signal peaked after 4 days and signal 
intensity was higher in FGF2 treated rats which also showed increased perfusion recovery 
[37]. Activated neutrophils and VCAM-1 and -integrin expression after femoral artery 
ligation have been investigated using targeted microbubbles in mice. An increase in signal 
intensity was observed which corresponded to the increase observed using 
immunohistochemical staining for these markers [38]. 
These examples of targeted microbubbles also create new possibilities for targeted drug 
delivery in general, as drugs can not only be directed to specific areas, but even to certain cell 
types expressing the respective target molecule. The expression of integrins on the activated 
endothelium during angiogenesis has been imaged non-invasively for example in both 
myocardial infarction and hind limb ischemia models [39-41]. Integrins and other molecules 
expressed on the endothelium of the developing collateral, such as ICAM-1, P-selectin and 
other activation markers, are therefore likely to form suitable and promising targets for 
targeted drug delivery in arteriogenesis [42].  
Microspheres (diameter > 10 µm) 
In addition to incorporating targeting molecules or the application of ultrasound to locally 
release arteriogenic factors using microbubbles, microspheres can be used to deliver 
arteriogenic compounds. Due to their larger diameter (> 10 µm) microspheres are “lodged” in 
the microcirculation where they are degraded and subsequently release their content. As the 
capillaries are blocked by the microspheres, their dosage is an important issue to be taken into 
account. While lower numbers do not lead to significant changes in oxygen supply, high 
microsphere numbers can lead to embolism and tissue necrosis, therapeutically used in 
oncological studies [43].  
In an ischemic hind limb model in rabbits, gelatin hydrogel microspheres were injected into 
the internal iliac artery bearing bFGF 21 days after ligation [44]. Detection of the 
radioactively labeled microspheres revealed that microspheres <10 µm were distributed 
throughout the body, while microspheres > 29 µm were mainly detected in the ischemic hind 
limb (~77%). Collateral flow, angiographic score and -SMA+ vessel density were 
significantly improved 28 days after injection when compared to PBS injection or 
intramuscular injection of bFGF bearing microspheres. Larger (59 µm) bFGF bearing 
hydrogel microspheres were also used to evaluate their efficacy in treating ischemia in 
ischemic skin flaps. Delivery of bFGF using microspheres improved neovascularization and 
reduced necrosis when compared to bolus injection of bFGF, indicating that sustained 
delivery using microspheres could enhance viability of the skin flap [45]. In a recent study it 
was shown that the sustained release of erythropoietin using an intramuscular injection of 
erythropoietin loaded microspheres improves blood flow eight weeks after surgery. 
Remarkably, the treated animals did not have enhanced blood flow until four weeks after 
treatment when compared to PBS treated animals [46]. 
Recently, G-CSF has been shown to stimulate arteriogenesis when incorporated into gelatin 
hydrogel microspheres, resulting in a higher perfusion recovery and an increased number of 
arterioles when compared to controls [47]. 
Drug eluting stents 
Since the development of intracoronary stents, it has been hypothesized that they could also 
be used as drug delivery platforms [48]. Research exploring the possibility to do so has 
mainly focused on drug eluting stents which could decrease or even prevent restenosis and the 
resulting pathology and morbidity amongst cardiovascular patients. In general, drug eluting 
stents are composed of a metal stent coated with biocompatible polymers which are degraded 
over time, thereby releasing the drug which is incorporated inside the polymer. More recently, 
whole stents have been made of degradable polymers leading to complete disintegration of 
the stents within a few months. Several studies have shown the decrease in restenosis rate 
after implantation of drug eluting stents [49-51], however the safety and overall benefit of 
drug eluting stents remain a point of discussion [52,53].
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Stents are usually not regarded as a delivery platform for the improvement of collateral vessel 
growth. In addition, several studies have shown that the collateral circulation might even be at 
risk after coronary stenting, as collateral vessel development is dependent on the altered blood 
flow due to a stenosis. One of the first studies to describe such a detrimental effect reported a 
more then 50% decrease in collateral flow index directly after stent placement [54]. 
Placement of drug eluting stents in patients with chronic total occlusion results in 
improvement of stenosis severity but also induces a rapid reduction of collateral flow putting 
the patients at higher risk for future ischemic events [55]. While collateral flow indices were 
diminished in >90% of patients receiving a drug eluting stent, only 55% of patients receiving 
a bare metal stent displayed insufficient collateral development [56]. Finally, drug eluting 
stents have also been used to deliver pro-arteriogenic compounds to the developing collateral 
circulation. After femoral artery ligation in rabbits, TGF-1 eluting, bare metal or polymer 
coated stents were deployed in the external iliac artery. TGF-1 release from the stents led to 
an increased collateral conductance when compared to rabbits treated with a control stent or a 
single TGF-1 bolus. This was supported by higher vascular proliferation rates. This study 
indicates that stents might serve as intra-arterial delivery platforms for cytokines [57]. 
Loading capacity and the targeted delivery of drugs directly to the intima might be enhanced 
using a novel stent design, which consists of honeycombed strut elements filled with stacked 
layers of drugs and polymers (Fig. =). This unique construction enables controlled and 
sustained release of drugs in various situations which require different pharmacokinetics and 
enable the targeted delivery of both vessel wall and vessel lumen with different drugs (Fig. 
=,) [58]. When tested in clinical trials, it was found that such a device was not only safe but 
that its prolonged release kinetics (30 days) resulted in a lower in-stent late loss, less volume 
obstruction and a reduced number of major adverse cardiac events when compared to a 
shorter release time span (10 days) or bare metal stents [59]. 

= A stent with honeycombed strut elements has the same overall design as a normal stent. However, the 
surface of the stent has small indentations which are filled with drugs which are released over time (A). As the 
small indentations are placed on both sides of the stent, the vessel wall and vessel lumen can be targeted with 
different drugs (B).  
Conclusion 
The use of targeted drug delivery in arteriogenesis is a relatively new but fast developing field 
of research. The research described in this chapter shows that targeted drug delivery is a 
promising tool to circumvent many of the problems often related with the therapeutic 
application of arteriogenic factors, such as a short half life of the drugs or severe systemic 
side effects when used in high concentrations.  
Two avenues of targeted drug delivery seem most promising: the use of microbubbles in 
combination with ultrasound and the lodging of larger sized microspheres in the 
microvasculature. The former has been the focus of many studies and results indicate high 
efficacy with almost no side effects, although concerns remain about the extensive use of 
ultrasound needed to destroy the microbubbles. However, a big advantage of microbubbles is 
that they can be administered intravenously as they are able to traverse the lungs because of 
their small size.  
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The use of microspheres does not involve a secondary technique such as ultrasound to release 
the encapsulated drugs and therefore does not have the risk of damaging tissue. However, 
microspheres have to be administered intra-arterially and locally as they are too large to travel 
through the pulmonary microcirculation and their efficacy is based on local lodging in the 
capillaries.  
Although many important issues yet need to be solved, the results obtained so far clearly 
illustrate the high potential of targeted drug delivery for therapeutic stimulation of 
arteriogenesis. 
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$  In patients with coronary artery disease, collateral arteries reroute the blood flow around coronary 
stenoses to the myocardial area at risk and preserve myocardial tissue perfusion. Several diagnostic modalities 
have been introduced over the years to quantify the capacity of the coronary collateral circulation. Although 
there is some controversy, many studies have demonstrated the association between sufficient collateral arteries 
and improved clinical outcome. Therefore, the therapeutic stimulation of collateral artery growth seems an 
appealing concept to improve clinical outcome of patients with coronary artery disease. This chapter discusses 
various modalities to quantify the capacity of the coronary collateral circulation. The relevance of collateral 
arteries in patient with coronary artery disease is discussed in more detail, and therapeutic options for the 
stimulation of collateral artery growth are reviewed. Finally, future perspectives are outlined.  
Introduction 
In the 1950s, Fulton demonstrated unequivocally the presence of small arteriolar vessels 
connecting different vascular territories of the normal human heart, using high resolution 
post-mortem angiography [1,2]. His findings definitively ended the long lasting dispute over 
the existence of arteriolar connections in the normal human heart. Fulton’s study was an 
extrapolation of previous studies by Baroldi et al., demonstrating expanding interconnections 
between coronary arteriolar networks upon coronary occlusions, using cast-corrosion models 
[3]. These observations formed the basis for the concept of arteriogenesis, the remodeling of 
pre-existing arteriolar connections into large collateral arteries upon arterial stenosis. 
Collateral arteries divert blood flow around the arterial stenosis, thereby partially or 
completely preventing ischemic damage. Depending on the location of the stenosis, collateral 
arteries may alleviate symptoms e.g. angina pectoris in coronary artery disease (CAD) and 
ischemic leg pain in peripheral artery disease (PAD). Although the clinical relevance of the 
human coronary collateral circulation in patients with CAD has been well recognized, it has 
also been a matter of debate. Whether the coronary collateral circulation is associated with 
improved outcome in patients with CAD is substantially influenced by the patient population, 
the modality to measure the capacity of the collateral circulation and the definition of 
endpoints. The focus of this chapter is to discuss diagnostic modalities to quantify the 
capacity of the coronary collateral circulation, the clinical relevance of arteriogenesis in 
patients with CAD, and to summarize current knowledge on the therapeutic modification of 
collateral artery growth.   

Assessment of the coronary collateral circulation 
When one of the coronary arteries becomes gradually obstructed, arteriolar connections 
between the donor artery (also called, the contralateral vessel) and the recipient artery (also 
called the ipsilateral vessel) expand and are transformed into large collateral vessels that 
divert the blood flow to the jeopardized vascular territory. Several methods have been 
developed to quantify collateral flow (Table 1), which all are based on the two assumptions 
that (1) blood flow distal to an arterial stenosis is the sum of the blood flow derived from the 
recipient coronary artery and collateral flow, and (2) that the blood flow distal to a total 
occluded coronary artery is completely dependent on collateral flow. 
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In the cardiac catheterization laboratory, angiography is the most widely used technique to 
assess the capacity of the collateral circulation in patients. In a landmark study, Rentrop et al. 
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showed that visualization of the collateral vessels depends on the existence of a pressure 
gradient between the different vascular territories [4]. In some of the CAD patients, collateral 
arteries are spontaneously visible on angiography. However, these so called “spontaneously 
visible” collateral arteries represent only a small fraction of the total collateral circulation. 
After creating a maximal pressure gradient by balloon coronary occlusion of the recipient 
artery, the so called “recruitable” collateral arteries become apparent by simultaneously 
injection of contrast in the donor artery, using a second arterial catheter. Using this approach, 
collateral flow can be graded according to the Rentrop classification: 0 = no filling; 1 = small 
side branches filled by collateral vessels; 2 = partial epicardial filling of the recipient artery by 
collateral vessels; 3 = complete epicardial filling of the recipient artery by collateral vessels 
[4]. In the absence of a total coronary occlusion, accurate grading of collateral flow thus 
requires a second arterial catheter for contrast injection into the donor artery during balloon 
coronary occlusion of the recipient artery. In clinical practice, a great advantage of the 
Rentrop classification is its wide availability. However, its accuracy is limited to 
documentation of spontaneous visible collateral vessels with a diameter >100µm [5,6]. 
Therefore, the Rentrop classification is a rather crude method to assess the total capacity of 
the collateral circulating. Another angiographic method to quantify the collateral flow is 
contrast washout collaterometry. Contrast washout collaterometry is based on the inverse 
relation between collateral flow and the time to contrast clearance injected distally into the 
balloon occluded recipient artery. Whereas an angiographic Rentrop score of 2 obtained 
during balloon coronary occlusion detects sufficient collaterals with 71% sensitivity and 68% 
specificity, a washout time of 11 heart beats accurately determines sufficient and insufficient 
collaterals with 88% sensitivity and 81% specificity [7]. 
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As compared to angiography, intracoronary blood flow and pressure measurements using 
guidewires equipped with Doppler crystal and/or pressure sensors enable more accurate 
quantification of the collateral flow. These wires facilitate assessment of collateral 
hemodynamics directly in the epicardial segments of the coronary arteries. The collateral flow 
can be qualitatively assessed with a Doppler-wire as an antegrade, retrograde or bidirectional 
flow velocity signal, depending upon the position of the tip of the guidewire in relation to the 
collateral flow direction [8-10]. In general, two methods are used to analyze the hemodynamic 
data obtained with these wires. The flow velocity-derived collateral flow index (CFIv) is the 
ratio between the coronary blood flow velocity (CFV) during intracoronary balloon occlusion 
of the recipient artery, and the CFV at the same location during vessel patency, following 
successful percutaneous coronary intervention (PCI) (CFIv = CFVocc / CFVpat) [10]. In a 
similar way, the pressure-derived collateral flow index (CFIp) is determined by simultaneous 
measurement of the mean aortic pressure (Pao), the mean central venous pressure (Pv) and the 
mean distal coronary pressure during balloon occlusion of the recipient artery (Pocc), (CFIp = 
(Pocc - Pv)/( Pao - Pv). Compared to angiographic grading, the intracoronary hemodynamic 
measurements have been demonstrated to be a much more reliable method for functional 
quantification of the coronary collateral flow [10]. CFIp and CFIv correlate well with each 
other (CFIv vs. CFIp: r = 0.8), and both methods are the reference methods for the assessment 
of the coronary collateral flow in clinical practice [11]. Importantly, each method is dependent 
on different physical laws. While the CFIv is affected by vessel diameter, tortuosity, 
branching and position of the tip of the guidewire, the CFIp is more influenced by the 
microvascular function [13] and conditions of elevated transmural stress, such as increased 
left ventricular end-diastolic pressure [14,15]. In the clinical setting, CFIp is easier to assess 
and has a better reproducibility, as the signal is not critically dependent upon the position of 
the tip of the wire in the epicardial coronary segment. Recently, direct volumetric 
measurements of coronary flow using thermo-dilution have emerged as another invasive 
method that quantifies the collateral flow. During continuous low-rate infusion of saline at 
room temperature, assessment of the infusion rate of saline, the temperature of the saline at 
the tip of the infusion catheter, and the distal blood temperature allow the quantification of 
coronary flow and resistance, rather than flow velocity [16]. Future studies are warranted to 
determine the feasibility and accuracy of this approach.  
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Angiographic 
Angiographic collateral 
Degree 
Visual  Easy Limited resolution 
Angiography – computer   
assisted    
Visual – computer assisted Easy; time consuming Not routinely performed 
  Angiographic collateral   
  degree  
Rentrop’s grade  Easy; standard method Angiographic assessment for 
recruitable collaterals requires a 
double injection technique; a 
second arterial puncture is 
required for injection into the 
donor artery prior to, and 
during balloon inflation in the 
recipient artery (culprit ) artery 
  Angiographic collateral   
  Degree 
Collateral connections  
Score 
Easy Optimal angiographic views 
required to avoid 
foreshortening 
Angiographic coronary  
Flow 
TIMI frame count 
Fourier spectral analysis 
Cineangiographic 
modelling 
Washout collaterometry 
Washout collaterometry 
does not require a 
second arterial 
puncture, is easy to do 
Dedicated software required for 
Fourier spectral analysis; 
subject to the effects of 
variation in contrast injection 
and alterations in distal 
microvascular resistance 
Physiological 
Intracoronary  
hemodynamics 
Pressure-derived collateral 
flow index 
Validated Expensive; relevant technology 
required as well as appropriate 
training 
Intracoronary    
hemodynamics 
Flow velocity-derived 
collateral flow index 
Validated Expensive; relevant technology 
required as well as appropriate 
training 
Perfusion imaging 
   Contrast  
   echocardiography 
Myocardial perfusion Easy; contrast may be 
administered by intra-
coronary or intravenous 
injection  
Invasive access still required to 
demonstrate a chronic total 
occlusion, or if antegrade flow 
is present, to obstruct flow by 
transient balloon occlusion 
   MRI Coronary blood flow and 
myocardial perfusion 
Accurate assessment of 
myocardial perfusion; 
may also provide 
information on 
myocardial viability 
Limited resolution 
   PET Myocardial perfusion Information on 
perfusion and metabolic 
function 
Expensive; off-line analysis 
   Myocardial scintigraphy  Myocardial perfusion Assessment of 
myocardial perfusion  
No direct assessment of 
collateral blood flow 
MRI, Magnetic resonance imaging; PET, positron emission tomography; TIMI, thrombolysis in myocardial infarction. 

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Several non-invasive strategies have been introduced over the years to assess the capacity of 
the coronary circulation i.e. myocardial contrast echocardiography (MCE), positron emission 
tomography (PET) and myocardial scintigraphy. The major disadvantage of these methods is 
that they require coronary angiography to either detect a complete occluded coronary artery, 
or to perform intracoronary balloon occlusion of the patent culprit coronary artery for 
accurately measuring collateral function (mL/min/g of myocardial tissue). Vogel et al.
investigated the feasibility of MCE with systemic administration of contrast, to assess the 
coronary collateral flow during intracoronary balloon occlusion. A close relationship was 
found between the absolute collateral-derived myocardial blood flow, as measured by MCE, 
and CFIp [15]. PET is an interesting research tool for quantification of the collateral flow; 
however, the technique is not very practical in a clinical setting [17]. Myocardial perfusion 
imaging after 99mTc-Sestamibi radionuclide injection has also been used to quantify collateral 
flow by evaluation of the extent of the perfusion defect during intracoronary balloon 
occlusion of the recipient artery [11]. Both magnetic resonance imaging (MRI) and multi-
slice computed tomography (CT) potentially can be used for assessment of the collateral 
circulation; however, the question remains whether small collateral connections can be 
delineated by these techniques in all myocardial segments.  
The clinical relevance of the coronary collateral circulation 
When a critical stenosis is present in one of the main coronary arteries, the perfusion of the 
area behind the stenosis is largely dependent on collateral flow. In case of insufficient 
collaterals, this myocardial area may be at risk for ischemia or infarction. Although many 
studies have shown that sufficient collateral arteries are associated with improved clinical 
outcome in patients with CAD, other studies have shown contradictory results (reviewed by 
Berry et al. [12]). The reason for these conflicting results is probably related to differences in 
methodology, such as patient population, the modality to measure the capacity of the 
collateral circulation, and the definition of endpoints. 
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It has long been assumed that coronary arteries are end-arteries in the absence of stenosis; 
however, even in entirely normal post-mortem human hearts, the presence of arteriolar 
connections between different vascular territories have been demonstrated [3]. At the cardiac 
catheterization laboratory, collateral flow has been detected during brief balloon coronary 
occlusion in patients with angiographically normal coronary arteries. In 20-25% of these 
patients, the collateral flow was sufficient to prevent electrocardiographic signs of myocardial 
ischemia [18]. Thus even in the absence of CAD, the collateral circulation is capable to 
protect against myocardial ischemia during brief coronary occlusion in some patients.
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In patients with stable CAD, many studies have shown an association between the collateral 
flow and improved clinical outcome. Sufficiently developed collateral arteries that prevent 
signs of myocardial ischemia (angina pectoris and electrocardiographic changes) during brief 
coronary occlusion are present in about one-third of patients with CAD [19]. In a patient 
study encompassing 100 patients with a total coronary occlusion, Werner et al. found an 
association between the collateral flow and the preservation of the regional left ventricular 
myocardial function [13]. Furthermore, it has been shown in CAD patients, that patients with 
a low CFIp (<0.23) have more ischemic events during one-year of follow up, as compared to 
patients with a high CFIp [20]. Moreover, in another large cohort of CAD patients, a clear 
reduction was observed in long-term cardiac mortality in CAD patients with a higher CFIp
(>0.25) [19]. Importantly, collateral arteries are an integrated part of the coronary circulation, 
and therefore, may exert different effects depending on their functionality and on the context. 
Well developed collaterals respond to vasodilators, such as nitroglycerin and adenosine, 
whereas the immature collaterals are less responsive [21]. Seiler et al. evaluated the incidence 
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of “coronary steal”, i.e. the redistribution of blood flow during vasodilation away from the 
area in need. Microvascular vasodilation, e.g. during exercise or pharmacological stimulation, 
may lower the pressure in the donor artery, resulting in a decreased blood flow via the 
collateral arteries to the collateral-dependent recipient artery. Coronary steal occurs in 10 
percent of the patients with a partial coronary stenosis and in one third of the patients with a 
chronic total coronary occlusion [13,22]. In the patients with a partial coronary stenosis, 
Seiler et al. further showed a positive association between the capacity of the collateral flow 
and the occurrence of steal from it. Patients with increased coronary steal during hyperemia 
showed less often signs of ischemia (i.e. angina and electrocardiographic changes) during 
intracoronary balloon occlusion, as compared to patients without coronary steal. The CAD 
patients with a low collateral flow and without coronary steal during hyperemia, seem to be 
more at risk for development of ischemia during hyperemia, as the collateral flow may be just 
capable of preventing ischemia at rest [22]. Taken together, collateral artery growth is 
obviously a protective mechanism against progressive atherosclerotic disease. However, it has 
to be acknowledged that the presence of collateral arteries is not always beneficial. For 
instance, in patients with a well-developed collateral circulation, collateral vessels may divert 
blood flow away from an ischemic area (collateral steal), and therefore, provoke ischemia 
[23]. This may explain the potential pro-ischemic effects of nifedipine in angina pectoris [24]. 
Furthermore, a well developed collateral circulation may adversely affect outcome in the 
setting of PCI, in view with its association with an increased risk for restenosis [25]. 
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In patients with an acute myocardial infarction, the vascular lesion progresses too fast or the 
collateral circulation develops too slowly to compensate for the abrupt obstructed antegrade 
coronary flow. Nevertheless, several studies have demonstrated a beneficial role of collateral 
arteries, which are present in approximately 10-35 percent of the patients presenting with 
acute myocardial infarction [26-28]. Patients with a higher Rentrop’s grade (2-3) have lower 
incidence of post-infarct heart failure, less occurrence of hemodynamic instability, improved 
myocardial tissue perfusion and smaller infarct size, as compared to the patients with a lower 
Rentrop’s grade (1-2). Moreover, mortality is reduced in patients with acute myocardial 
infarction that have well developed collateral arteries (4% vs. 9% at 6 months; P = 0.01). 
Although the presence of collateral arteries at the time of primary PCI is related to better 
outcome, it is important to note that patients with acute myocardial infarction display normal 
patency of epicardial arteries after successful primary PCI. Therefore, after primary PCI the 
growth of collateral arteries does not occur because the trigger for arteriogenesis, a pressure 
deficit between a donor artery and the recipient artery, is not present. In case of failure of 
reperfusion therapy, angiographic studies have shown that collateral vessels that are initially 
absent can become apparent within 10-14 days following sustained coronary occlusion after 
acute myocardial infarction [29,30]. Survival after acute myocardial infarction without 
successful restoration of the epicardial blood flow is related to recruitability of the collateral 
arteries [31]. 
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Most studies, investigating factors important for arteriogenesis, report the severity of stenosis 
as the most important predictor of collateral flow [32,33]. Piek et al. further investigated the 
predictive value of several clinical and angiographic variables for collateral flow in 105 
patients with single vessel CAD. Duration of angina, the severity of stenosis, and proximal 
lesion location were found to be independent factors that were positively associated with the 
collateral flow [32]. With regard to risk factors associated with CAD, it has been suggested 
that hypertension may display positive effects on collateral artery growth [7], while metabolic 
disorders may inhibit this process; however, evidence for this is scarce. In a large patient 
study, no difference was found in CFIp between the non-diabetic patients (n = 437) and the 
diabetic patients (n = 89). On the other hand, total serum cholesterol showed a trend toward 
higher values in the group with a low CFIp (n = 307) as compared to the group with a high 
CFIp (n = 143). However this trend did not reach statistical significance (P = 0.09) [33,34]. 
Remarkably, a large heterogeneity exists in the extent of collateral flow, even amongst 
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patients without CAD, or, with similar severity of CAD [18,32]. The reason for this is unclear 
and is probably related to a certain genetic background or environmental factors. 
Therapeutic augmentation of collateral artery growth 
The beneficial role of collateral vessels in patients with CAD justifies the search for 
therapeutic strategies aimed at augmentation of collateral artery growth. Since collateral 
artery growth is induced by an increase in shear stress, physical exercise would theoretically 
be a stimulator of collateralization. Furthermore, several growth factors as well as other 
cytokines and proteins that influence collateral artery growth have been shown to augment 
collateralization in experimental models (Table 2) [35]. Therefore, most of the factors have 
been tested in clinical trials.  
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There is emerging evidence that physical exercise augments the collateral flow in stable CAD 
patients [36]. Zbinden et al. assessed the collateral flow in the culprit coronary artery and in a 
normal coronary artery in 40 CAD patients undergoing elective PCI. The patients were 
divided in an exercise training group and a sedentary group. After 3 months, a dose-response 
relation was found between the collateral flow augmentation and the exercise capacity gained 
[37]. Recently, external counterpulsation has been investigated in patients with CAD, as a 
non-invasive alternative approach to active physical exercise. External counterpulsation is 
proposed to stimulate collateral artery growth via an increase in shear stress. Interestingly, the 
CFIp significantly increased in the CAD patients treated by external counterpulsation, whereas 
no change was observed in the control group [38].     
%2
After granulocyte-macrophage colony-stimulating factor (GM-CSF) was shown to increase 
the lifespan of monocytes/macrophages at sites of developing collateral arteries in an 
experimental setting, GM-CSF evolved as a potential stimulator of collateral artery growth 
[39]. In 2001, Seiler et al. randomized 21 patients with extensive CAD to treatment with GM-
CSF or placebo. The authors showed an increase in collateral flow in the GM-CSF group as 
compared to the placebo-group [40]. In their most recent study, two patients of the treatment 
group developed an acute coronary syndrome, and the study was prematurely stopped [41]. 
Although GM-CSF treatment may lead to enhanced collateral flow in CAD patients, safety 
issues remained a concern. The effect of GM-CSF administration was also assessed in PAD 
patients; however, no effect of GM-CSF treatment was found on the walking distance or 
exercise capacity [42,43]. Aside from GM-CSF, the role of granulocyte colony-stimulating 
factor (G-CSF), as a stimulator of collateral artery growth has also been investigated. It has 
long been assumed that G-CSF may potentiate collateral artery growth by increasing stem cell 
mobilization from the bone marrow into the peripheral blood. These cells were thought to 
stimulate collateralization by their paracrine effects. However, it has been shown that the 
stimulating effects of G-CSF are probably in part also mediated by the stimulation of 
leukocyte adhesion [52]. Very recently, Meier et al. showed in a randomized patient study 
that a 2-week period with subcutaneous G-CSF treatment increases the CFI in patients with 
chronic stable CAD, as compared to placebo treatment (P < 0.0001), suggesting that G-CSF 
treatment may enhance arteriogenesis in CAD patients [44].   
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The effect of several fibroblast growth factors on collateral artery growth have been tested in 
clinical trials, as this factor not only induces endothelial cell proliferation but also smooth 
muscle cell proliferation and hence, potentially stimulates collateralization. Interestingly, 
Laham et al. implanted FGF-2 loaded pellets in territories that could not be revascularized in 
patients undergoing coronary artery bypass grafting (CABG). After 3 months, the perfusion 
defect decreased in the group receiving the highest dose of FGF-2 [50]. In contrast, the largest 
Arteriogenesis                                                                                                van der Laan et al. 173
controlled clinical trial using FGF-2 in 337 patients with CAD did not show an effect on 
exercise tolerance and myocardial perfusion imaging [49]. In PAD patients, the results of the 
TRAFFIC study showed an increased walking time at 90 days after FGF-2 treatment, 
suggesting a pro-arteriogenic effect [47]. The pro-arteriogenic effects of FGF-4 are less well 
investigated. In patients with stable CAD, a serotype 5 adenovirus encoding for the FGF-4 
gene was administered intra-coronary, to achieve prolonged FGF-4 release into the coronary 
circulation. Initial results showed a promising trend towards an improved myocardial 
perfusion after 8 weeks of follow-up, as measured with single-photon emission computed 
tomography (SPECT) [48]. However, a larger follow-up study was prematurely abrogated, as 
the change in the primary endpoint at interim analysis at 12 weeks would not reach 
significance [53]. 
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Seiler et al. [40] CAD GM-CSF IC and SC Increased CFI 
Zbinden et al.[41] CAD GM-CSF SC Increased CFI; prematurely terminated because 
two patients developed acute coronary 
syndrome 
START [42] PAD GM-CSF SC No difference in maximal walking distance 
after 14 or 90 days 
Subramaniyam et 
al. [43] 
PAD GM-CSF SC Non-significant increase in exercise capacity 
and improvement of endothelial function 
Meier et al. [44] CAD G-CSF SC Increased CFI; reduced electrocardiographic 
signs of ischemia upon balloon coronary 
occlusion 
Grossman et al.
[45] 
PAD DEL-1 plasmid IM No change in exercise capacity at 30, 90 and 
180 days 
Belardinelli et al.
[46]  
CAD Dipyridamole Orally Treatment improved coronary collateralization, 
especially when combined with exercise 
TRAFFIC [47] PAD FGF-2 IA Increase in peak walking time at 90 days; 
double dose no better than single dose 
FIRST [49] CAD FGF-2 IC No significant difference in exercise tolerance 
Laham et al. [50]  CAD FGF-2 Perivascular Non-significant improvement of myocardial 
perfusion with high dose treatment 
Grines et al. [48]  CAD Adenoviral 
FGF-4 
IC Non-significant improvement of myocardial 
perfusion 
VIVA [51] CAD VEGF165 IC and IV High dose treatment improved angina; no 
change in exercise capacity 
CAD, coronary artery disease; CFI, collateral flow index; FGF, fibroblast growth factor; G-CSF; granulocyte colony-
stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IA, intra-arterially; IC, intracoronary; IM, 
intramuscularly; IV, intravenously; PAD, peripheral arterial disease; SC, subcutaneously; VEGF, vascular endothelial growth 
factor. 
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The most widely studied growth factor with regard to vascular growth is VEGF. This factor is 
known to stimulate angiogenesis i.e. capillary growth, by stimulating endothelial 
proliferation. However, some evidence is available for effects also on collateral artery growth. 
Positive results from small patient studies led to the initiation of a larger clinical study. 
However, the VIVA trial, using VEGF165 in 178 patients with CAD, did not show an effect 
on its primary endpoint, walking time [51]. 
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From bedside to bench 
Given the many dissimilarities between the experimental models and patients with CAD as 
discussed below, it has been suggested that the translation of knowledge from bench to 
bedside may not be the ideal approach for the design of new therapies for patients [35]. A 
better understanding of collateral artery growth in patients is necessary for the design of 
successful treatment strategies that are clinical applicable. Because of the large heterogeneity 
in the extent collateral artery growth upon arterial stenosis in patients, pilot studies have now 
focused on the identification of targets that relate to the capacity of the collateral circulation. 
Schirmer et al. dichotomized 50 patients with single vessel CAD according to their CFIp and 
compared the transcriptome of the monocytes between these 2 groups. Interestingly, pathway 
analyses showed that genes related to the interferon-beta pathway, were highly expressed in 
the monocytes from patient with a low CFIp. Moreover, the same research group 
demonstrated the inhibitory effects of interferon-beta on collateral artery growth in a murine 
hindlimb model, and thus, accomplished to validate their findings using a “bedside to bench” 
approach. Collectively, these results provide a novel mechanism involved in the regulation of 
arteriogenesis [54]. In another patient study, coronary collateral blood was samples from 60 
patients with CAD to investigate cytokine levels in the collateral circulation. Interestingly, in 
the coronary collateral samples increased plasma levels were found for basic fibroblast 
growth factor, eotaxin, macrophage migration inflammatory factor, monocyte chemoattractant 
protein-1, and transforming growth factor-beta, while stem cell factor and stem cell growth 
factor-beta were decreased, as compared to coronary artery samples. These findings provide 
important insights into the importance of the several cytokines for collateral artery growth in 
CAD patients [55]. Based on the results from the patient studies, new therapeutic strategies 
have been designed to stimulate collateralization, which are currently under investigation for 
their feasibility. 
Discussion and Conclusions 
The importance of collateral artery growth has been recognized for many years. Well-
developed collateral arteries are associated with reduced morbidity and mortality in patients 
with CAD. Likewise, therapeutic stimulation of collateralization seems an appealing concept 
to improve outcome. It had been estimated that 25-30 percent of the patients with CAD 
cannot be revascularized by PCI or CABG [34]. Hence, the stimulation of collateral artery 
growth, especially in this patient group, may be a valuable therapy. Catheter based 
hemodynamic measurements at the cardiac catheterization laboratory have opened new 
avenues to investigate the dynamic behavior of the coronary collateral circulation in patients 
with CAD. Additionally, these measurements provide an important tool to assess the efficacy 
of therapies, aiming at the improvement of collateral flow.  
Physical exercise would theoretically be the ideal therapeutic option for the stimulation of 
arteriogenesis, since an increase in shear stress is the primary stimulus for remodeling of the 
arterioles. However, evidence in support of this hypothesis is still scarce, which may be 
related to use of inaccurate angiographic methods, insufficient patient numbers, or change in 
coronary stenosis severities [56,57]. Future studies are warranted to further evaluate the 
potential of therapies that increase shear stress. In the last decades, the exploration of 
collateral artery growth in experimental models has resulted in the identification of several 
growth factors involved in this process. However, the results of randomized clinical trials 
testing the effect of these growth factors on collateral artery growth have, in general, been 
disappointing. One should take into consideration several matters that may explain this 
controversy. For instance, the methods used in experimental models to assess collateral flow, 
such as laser-Doppler perfusion imaging, and microsphere perfusion under conditions of 
maximal vasodilation, are not feasible in patients. It is likely that the use of endpoints such as 
walking time or angina pectoris for the assessment of therapy in the patient trials are too crude 
to discriminate a subtle change in collateral flow over time. In addition, the angiographically 
based Rentrop-score does not accurately assess collateral flow, while advanced intra-coronary 
hemodynamic measurements for accurate assessment of collateral flow have been employed 
in only few studies. It should be further noted that many growth factors are also involved in 
the formation of small capillaries. Therefore, these growth factors may not have augmented 
the growth of collateral arteries, but only the development of small capillaries. In patients 
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with CAD, large collateral arteries are likely to be much more effective in the restoration of 
myocardial perfusion than small capillaries [58]. Another problem is treatment strategy. 
While several treatment strategies have been thoroughly investigated in experimental models, 
there are many uncertainties about optimal timing, dosage, delivery strategy and the need for 
multiple growth factors in patients. Finally, there are many genomic and biological 
dissimilarities between mice and man. An experimental model mimicking elderly patients 
with CAD and comorbidity such as diabetes mellitus and dyslipidemia, does not exist. This 
may explain why attempts to translate experimental findings into clinical practice have been 
unsuccessful, so far. Further research should focus on the molecular and cellular mechanisms 
involved in collateral artery growth in man, to develop new strategies to stimulate this 
process. Since large heterogeneity exists in the collateral response amongst patients with 
CAD, comparative studies of patients with either a reduced collateral flow or enhanced 
collateral flow may provide important insights into the background mechanisms involved in 
this process [54]. Integration of this knowledge in the design of future clinical trials may lead 
to the clinical implementation of therapeutic augmentation of collateral artery growth.  
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$ Novel data has provided evidence for new approaches to the treatment of stable coronary artery 
disease. In a recent clinical trial it was demonstrated that the non-invasive promotion of coronary collateral 
artery growth is possible in patients with coronary artery disease. The technique of external counterpulsation 
(ECP), an art of “passive training”, was used to increase physical forces that stimulate arteriogenesis. The 
Arteriogenesis Network 2 Trial (ArtNet 2) provided the first data for direct stimulation of coronary 
arteriogenesis by using invasive intracoronary pressure measurements to evaluate changes of the collateral blood 
flow after the ECP therapy. This chapter presents the main principles and effects of the ECP therapy in patients 
with cardiovascular disease. The data form the ArtNet 2 trial will be discussed in this chapter in detail. 

Introduction to the External Counterpulsation 
The term external counterpulsation refers to a non-invasive device used to achieve a diastolic 
augmentation analogue to that of the intra-aortic balloon counterpulsation. External 
counterpulsation was initially developed to help patients with acute myocardial infarction and 
heart failure as a non-invasive alternative to the intra-aortic balloon (IABP) [1-3]. The first 
experiments and clinical trials with external counterpulsation took place about 40 years ago, 
investigating the acute hemodynamic effects on the left ventricular workload and the coronary 
perfusion [3-5]. However, the first hydraulic device of counterpulsation proved to be less 
effective than the IABP for the treatment of cardiogenic shock [6]. An alternative non-
invasive counterpulsation device based on air-filled cuffs came into use in the late 1970s [7]. 
The currently used counterpulsation systems are based on the latter technique.  
ECP is nowadays indicated in the treatment of the refractory angina pectoris as suggested by 
the guidelines [8]. Other approved indications for use include unstable angina, congestive 
heart failure, acute myocardial infarction and cardiogenic shock [9]. The clinical benefits for 
patients with CAD include diminution of anginal symptoms, reduced uptake of nitroglycerine, 
improvement of the exercise tolerance and quality of life [10]. Three of four patients with 
refractory angina experience an improvement of at least one class in the classification of the 
Canadian Cardiovascular Society of Cardiology (CCS) and 38% of them of at least two 
classes immediately after the therapy. For most of the patients the benefits can be sustained up 
to three years after completion of the therapy [11]. The exercise capacity is also improved in 
the majority of patients [12-14]. Recent studies have demonstrated the safety and 
effectiveness of the method in patients with mild to moderate heart failure. In a clinical trial, 
exercise tolerance and functional class in classification of the New York Heart Association 
(NYHA) were improved after the therapy [15]. A retrospective analysis in patients with 
refractory angina demonstrated a significant reduction of the systolic pressure after a course 
of ECP [16]. The therapy may also be effective in other conditions such as hepatorenal 
syndrome [17], restless leg syndrome [18], erectile dysfunction [19], tinnitus [20] and, as has 
been shown recently, ischemic stroke [21]. 
Technical characteristics of ECP 
The external counterpulsation therapy consists of electrocardiographic-triggered 
compressions of the lower extremities induced in the early diastolic phase followed by 
decompressions at the systolic phase of the cardiac cycle. Three pairs of cuffs, applied on the 
calves, lower and upper thighs, are inflated from distal to proximal during early diastole. The 
compressions result in augmented diastolic pressure and flow as well as in increased venous 
return. The cuffs are then rapidly deflated at the onset of systole leading to reduced vascular 
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resistance. The sequence of inflation and deflation during the therapy leads to increased 
diastolic pressure (diastolic augmentation) and decreased systolic pressure (systolic unloading 
– Fig. <). Increased perfusion of the brain, liver, kidneys and myocardium during the therapy 
was demonstrated by duplexsonography and transesophageal echocardiography [22]. The 
synchronization of the compressions with the cardiac cycle takes place automatically through 
a 3-canal ECG. The inflation-deflation activity is monitored by a finger plethysmography 
displaying respectively the systolic and diastolic amplitudes which are useful for the optimal 
adjustment of the therapy. Whereas the principal operation of ECP is automatic, the operator 
can optimize the hemodynamic effect by modifying the times of inflation and deflation of the 
cuffs. This adjustment is based on the achieved diastolic and systolic curves which are 
depicted continuously on the monitor of the device. From these curves the D/S ratio is 
automatically calculated. Previous trials have showed that an increase of the ratio during the 
treatment period is related to a better effect and outcome of the therapy [23]. Patients with the 
greatest increase of the ratio have the greatest reduction in angina class [24]. However, other 
trials suggest that the therapy is effective independent of an improvement of the ratio [25]. A 
maximal hemodynamic effect is achieved by an index of 1.5 or greater [26].  

 < Finger plethysmography for the calculation of the D/S ratio and adjustment of the therapy. Links, 
before activation of ECP only a systolic wave can be seen. Right, after activation of ECP a second diastolic wave 
is produced. 
D/S ratio= diastolic augmentation amplitude /systolic augmentation amplitude.  
A typical course of ECP includes 35 outpatient treatments administered as 1-hour daily 
sessions over 7 weeks. This standard duration of counterpulsation treatment is based on 
empiric data derived from studies in China and has been proposed as the optimal course based 
on data from the international EECP® Patient Registry [27]. 
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Mechanism of action  
Though the technical principle of external counterpulsation is simple, the physiological 
response, especially the hemodynamic effects, is complex and the mechanism of action seems 
to be multilateral. Four main hypotheses are so far proposed to explain the clinical effects of 
ECP: i.) adaptive proliferation of coronary collateral arteries (arteriogenesis), ii) improvement 
of endothelial function, iii) improvement of left ventricular function and iv) decrease in 
peripheral resistances.  
The first two hypotheses share a biomechanical effect of ECP: the increase of shear stress. 
Michaels and colleagues investigated by intracoronary pressure measurements and 
intracoronary Doppler flow the acute effect of ECP on cardiac function and circulation. They 
showed that during ECP intracoronary peak diastolic pressure was increased by 93% while 
peak systolic pressure was reduced by 15%. The peak diastolic coronary flow velocity was 
increased by 109% suggesting an improvement in coronary blood velocity [29]. In another 
study an increase of the blood flow volume in the brachial artery was demonstrated while the 
diameter of the brachial artery  remained unchanged during counterpulsation [30].  
The fluid shear stress () is proportional to the blood flow (Q), the blood viscosity () and 
inversely related to the radius (R) of a vessel upon the equation  = 4Q/R3. Taking into 
account the latter data, it is suggested that during ECP the shear stress in the vascular system 
is increased. Elevated levels of shear stress are crucial for the maintenance and improvement 
of endothelial function as well as for arteriogenesis [31,32]. The hypothesis of arteriogenesis 
will be discussed later in detail. 
The hypothesis of improvement of the endothelial function is supported by clinical and 
experimental data. It is not only the increased shear stress but also the increased number of 
arterial pulsations per cardiac cycle during the counterpulsation therapy which exerts 
beneficial effects to the endothelium [33]. During the therapy a second pulsation occurs 
during diastole for each heart beat. By performing functional tests for the assessment of the 
peripheral endothelial function such as brachial artery flow-mediated dilation (FMD) or 
reactive hyperemia-peripheral arterial tonometry (RH-PAT) an improvement of the 
endothelium in response to ECP has been shown [34,35]. Circulating levels of important 
mediators of the endothelial function (cGMP and nitric oxide) are also elevated after ECP 
suggesting a positive effect of the therapy on the endothelial function [36,37]. It has also been 
reported that ECP reduces the circulating levels of inflammatory cytokines. Casey and 
colleagues demonstrated a reduction of the levels of the tumor necrosis factor- (TNF-), 
monocyte chemoattractant protein-1 (MCP-1) and vascular adhesion molecule-1 (VSCM-1) 
after ECP. Furthermore, stabilization of the endothelium, an effect similar to exercise training, 
was demonstrated in hyperocholesterolemic pigs [38].  
Other investigators showed reduced arterial stiffness post-ECP indicating peripheral 
vasodilatation and decrease of the peripheral resistances [39]. The increased artery stiffness is 
furthermore associated with reduced coronary blood flow possibly due to increased left 
ventricular workload and reduced coronary artery diastolic filling [40]. Briefly, ECP improves 
the peripheral endothelial function and reduces the peripheral resistances whereas no data 
exists about similar effects on the coronary endothelium.  
The fourth hypothesis, supporting an improved left ventricular function, remains to the date in 
question. On the one hand, it has been shown that the left ventricular end-diastolic volume is 
decreased after the therapy and the left ventricular ejection fraction (LVEF), if abnormal at 
baseline, is increased after ECP [41]. Other investigators demonstrated that a marker of the 
left ventricular filling, the lung/heart ratio was reduced after ECP [42]. The decrease of the 
lung/heart ratio indicates a decrease of the LVEDP and left ventricular end diastolic volume  
[43,44]. A significant reduction of the atrial natriuretic peptide (ANP) and brain natriuretic 
peptide (BNP) is also demonstrated in response to a course of ECP [45]. However, in a 
recently published study no improvement of any index of the left ventricular systolic and 
diastolic function was seen [46].  
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Arteriogenesis as possible mechanism of action 
The hypothesis of arteriogenesis goes back to the 1970s. Jacobey and Rosenzweig examined 
post-mortem angiograms of dogs which were initially submitted to an acute or chronic 
myocardial infarction and consequently treated with counterpulsation therapy. They showed 
enhanced epicardial and sub-endocardial collateralization and reduced infarct size in dogs 
treated with counterpulsation compared to control dogs [47,48]. In a recent study, canines 
with myocardial ischemia were treated with an external counterpulsation model similar to that 
which is currently used in humans. The animals were submitted to occlusion of a coronary 
artery before being randomized in the active ECP group or the control group. After 6 weeks of 
counterpulsation, the perfusion defects in the initial ischemic infarcted areas were attenuated 
in the active group [49]. The improvement of the perfusion only in the ischemic areas 
suggests an angiogenic effect of the method. 
Indirect evidence for the arteriogenic effect of ECP in humans comes from several studies 
having demonstrated improved myocardial perfusion after ECP. Masuda et al. [45] conducted 
a prospective study of 11 patients with at least one coronary stenosis (> 90%) before and after 
treatment with ECP. Myocardial perfusion, assessed by dipyrimadole 13N-ammonia positron 
emission tomography (PET) increased after ECP suggesting an arteriogenic effect of the 
therapy [45]. Improved myocardial perfusion by myocardial scintigraphy and reduction of 
wall abnormalities assessed by stress echocardiography are evidenced by many clinical trials 
[13,14,50-55]. Most of the studies demonstrated that the reduced myocardial ischemia 
correlates with an improvement of the anginal symptoms suggesting recruitment and 
proliferation of collaterals as the most possible mechanism. However, two other studies 
showed no effect of ECP on myocardial perfusion despite a clinical improvement of the 
patients which was attributed by the authors as being a peripheral effect of the therapy 
[12,56]. The growth of collateral arteries distal to a stenosis leads to improvement of the 
regional perfusion at rest which increases further during a stress test when recruitment of 
collaterals occurs under myocardial ischemia. However, an improvement of the coronary 
endothelial function can also be detected in an imaging test as an improvement of myocardial 
blood flow at rest or under physical exercise. It is therefore obvious that both improvement of 
the endothelial function or the collateral growth after ECP could be detected as improved 
myocardial perfusion in the imaging tests of the previous studies. Furthermore, in the majority 
of the trials physical exercise tests (e.g., treadmill SPECT) were used to evaluate the effect of 
EECP on myocardial blood flow. By using these methods a possible contribution of the 
coronary endothelium to the coronary blood flow cannot be excluded. It is known that an 
impaired coronary endothelium may partly contribute to the perfusion defects demonstrated 
by SPECT [57,58] or inversely the improvement of the myocardial ischemia after ECP may 
be partly attributed to improved coronary endothelial function. Furthermore, these tests were 
mostly performed at the same levels of exercise (same double product) before and after ECP. 
In this case reduced myocardial oxygen demand due to a peripheral training effect and 
lowered peripheral vascular resistance supports the fourth hypothesis (peripheral training 
effect) as a possible mechanism for the attenuation of perfusion defects. 
Only one study, performed from Urano and colleagues [13], had till recently used an invasive 
but unfortunately inaccurate method (Rentrop score) to assess a possible arteriogenic effect of 
ECP. In this study SPECT and coronary angiography with assessment of the Rentrop score 
were performed before and after ECP in patients with at least one residual coronary stenosis. 
The reduction of the perfusion defects in SPECT was not accompanied by a significant 
increase of the Rentrop score but it was related to a reduction of the left ventricular end-
diastolic pressure [13].  
Direct evidence for arteriogenic effect: the Art.Net. 2 trial 
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The Arteriogenesis Network performed between 2007 and 2008 a clinical trial in patients with 
stable coronary artery disease to provide clinical data to examine whether arteriogenesis is the 
main mechanism underlying the beneficial effects of ECP. Other aims of the trial were to 
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investigate if myocardial blood flow improves after ECP and if this improvement correlates 
with the clinical response to the therapy. 
By using the gold standard invasive method to detect myocardial collateral-dependent blood 
flow, the CFIp (pressure-derived Collateral Flow Index), we demonstrated a direct therapeutic 
effect of ECP on coronary collaterals in patients with stable angina pectoris and significant 
coronary stenosis. 
The detailed design of the trial is published elsewhere [59]. Briefly, 23 patients met the 
following major inclusion criteria: (1) angiographically stenosis (>70%) of one major 
coronary artery diagnosed by visual assessment within the last 2 months; (2) no previous 
infarction in the myocardial region of interest (ROI) for the assessment of collateral blood 
flow; (3) positive non-invasive ischemic testing for the ROI and fractional flow reserve (FFR) 
< 0.8 and were included in the trial. Included study participants were randomized in a 2:1 
manner to the ECP and the control group. Patients in the ECP-group received 35 hours of 
treatment over 7 weeks (5h/week) with an EECP-TS3 device (Vasomedical Inc., NY). 
Clinical symptoms, status and the diastolic-to-systolic ratio (D/S) were registered at each 
treatment session. ECP was performed by applying cuff pressures between 200-240mmHg to 
achieve a target D/S ratio > 1.0. To compensate for the non-therapy-related effect of ECP, the 
control-group had over 7 weeks 5 times/week a walk-in appointment (for non-study-related 
diagnostics, nutrition-counseling and physician’s appointment).  
The primary endpoints of the trial, the collateral flow index and fractional flow reserve, were 
estimated invasively during cardiac catheterization procedures before and after the period of 7 
weeks. FFR was calculated as FFR=Pd - Pv / Pa – Pv [60] and was used as a major inclusion 
criterion but also as endpoint to assess effects of ECP on the myocardial blood flow. The CFIp 
was estimated based on the next equation: CFIp=(Pw-Pv)/(Pa-Pv) [61]. So, all patients twice 
underwent a cardiac catheterization examination with invasive coronary pressure 
measurements. No percutaneous coronary intervention was performed during the first 
diagnostic invasive procedure. During the invasive follow-up at week 8 and after having 
assessed the study-related hemodynamic measurements revascularization was performed or 
not based on the FFR value and according to the guidelines [19].  
To assess symptoms standardized questionnaires on the CCS and the NYHA functional class 
were used. Within 3 weeks prior to the invasive diagnostics oral antihypertensive medication 
was adjusted to meet the guideline recommendations [62]. Baseline medication thereafter 
remained unchanged. Throughout the study patients were instructed not to change their daily 
activity.  
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In the ECP-group the CFIp increased from 0.08±0.01 to 0.15±0.02 (no units, p<0.001), 
whereas the control group showed no variance of the index (0.15±0.03 to 0.14±0.02, p=0.7) 
demonstrating growth of collateral arteries in patients treated with ECP. In accordance to the 
CFIp, the FFR index increased in the ECP group from 0.68±0.03 to 0.79±0.03 (no units, 
p=0.001) but not in the control group (0.68±0.06 to 0.70±0.05, p=0.4). In the ECP group after 
treatment a significant reduction of the CCS classification was achieved (p=0.008) whereas in 
the control group no change (p=0.25) was observed. The severity of dyspnea (NYHA scale) 
was reduced after ECP (p<0.001) but not within the control (p=0.28). At the end of the 
therapy 81% of the ECP patients were free of angina pectoris (CCS=0) compared to 56% at 
baseline. In the control group at baseline and after 7 weeks only one patient (14.3%) was free 
of angina. No patient treated with ECP had an increase in angina class or remained in CCS > 
II after the therapy. The detailed results of the trial are presented elsewhere [63]. 
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Important hallmarks of arteriogenesis are enhanced levels of shear stress across recruited 
collateral pathways. Experimentally a therapeutic increase in shear stress may be achieved via 
artificial stenosis, ligation or arterio-venous shunting distal the site of occlusion/stenosis [65]. 
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ECP increases arterial shear stress even in the absence of a stenosis [66]. In humans, it is 
proposed as an elegant method to non-invasively enhance shear stress in the arterial system 
(within the cardiac diastole without increasing heart rate) [28,67]. In this proof-of-concept 
trial we evaluated whether counterpulsation leads to a significant change in CFIp and FFR as 
compared to the natural time course under optimal medical treatment.  
The primary hypothesis of the Art.Net.-2 trial was to investigate the direct effects of 
counterpulsation on collateral function in patients with stable angina pectoris using the CFIp. 
The latter is currently the gold standard for the assessment of the collateral circulation. CFIp 
expresses the maintained collateral blood flow during coronary occlusion relative to normal 
antegrade flow during vessel patency [61]. In contrast to several other trials – which detected 
CFIp either at single time points or performed CFIp measurement within the PCI procedure – 
the ArtNet2 trial assessed CFIp at two longitudinal time points: baseline and follow up after 7 
weeks. We observed a significant increase of collateral blood flow after ECP treatment, 
whereas in the control group no change was observed. At the end of the therapy course 6/16 
patients in the ECP group versus 1/7 patients in the control group were deferred from 
angioplasty. In summary, the significant increase in CFIp is supported by a second functional 
endpoint, the FFR. The concurrent improvement of the CFIp and FFR in angiographically 
unchanged coronary arteries is evidence that the collateral arteries contribute to the improved 
myocardial blood flow which leads to the clinical improvement of the patient. The FFR takes 
into account the contribution of collaterals as long as the distal coronary pressure during 
maximal hyperemia reflects both antegrade and retrograde flow [68]. Thus, pressure-derived 
myocardial blood flow reserve improved upon ECP treatment significantly, reflecting the 
improvement of myocardial blood flow in the area at risk. 
In the current trial the reduction in angina seen in all of the pre,ECP symptomatic patients was 
related to an improvement of the coronary functional status; suggesting that the amelioration 
of angina is considerably depending on the improvement of myocardial blood flow. However, 
due to the small number of symptomatic patients this data has to be further investigated in 
future trials. Since all patients, including those who where free of angina at baseline, had an 
improvement of effort-related dyspnea, the latter beneficial effect of ECP is likely to depend 
on synergistic effects; including improved diastolic function, increased exercise capacity and 
decreased peripheral vasculature resistance [35,69,70]. 
It is known that the growth of collateral arteries in humans, in contrast to those in animals, is a 
process which takes place during weeks to months [71]. In this trial the significant decrease of 
CCS and NYHA class was obtained in the second half of the therapy, suggesting that the 
commonly used ECP protocol of about > 30 hours of therapy is appropriate for an adequate 
clinical response.  
The results of the Art.Net 2 trial were recently verified by another clinical study using CFIp 
and FFR as endpoints [72]. In the latter trial a very similar improvement of the CFIp of 0.075 
was demonstrated only in the ECP group. In the sham group, treated with ECP at cuff pressure 
of 80mmHg, no change of the CFIp or the FFR was seen. Furthermore, the improvement of 
the CFIp was correlated with increased peripheral flow-mediated dilation (FMD) supporting 
the hypothesis that vasodilatation is important in the process of arteriogenesis. 
Conclusions 
The external counterpulsation seems to be a safe, non-invasive method to stimulate 
arteriogenesis in patients with stable angina pectoris. Based on diastolic augmentation and 
consequently enhanced shear forces, this concept of “passive coronary training” may serve as 
a valuable complementary treatment strategy to promote myocardial collateral growth in 
patients beyond active training or in patients who are not able to perform regular 
cardiovascular training. The current data from the two independently designed and performed 
trials mentioned above indicate a clear arteriogenic effect of ECP. As long as ECP is a therapy 
with almost no side effects when applied in an appropriately selected population, a 
supplementary use of the therapy beyond standard medication could be feasible for a large 
number of patients with stable CAD. However, the therapy is currently not broadly used 
basically due to the time needed to complete a course (7 weeks) and the relative high costs, 
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not covered in many countries by the insurance. Further pitfalls of current ECP treatment 
forms include the relative high noise during treatment and the unspecific approach (non-
personalized treatment).  
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Formation of the collateral arterial network during embryogenesis, the genetic and 
environmental factors influencing native collateral artery circulation as well as local and 
systemic mechanisms modulating collateral artery growth in the adult are research topics, 
currently receiving much attention.  Although in the early stages, we are beginning more and 
more to comprehend the complex regulation involved.  
Virtually every organ of the body is equipped with an arteriolar network; however, the 
number of arteriolar anastomoses seems to vary widely between individuals. Large variation 
in clinical outcomes of patients with vascular occlusive diseases might reflect differences in 
the capacity of remodeling, although only to the extent of pre-existing collaterals. Since a well 
formed arteriolar network is the pre-requisite for life and tissue saving arteriogenesis during 
vascular occlusive diseases a lot of emphasis is being put on the identification of the 
responsible genetic loci and genetic programs controlling the number, size and maintenance 
of arteriolar anastomoses during embryonic development as well as in postnatal development.  
Until recently, most studies focusing on vascular development, i.e. angiogenesis, 
investigated embryonic principles in the adult organism under patho-physiological 
conditions such as ischemia or during tumor growth. However, angiogenesis and 
arteriogenesis, as well as collaterogenesis (formation of collaterals), differ considerably. 
Alternative approaches aiming at understanding the molecular mechanisms governing the 
collateral formation and branching pattern in the embryo had just begun. 
Factors like VEGF-A, VEGFR-1, Angiopoietin-2, PDGF-B and CLIC 4 have been identified 
to be important in formation and maturation of the proto-collateral plexus. The Notch 
signaling pathway has been identified to be essential for arterial development and growth, 
both during development and after birth. Furthermore, it is clear that hemodynamic forces and 
increased blood flow conduct the orchestrated action. Although still a hypothesis, it is 
becoming more and more evident that (neo-)collaterals form from fusion of capillary-like 
branches from established arterioles rather than de novo. The process of “upgrading” 
capillaries into small arterioles is likely to be a very slow process and it is uncertain whether it 
has any physiological relevance during the early phase after arterial occlusion. However, 
experimental evidence has clearly shown a positive association between the number of 
preexisting arterioles and the outcome of vascular obstructions. Patients at risk with sparse 
collaterals might benefit from collateralogenic therapies before an obstructive vascular event 
occurs, profiting from the existence of collaterals and subsequent therapies augmenting 
collateral artery growth.  
Investigations on the molecular mechanisms governing the formation of collaterals in the 
embryo are designed to provide clues regarding the signaling molecules responsible for the 
formation of neocollaterals in the adult. It is, therefore, a future challenge to identify the full 
repertoire of genetic mechanisms and molecules involved in the formation of proper 
collaterals being eventually able to offer effective therapeutic approaches. 
Another challenging task will be to unravel the process of pruning. Again, studies of the 
embryonic and fetal, but also adult organism, might further the knowledge on maintenance of 
collaterals. In particular the embryonic and fetal vasculature is highly plastic and 
hemodynamic forces, but also environmental influences, are likely to determine the fate of 
collaterals either in the direction to be sustained or pruned. However, the exact molecular 
mechanisms remain to be elucidated in order to be able to prevent pruning and warrant   
abundant collateralization. 
Although arteriogenesis per se is defined as the growth of pre-existing collaterals, it is of 
similar importance to define the mechanisms of collaterogenesis. Epigenetic regulations are 
very likely to be involved in both processes. Epigenetics defines the heritable changes in 
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genome function that occur without a change in DNA sequence. It involves DNA methylation 
but also histone modifications regulating the “on”/”off” state of gene expression. Currently, 
little data on epigenetics and collaterogenesis or arteriogenesis are available. Nevertheless it is 
clear that epigenetic regulations play a major role in both processes. Certain genes, such as 
eNOS, FGF-2, PDGF, SRF, that are known to have mechanistic functions in collateral 
formation as well as growth, fall under epigenetic regulation. To define all the genes involved 
in collaterogenesis and arteriogenesis is certainly a future task; however, it will be a greater 
challenge to identify the elicitors of epigenetic modifications. The fundamental question is, 
what induces the epigenetic regulation of a single gene (or multiple genes) during various life 
stages, e.g. during pregnancy, during normal life and in an aged person? What are the 
environmental influences, what are the effects of nutrition, and finally - and even more 
difficult to define - what influence does the status of an individual’s psychic well-being have? 
Whereas collaterogenesis is a relatively new discipline, in-depth investigations on 
arteriogenesis started about 15 years ago. Accordingly, our knowledge on signal transduction 
cascades after activation of the endothelium, beginning with the activation of the Rho-kinase 
pathway and resulting in the downstream activation of the cell cycle regulator Egr-1, as well 
as the influences of bone-marrow derived cells (monocytes, T-cells), is much larger in 
arteriogenesis. However, our understanding how the mechanical force, the increased fluid 
shear stress that is the trigger of arteriogenesis, is translated and induces the diverse biological 
reactions which lead to vascular cell proliferation and outward remodeling, is still poor. The 
initial understanding of the functional role of ions (in particular Ca2+) as well as ion channels 
(i.e. TRPV4), which began when the book “Arteriogenesis” was published by Wolfgang 
Schaper and Jutta Schaper in 2004, has now deepened significantly. However, the 
mechanistic function of NO and NO-synthases is less clear. Nitric oxide is anti-proliferative 
for SMCs and counter-acts the adhesion of leukocytes to the endothelium – two processes of 
fundamental importance for arteriogenesis. Yet NO, (or NO-synthases), are indispensable for 
proper collateral artery growth. Nitric oxide synthases, eNOS, iNOS and nNOS all seem to 
have elementary roles in this process, although they might substitute each other at least in 
part. And what about NO-donors? Administration of NO-donors like detaNONOate was 
shown to dramatically promote collateral artery growth. However, is it really NO? All forms 
of nitrogen can be changed into each other. Is nitrogen itself the important element? And what 
about ROS like H2O2? What about uncoupling eNOS resulting in increased H2O2 production? 
Or is it H2O2 that increases NO through eNOS activation and may also induce an NO-
insensitive state? The correct redox balance seems to play the utmost fundamental role, not 
only for vascular cell proliferation, but also for the translation of the mechanical force (fluid 
shear stress) into the certain biological reactions. A thorough understanding of the function of 
the redox state will be one of the outstanding tasks for the future. 
Finally, it will be a major challenge to transfer the knowledge from bench to bedside. 
Currently, approaches to promote arteriogenesis in the clinic have failed – except external 
counterpulsation. This is likely to be based on the fact the collateral artery growth is a multi-
factorial process; almost excluding that on single substance may do the job. Thymosin β4
might present a promising exception. This peptide is not only of particular interest because it 
promotes arteriogenesis efficiently – at least in experimental settings – but also due to its anti-
inflammatory feature not promoting atherosclerosis in parallel. Local drug delivery systems 
currently developed are promising tools finally rendering it possible to achieve a targeted and 
sustained drug delivery enabling effective arteriogenic therapies without severe systemic side 
effects. 
Still a lot of work remains to be done. Hopefully, we will make it, like the bird will catch the 
(yet for us invisible) fish. However, we should not forget that the stakes are high: clinicians 
are very successful with their interventional techniques to open occluded arteries and we have 
to be better than them. 
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